



INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification ⁷ : C07C 237/22, C07D 211/60, 217/26, 209/42, 215/233, 213/64, 277/10, A61K 31/195, 31/33		A1	(11) International Publication Number: WO 00/23421 (43) International Publication Date: 27 April 2000 (27.04.00)
<p>(21) International Application Number: PCT/US99/24756</p> <p>(22) International Filing Date: 22 October 1999 (22.10.99)</p> <p>(30) Priority Data: 09/177,546 22 October 1998 (22.10.98) US</p> <p>(71) Applicant (for all designated States except US): IDUN PHARMACEUTICALS, INC. [US/US]; Suite 300, 11085 North Torrey Pines Road, La Jolla, CA 92037 (US).</p> <p>(72) Inventors; and</p> <p>(75) Inventors/Applicants (for US only): KARANEWSKY, Donald, S. [US/US]; 1797 Continental Lane, Escondido, CA 92029 (US). KALISH, Vincent, J. [US/US]; 344 Dubois Road, Annapolis, MD 21401 (US). ROBINSON, Edward, D. [US/US]; 3567 Tony Drive, San Diego, CA 92122 (US). ULLMAN, Brett, R. [US/US]; 4021 Richmond Street #6, San Diego, CA 92103 (US).</p> <p>(74) Agents: HERMANN, Karl, R. et al.; Seed and Berry LLP, 6300 Columbia, 701 Fifth Avenue, Seattle, WA 98104-7092 (US).</p>		<p>(81) Designated States: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, ARIPO patent (GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RI, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).</p> <p>Published <i>With international search report. Before the expiration of the time limit for amending the claims and to be republished in the event of the receipt of amendments.</i></p>	
<p>(54) Title: (SUBSTITUTED)ACYL DIPEPTIDYL INHIBITORS OF THE ICE/ced-3 FAMILY OF CYSTEINE PROTEASES</p> <p>(57) Abstract</p> <p>This invention is directed to novel (substituted)acyl dipeptidyl ICE/ced-3 family inhibitor compounds. The invention is also directed to pharmaceutical compositions containing these compounds, as well as the use of such compositions in the treatment of patients suffering inflammatory, autoimmune and neurodegenerative diseases, for the prevention of ischemic injury, and for the preservation of organs that are to undergo a transplantation procedure.</p>			

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AL	Albania	ES	Spain	LS	Lesotho	SI	Slovenia
AM	Armenia	FI	Finland	LT	Lithuania	SK	Slovakia
AT	Austria	FR	France	LU	Luxembourg	SN	Senegal
AU	Australia	GA	Gabon	LV	Latvia	SZ	Swaziland
AZ	Azerbaijan	GB	United Kingdom	MC	Monaco	TD	Chad
BA	Bosnia and Herzegovina	GE	Georgia	MD	Republic of Moldova	TG	Togo
BB	Barbados	GH	Ghana	MG	Madagascar	TJ	Tajikistan
BE	Belgium	GN	Guinea	MK	The former Yugoslav Republic of Macedonia	TM	Turkmenistan
BF	Burkina Faso	GR	Greece			TR	Turkey
BG	Bulgaria	HU	Hungary	ML	Mali	TT	Trinidad and Tobago
BJ	Benin	IE	Ireland	MN	Mongolia	UA	Ukraine
BR	Brazil	IL	Israel	MR	Mauritania	UG	Uganda
BY	Belarus	IS	Iceland	MW	Malawi	US	United States of America
CA	Canada	IT	Italy	MX	Mexico	UZ	Uzbekistan
CF	Central African Republic	JP	Japan	NE	Niger	VN	Viet Nam
CG	Ch ^o go	KE	Kenya	NL	Netherlands	YU	Yugoslavia
CH	Switzerland	KG	Kyrgyzstan	NO	Norway	ZW	Zimbabwe
CI	Côte d'Ivoire	KP	Democratic People's Republic of Korea	NZ	New Zealand		
CM	Cameroon			PL	Poland		
CN	China	KR	Republic of Korea	PT	Portugal		
CU	Cuba	KZ	Kazakhstan	RO	Romania		
CZ	Czech Republic	LC	Saint Lucia	RU	Russian Federation		
DE	Germany	LI	Liechtenstein	SD	Sudan		
DK	Dennmark	LK	Sri Lanka	SE	Sweden		
EE	Estonia	LR	Liberia	SG	Singapore		

(SUBSTITUTED)ACYL DIPEPTIDYL INHIBITORS OF THE
ICE/ced-3 FAMILY OF CYSTEINE PROTEASES

Technical Field

5 The present invention relates to novel classes of compounds which are inhibitors of interleukin-1 β converting enzyme and related proteases ("ICE/ced-3 family of cysteine proteases"), as well as to pharmaceutical compositions comprising these compounds and to methods of using such pharmaceutical compositions.

Background of the Invention

10 Interleukin 1 ("IL-1") is a major pro-inflammatory and immunoregulatory protein that stimulates fibroblast differentiation and proliferation, the production of prostaglandins, collagenase and phospholipase by synovial cells and chondrocytes, basophil and eosinophil degranulation and neutrophil activation. Oppenheim, J.H. *et al.*, *Immunology Today*, 7:45-56 (1986). As such, it is involved in 15 the pathogenesis of chronic and acute inflammatory and autoimmune diseases. IL-1 is predominantly produced by peripheral blood monocytes as part of the inflammatory response. Mosely, B.S. *et al.*, *Proc. Nat. Acad. Sci.*, 84:4572-4576 (1987); Lonnemann, G. *et al.*, *Eur. J. Immunol.*, 19:1531-1536 (1989).

IL-1 β is synthesized as a biologically inactive precursor, proIL-1 β . 20 ProIL-1 β is cleaved by a cysteine protease called interleukin-1 β converting enzyme ("ICE") between Asp-116 and Ala-117 to produce the biologically active C-terminal fragment found in human serum and synovial fluid. Sleath, P.R. *et al.*, *J. Biol. Chem.*, 265:14526-14528 (1992); A.D. Howard *et al.*, *J. Immunol.*, 147:2964-2969 (1991).

ICE is a cysteine protease localized primarily in monocytes. In addition 25 to promoting the pro-inflammatory and immunoregulatory properties of IL-1 β , ICE, and particularly its homologues, also appear to be involved in the regulation of cell

death or apoptosis. Yuan, J. *et al.*, Cell, 75:641-652 (1993); Miura, M. *et al.*, Cell, 75:653-660 (1993); Nett-Giordalisi, M.A. *et al.*, J. Cell Biochem, 17B:117 (1993). In particular, ICE or ICE/ced-3 homologues are thought to be associated with the regulation of apoptosis in neurodegenerative diseases, such as Alzheimer's and 5 Parkinson's disease. Marx, J. and M. Baringa, Science, 259:760-762 (1993); Gagliardini, V. *et al.*, Science, 263:826-828 (1994).

Thus, disease states in which inhibitors of the ICE/ced-3 family of cysteine proteases may be useful as therapeutic agents include: infectious diseases, such as meningitis and salpingitis; septic shock, respiratory diseases; inflammatory 10 conditions, such as arthritis, cholangitis, colitis, encephalitis, endocerolitis, hepatitis, pancreatitis and reperfusion injury, ischemic diseases such as the myocardial infarction, stroke and ischemic kidney disease; immune-based diseases, such as hypersensitivity; auto-immune diseases, such as multiple sclerosis; bone diseases; and certain neurodegenerative diseases, such as Alzheimer's and Parkinson's disease. Such 15 inhibitors are also useful for the repopulation of hematopoietic cells following chemo- and radiation therapy and for prolonging organ viability for use in transplantation.


ICE/ced-3 inhibitors represent a class of compounds useful for the control of the above-listed disease states. Peptide and peptidyl inhibitors of ICE have been described. However, such inhibitors have been typically characterized by 20 undesirable pharmacologic properties, such as poor oral absorption, poor stability and rapid metabolism. Plattner, J.J. and D.W. Norbeck, in Drug Discovery Technologies, C.R. Clark and W.H. Moos, Eds. (Ellis Horwood, Chichester, England, 1990), pp. 92-126. These undesirable properties have hampered their development into effective drugs.

25 Accordingly, the need exists for compounds that can effectively inhibit the action of the ICE/ced-3 family of proteases, for use as agents for preventing unwanted apoptosis and for treating chronic and acute forms of IL-1 mediated diseases, such as inflammatory, autoimmune or neurodegenerative diseases. The present invention satisfies this need and provides further related advantages.

Summary of the Invention

In general, the compounds of this invention incorporate an aryl or heteroaryl substituted acyl group as a dipeptide mimetic. The resulting compounds exhibit improved properties relative to their peptidic counterparts, for example, such as 5 improved cell penetration or improved absorption and metabolic stability resulting in enhanced bioavailability.

One aspect of the instant invention is the compounds of the Formula I:



Formula I

10 wherein A, B, X, n, q, R¹, R² and R³ are as defined below, as well as pharmaceutically acceptable salts thereof.

A further aspect of the instant invention is a pharmaceutical composition comprising a compound of the above Formula I and a pharmaceutically-acceptable carrier therefor.

15 Another aspect of this invention involves a method for treating an autoimmune disease comprising administering an effective amount of a pharmaceutical composition discussed above to a patient in need of such treatment.

Yet another aspect of the instant invention is a method for treating an inflammatory disease comprising administering an effective amount of a 20 pharmaceutical composition discussed above to a patient in need of such treatment.

A further aspect of the instant invention is a method for treating a neurodegenerative disease comprising administering an effective amount of a pharmaceutical composition discussed above to a patient in need of such treatment.

Another aspect of the instant invention is a method of preventing ischemic injury to a patient suffering from a disease associated with ischemic injury comprising administering an effective amount of the pharmaceutical composition discussed above to a patient in need of such treatment.


5 A further aspect of the instant invention is a method for expanding of
hematopoietic cell populations and/or enhancing their survival by contacting the cells
with an effective amount of the pharmaceutical composition discussed above. Cell
populations included in the method of the invention include (but are not limited to)
granulocytes, monocytes, erythrocytes, lymphocytes and platelets for use in cell
10 transfusions.

An alternate aspect of the instant invention is a method of prolonging the viability of an organ that has been removed from the donor for the purpose of a future transplantation procedure, which comprises applying an effective amount of the pharmaceutical composition discussed above to the organ, thereby prolonging the viability of the organ as compared to an untreated organ. The organ may be an intact organ, or isolated cells derived from an organ (e.g., isolated pancreatic islet cells, isolated dopaminergic neurons, blood or hematopoietic cells).

These and other aspects of this invention will be evident upon reference to the following detailed description.

20 Detailed Description of the Invention

As mentioned above, one aspect of the instant invention is the compounds of the Formula I:



Formula I


wherein:

n is 0, 1 or 2;

q is 1 or 2;


X is CH₂, C=O, O, S, NH, C=ONH or CH₂OC=ONH;

A is a natural or unnatural amino acid of Formula IIa-i:



B is a hydrogen atom, a deuterium atom, C₁₋₁₀ straight chain or branched alkyl, cycloalkyl, phenyl, substituted phenyl, naphthyl, substituted naphthyl, 2-benzoxazolyl, substituted 2-oxazolyl, (CH₂)_mcycloalkyl, (CH₂)_mphenyl, (CH₂)_m(substituted phenyl), (CH₂)_m(1 or 2-naphthyl), (CH₂)_mheteroaryl, halomethyl, CO₂R¹³, CONR¹⁴R¹⁵, CH₂ZR¹⁶, CH₂OCO(aryl), CH₂OCO(substituted aryl), CH₂OCO(heteroaryl), CH₂OCO(substituted heteroaryl), or

$\text{CH}_2\text{OPO}(\text{R}^{17})\text{R}^{18}$, where Z is an oxygen or a sulfur atom, or B is a group of the Formula IIIa-c:



5 R^1 is phenyl, substituted phenyl, naphthyl, substituted naphthyl, heteroaryl, or substituted heteroaryl;

10 R^2 is hydrogen, alkyl, cycloalkyl, phenyl, substituted phenyl, $(\text{CH}_2)_m\text{NH}_2$, $(\text{CH}_2)_m\text{NHCOR}^{10}$, $(\text{CH}_2)_m\text{N}(\text{C}=\text{NH})\text{NH}_2$, $(\text{CH}_2)_p\text{CO}_2\text{R}^3$, $(\text{CH}_2)_p\text{OR}^{11}$, $(\text{CH}_2)_p\text{SR}^{12}$, $(\text{CH}_2)_m\text{cycloalkyl}$, $(\text{CH}_2)_m\text{phenyl}$, $(\text{CH}_2)_m(\text{substituted phenyl})$, $(\text{CH}_2)_m(1 \text{ or } 2\text{-naphthyl})$, or $(\text{CH}_2)_m\text{heteroaryl}$, wherein heteroaryl includes (but is not limited to) substituted or unsubstituted pyridyl, thienyl, furyl, thiazolyl, imidazolyl, pyrazolyl, isoaxazolyl, pyrazinyl, pyrimidyl, triazinyl, tetrazolyl, and indolyl;

15 R^3 is hydrogen, alkyl, cycloalkyl, (cycloalkyl)alkyl, phenylalkyl, or substituted phenylalkyl;

and wherein

20 R^4 is alkyl, cycloalkyl, phenyl, substituted phenyl, $(\text{CH}_2)_m\text{NH}_2$, $(\text{CH}_2)_m\text{NHCOR}^{10}$, $(\text{CH}_2)_m\text{N}(\text{C}=\text{NH})\text{NH}_2$, $(\text{CH}_2)_p\text{CO}_2\text{R}^3$, $(\text{CH}_2)_p\text{OR}^{11}$, $(\text{CH}_2)_p\text{SR}^{12}$, $(\text{CH}_2)_m\text{cycloalkyl}$, $(\text{CH}_2)_m\text{phenyl}$, $(\text{CH}_2)_m(\text{substituted phenyl})$, $(\text{CH}_2)_m(1 \text{ or } 2\text{-naphthyl})$, or $(\text{CH}_2)_m\text{heteroaryl}$, wherein heteroaryl includes (but is not limited to) pyridyl, thienyl, furyl, thiazolyl, imidazolyl, pyrazolyl, isoaxazolyl, pyrazinyl, pyrimidyl, triazinyl, tetrazolyl, and indolyl;

R^{4a} is hydrogen or methyl, or R^4 and R^{4a} taken together are $-(CH_2)_d-$ where d is an integer from 2 to 6;

R^5 is phenyl, substituted phenyl, $(CH_2)_p$ phenyl, $(CH_2)_p$ (substituted phenyl), cycloalkyl, or benzofused cycloalkyl;

5 R^6 is hydrogen, alkyl, cycloalkyl, phenyl, substituted phenyl, $(CH_2)_m$ cycloalkyl, $(CH_2)_m$ phenyl, $(CH_2)_m$ (substituted phenyl), or $(CH_2)_m$ (1 or 2-naphthyl);

10 R^7 is hydrogen, fluorine, oxo (*i.e.*, =O), alkyl, cycloalkyl, phenyl, substituted phenyl, naphthyl, $(CH_2)_m$ cycloalkyl, $(CH_2)_m$ phenyl, $(CH_2)_m$ (substituted phenyl), $(CH_2)_m$ (1 or 2-naphthyl), OR¹¹, SR¹², or NHCOR¹⁰;

R^8 is hydrogen, oxo, alkyl, cycloalkyl, phenyl, substituted phenyl, naphthyl, $(CH_2)_m$ cycloalkyl, $(CH_2)_m$ phenyl, $(CH_2)_m$ (substituted phenyl), or $(CH_2)_m$ (1 or 2-naphthyl);

15 R^9 is alkyl, cycloalkyl, $(CH_2)_m$ cycloalkyl, $(CH_2)_m$ phenyl, $(CH_2)_m$ (substituted phenyl), $(CH_2)_m$ (1 or 2-naphthyl), or COR¹⁰;

R^{10} is hydrogen, alkyl, cycloalkyl, phenyl, substituted phenyl, naphthyl, $(CH_2)_m$ cycloalkyl, $(CH_2)_m$ phenyl, $(CH_2)_m$ (substituted phenyl), $(CH_2)_m$ (1 or 2-naphthyl), OR¹³, or NR¹⁴R¹⁵;

20 R^{11} is hydrogen, alkyl, cycloalkyl, phenyl, substituted phenyl, naphthyl, $(CH_2)_m$ cycloalkyl, $(CH_2)_m$ phenyl, $(CH_2)_m$ (substituted phenyl), or $(CH_2)_m$ (1 or 2-naphthyl);

25 R^{12} is alkyl, cycloalkyl, phenyl, substituted phenyl, naphthyl, $(CH_2)_m$ cycloalkyl, $(CH_2)_m$ phenyl, $(CH_2)_m$ (substituted phenyl), or $(CH_2)_m$ (1 or 2-naphthyl);

R^{13} is alkyl, cycloalkyl, $(CH_2)_m$ cycloalkyl, $(CH_2)_m$ phenyl, $(CH_2)_m$ (substituted phenyl), or $(CH_2)_m$ (1 or 2-naphthyl);

R¹⁴ is hydrogen, alkyl, cycloalkyl, phenyl, substituted phenyl, naphthyl, substituted naphthyl, (CH₂)_mcycloalkyl, (CH₂)_mphenyl, (CH₂)_m(substituted phenyl), or (CH₂)_m(1 or 2-naphthyl);

R¹⁵ is hydrogen or alkyl; or

5 R¹⁴ and R¹⁵ taken together form a five, six or seven membered carbocyclic or heterocyclic ring, such as morpholine or N-substituted piperazine;

10 R¹⁶ is phenyl, substituted phenyl, naphthyl, substituted naphthyl, heteroaryl, (CH₂)_mphenyl, (CH₂)_m(substituted phenyl), (CH₂)_m(1 or 2-naphthyl), or (CH₂)_mheteroaryl;

15 R¹⁷ and R¹⁸ are independently alkyl, cycloalkyl, phenyl, substituted phenyl, naphthyl, or phenylalkyl, substituted phenylalkyl, or (cycloalkyl)alkyl;

R¹⁹ and R²⁰ are independently hydrogen, alkyl, phenyl, substituted phenyl, (CH₂)_mphenyl, or (CH₂)_m(substituted phenyl), or R¹⁹ and R²⁰ taken together are -(CH=CH)₂-;

R²¹ is hydrogen, alkyl, phenyl, substituted phenyl, (CH₂)_mphenyl, (CH₂)_m(substituted phenyl);

R²², R²³ and R²⁴ are independently hydrogen or alkyl;

20 Y¹ is CH₂, (CH₂)₂, (CH₂)₃, or S;

Y² is O or NR²⁴;

Y³ is CH₂, O, or NR²⁴;

a is 0 or 1 and b is 1 or 2, provided that when a is 1 then b is 1;

c is 1 or 2, provided that when c is 1 then a is 0 and b is 1;

25 m is 1, 2, 3 or 4; and

p is 1 or 2;

or a pharmaceutically acceptable salt thereof.

As used herein, the term "alkyl" means a straight or branched C₁ to C₃ carbon chain such as methyl, ethyl, tert-butyl, iso-propyl, n-octyl, and the like. The term "lower alkyl" means a straight or branched C₁ to C₆ carbon chain, such as methyl,
5 ethyl, iso-propyl, and the like.

The term "cycloalkyl" means a mono-, bi-, or tricyclic ring that is either fully saturated or partially unsaturated. Examples of such a ring include cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, adamantyl, cyclooctyl, cis- or trans decalin, bicyclo[2.2.1]hept-2-ene, cyclohex-1-enyl, cyclopent-1-enyl, 1,4-
10 cyclooctadienyl, and the like.

The term "(cycloalkyl)alkyl" means the above-defined alkyl group substituted with one of the above cycloalkyl rings. Examples of such a group include (cyclohexyl)methyl, 3-(cyclopropyl)-n-propyl, 5-(cyclopentyl)hexyl, 6-(adamantyl)hexyl, and the like.

15 The term "substituted phenyl" specifies a phenyl group substituted with one or more, and preferably one or two, substituents chosen from halogen, hydroxy, protected hydroxy, cyano, nitro, trifluoromethyl, alkyl, alkoxy, acyl, acyloxy, carboxy, protected carboxy, carboxymethyl, protected carboxymethyl, hydroxymethyl, protected hydroxymethyl, amino, protected amino, (monosubstituted)amino, protected
20 (monosubstituted)amino, (disubstituted)amino, carboxamide, protected carboxamide, N-(lower alkyl)carboxamide, protected N-(lower alkyl)carboxamide, N,N-di(lower alkyl)carboxamide, N-((lower alkyl)sulfonyl)amino, N-(phenylsulfonyl)amino or by a substituted or unsubstituted phenyl group, such that in the latter case a biphenyl or naphthyl group results.

25 Examples of the term "substituted phenyl" includes a mono- or di(halo)phenyl group such as 2-, 3- or 4-chlorophenyl, 2,6-dichlorophenyl, 2,5-dichlorophenyl, 3,4-dichlorophenyl, 2-,3- or 4-bromophenyl, 3,4-dibromophenyl, 3-chloro-4-fluorophenyl, 2-, 3- or 4-fluorophenyl and the like; a mono or di(hydroxy)phenyl group such as 2-, 3-, or 4-hydroxyphenyl, 2,4-dihydroxyphenyl, the

protected-hydroxy derivatives thereof and the like; a nitrophenyl group such as 2-, 3-, or 4-nitrophenyl; a cyanophenyl group, for example, 2-,3- or 4-cyanophenyl; a mono- or di(alkyl)phenyl group such as 2-, 3-, or 4-methylphenyl, 2,4-dimethylphenyl, 2-, 3- or 4-(iso-propyl)phenyl, 2-, 3-, or 4-ethylphenyl, 2-, 3- or 4-(n-propyl)phenyl and the like; a mono or di(alkoxy)phenyl group, for example, 2,6-dimethoxyphenyl, 2-, 3- or 4-(iso-propoxy)phenyl, 2-, 3- or 4-(t-butoxy)phenyl, 3-ethoxy-4-methoxyphenyl and the like; 2-, 3- or 4-trifluoromethylphenyl; a mono- or dicarboxyphenyl or (protected carboxy)phenyl group such as 2-, 3- or 4-carboxyphenyl or 2,4-di(protected carboxy)phenyl; a mono- or di(hydroxymethyl)phenyl or (protected hydroxymethyl)phenyl such as 2-, 3- or 4-(protected hydroxymethyl)phenyl or 3,4-di(hydroxymethyl)phenyl; a mono- or di(aminomethyl)phenyl or (protected aminomethyl)phenyl such as 2-, 3- or 4-(aminomethyl)phenyl or 2,4-(protected aminomethyl)phenyl; or a mono- or di(N-(methylsulfonylamino))phenyl such as 2, 3 or 4-(N-(methylsulfonylamino))phenyl. Also, the term "substituted phenyl" represents disubstituted phenyl groups wherein the substituents are different, for example, 3-methyl-4-hydroxyphenyl, 3-chloro-4-hydroxyphenyl, 2-methoxy-4-bromophenyl, 4-ethyl-2-hydroxyphenyl, 3-hydroxy-4-nitrophenyl, 2-hydroxy-4-chlorophenyl, and the like.

The term "phenylalkyl" means one of the above phenyl groups attached to one of the above-described alkyl groups, and the term "substituted phenylalkyl" means that either the phenyl or the alkyl, or both, are substituted with one or more of the above-identified substituents. Examples of such groups include 2-phenyl-1-chloroethyl, 2-(4'-methoxyphenyl)ethyl, 4-(2',6'-dihydroxy phenyl)n-hexyl, 2-(5'-cyano-3'-methoxyphenyl)n-pentyl, 3-(2',6'-dimethylphenyl)n-propyl, 4-chloro-3-aminobenzyl, 6-(4'-methoxyphenyl)-3-carboxy(n-hexyl), 5-(4'-aminomethylphenyl)-3-(aminomethyl)n-pentyl, 5-phenyl-3-oxo-n-pent-1-yl, (4-hydroxynaphth-2-yl)methyl, and the like.

The term "substituted naphthyl" means a naphthyl group substituted with one or more of the above-identified substituents, and the term "(1 or 2

"naphyl)alkyl" means a naphthyl attached to one of the above-described alkyl groups at the 1 or 2 position.

The terms "halo" and "halogen" refer to the fluoro, chloro, bromo or iodo groups. These terms may also be used to describe one or more halogens, which 5 are the same or different. Preferred halogens in the context of this invention are chloro and fluoro.

The term "aryl" refers to aromatic five and six membered carbocyclic rings. Six membered rings are preferred.

The term "heteroaryl" denotes optionally substituted aromatic 10 five-membered or six-membered heterocyclic rings that have 1 to 4 heteroatoms, such as oxygen, sulfur and/or nitrogen atoms, in particular nitrogen, either alone or in conjunction with sulfur or oxygen ring atoms.

The following ring systems are representative examples of the 15 heterocyclic radicals denoted by the term "heteroaryl" (whether substituted or unsubstituted): thienyl, furyl, pyrrolyl, pyrrolidinyl, imidazolyl, isoxazolyl, triazolyl, thiadiazolyl, oxadiazolyl, tetrazolyl, thiatriazolyl, oxatriazolyl, pyridyl, pyrimidyl, pyrazinyl, pyridazinyl, oxazinyl, triazinyl, thiadiazinyl tetrazolo, 1,5-[b]pyridazinyl and purinyl, as well as benzo-fused derivatives, for example, benzoxazolyl, benzothiazolyl, benzimidazolyl and indolyl.

Substituents for the above optionally substituted heteroaryl rings are 20 from one to three halo, trihalomethyl, amino, protected amino, amino salts, mono-substituted amino, di-substituted amino, carboxy, protected carboxy, carboxylate salts, hydroxy, protected hydroxy, salts of a hydroxy group, lower alkoxy, lower alkylthio, lower alkyl, substituted alkyl, cycloalkyl, substituted cycloalkyl, 25 (cycloalkyl)alkyl, substituted (cycloalkyl)alkyl, phenyl, substituted phenyl, phenylalkyl, and substituted phenylalkyl groups.

Substituents for the heteroaryl group are as defined above, or as set forth below. As used in conjunction with the above substituents for heteroaryl rings, "trihalomethyl" can be trifluoromethyl, trichloromethyl, tribromomethyl or

triodomethyl, "lower alkoxy" means a C₁ to C₄ alkoxy group, similarly, "lower alkylthio" means a C₁ to C₄ alkylthio group. The term "substituted lower alkyl" means the above-defined lower alkyl group substituted from one to three times by a hydroxy, protected hydroxy, amino, protected amino, cyano, halo, trifluoromethyl,

5 mono-substituted amino, di-substituted amino, lower alkoxy, lower alkylthio, carboxy, protected carboxy, or a carboxy, amino, and/or hydroxy salt.

As used in conjunction with the substituents for the heteroaryl rings, the terms "substituted (cycloalkyl)alkyl" and "substituted cycloalkyl" are as defined above substituted with the same groups as listed for a "substituted alkyl" group. The term

10 "(monosubstituted)amino" refers to an amino group with one substituent chosen from the group consisting of phenyl, substituted phenyl, alkyl, substituted alkyl, C₁ to C₇ acyl, C₂ to C₇ alkenyl, C₂ to C₇ substituted alkenyl, C₂ to C₇ alkynyl, C₇ to C₁₆ alkylaryl, C₇ to C₁₆ substituted alkylaryl and heteroaryl group. The (monosubstituted)amino can additionally have an amino-protecting group as encompassed by the term "protected

15 (monosubstituted)amino." The term "(disubstituted)amino" refers to amino groups with two substituents chosen from the group consisting of phenyl, substituted phenyl, alkyl, substituted alkyl, C₁ to C₇ acyl, C₂ to C₇ alkenyl, C₂ to C₇ alkynyl, C₇ to C₁₆ alkylaryl, C₇ to C₁₆ substituted alkylaryl and heteroaryl. The two substituents can be the same or different. The term "heteroaryl(alkyl)" denotes an alkyl group as defined above,

20 substituted at any position by a heteroaryl group, as above defined.

Furthermore, the above optionally substituted five-membered or six-membered heterocyclic rings can optionally be fused to a aromatic 5-membered or 6-membered aryl or heteroaryl ring system. For example, the rings can be optionally fused to an aromatic 5-membered or 6-membered ring system such as a pyridine or a

25 triazole system, and preferably to a benzene ring.

The term "pharmaceutically-acceptable salt" encompasses those salts that form with the carboxylate anions and includes salts formed with the organic and inorganic cations such as those chosen from the alkali and alkaline earth metals, (for example, lithium, sodium, potassium, magnesium, barium and calcium); and

30 ammonium ion; and the organic cations (for example, dibenzylammonium,

benzylammonium, 2-hydroxyethylammonium, bis(2-hydroxyethyl)ammonium, phenylethylbenzylammonium, dibenzylethylenediammonium, and like cations.) Other cations encompassed by the above term include the protonated form of procaine, quinine and N-methylglucosamine, the protonated forms of basic amino acids such as 5 glycine, ornithine, histidine, phenylglycine, lysine, and arginine. Furthermore, any zwitterionic form of the instant compounds formed by a carboxylic acid and an amino group is referred to by this term. A preferred cation for the carboxylate anion is the sodium cation. Furthermore, the term includes salts that form by standard acid-base reactions with basic groups (such as amino groups) and includes organic or inorganic 10 acids. Such acids include hydrochloric, sulfuric, phosphoric, acetic, succinic, citric, lactic, maleic, fumaric, palmitic, cholic, pamoic, mucic, D-glutamic, D-camphoric, glutaric, phthalic, tartaric, lauric, stearic, salicyclic, methanesulfonic, benzenesulfonic, sorbic, picric, benzoic, cinnamic, and the like acids.

The compounds of Formula I may also exist as solvates and hydrates. 15 Thus, these compounds may crystallize with, for example, waters of hydration, or one, a number of, or any fraction thereof of molecules of the mother liquor solvent. The solvates and hydrates of such compounds are included within the scope of this invention.

The term "carboxy-protecting group" as used herein refers to one of the 20 ester derivatives of the carboxylic acid group commonly employed to block or protect the carboxylic acid group while reactions are carried out on other functional groups on the compound. Examples of such carboxylic acid protecting groups include t-butyl, 4-nitrobenzyl, 4-methoxybenzyl, 3,4-dimethoxybenzyl, 2,4-dimethoxybenzyl, 2,4,6-trimethoxybenzyl, 2,4,6-trimethylbenzyl, pentamethylbenzyl, 25 3,4-methylenedioxybenzyl, benzhydryl, 4,4'-dimethoxytrityl, 4,4',4"-trimethoxytrityl, 2-phenylpropyl, trimethylsilyl, t-butyldimethylsilyl, phenacyl, 2,2,2-trichloroethyl, β-(trimethylsilyl)ethyl, β-(di(n-butyl)methylsilyl)ethyl, p-toluenesulfonyleethyl, 4-nitrobenzylsulfonyleethyl, allyl, cinnamyl, 1-(trimethylsilylmethyl)-propenyl and like moieties. The species of carboxy-protecting group employed is not critical so long as 30 the derivatized carboxylic acid is stable to the conditions of subsequent reaction(s) and

can be removed at the appropriate point without disrupting the remainder of the molecule. Further examples of these groups are found in C.B. Reese and E. Haslam, "Protective Groups in Organic Chemistry," J.G.W. McOmie, Ed., Plenum Press, New York, NY, 1973, Chapter 5, respectively, and T.W. Greene and P.G.M. Wuts,
5 "Protective Groups in Organic Synthesis," 2nd ed., John Wiley and Sons, New York, NY, 1991, Chapter 5, each of which is incorporated herein by reference. A related term is "protected carboxy," which refers to a carboxy group substituted with one of the above carboxy-protecting groups.

The term "hydroxy-protecting group" refers to readily cleavable groups
10 bonded to hydroxyl groups, such as the tetrahydropyranyl, 2-methoxyprop-2-yl, 1-ethoxyethyl-1-yl, methoxymethyl, β -methoxyethoxymethyl, methylthiomethyl, t-butyl, t-amyl, trityl, 4-methoxytrityl, 4,4'-dimethoxytrityl, 4,4',4"-trimethoxytrityl, benzyl, allyl, trimethylsilyl, (t-butyl)dimethylsilyl, 2,2,2-trichloroethoxycarbonyl, and the like.

Further examples of hydroxy-protecting groups are described by C.B.
15 Reese and E. Haslam, "Protective Groups in Organic Chemistry," J.G.W. McOmie, Ed., Plenum Press, New York, NY, 1973, Chapters 3 and 4, respectively, and T.W. Greene and P.G.M. Wuts, "Protective Groups in Organic Synthesis," Second Edition, John Wiley and Sons, New York, NY, 1991, Chapters 2 and 3. A preferred hydroxy-protecting group is the tert-butyl group. The related term "protected hydroxy"
20 denotes a hydroxy group bonded to one of the above hydroxy-protecting groups.

The term "amino-protecting group" as used herein refers to substituents
of the amino group commonly employed to block or protect the amino functionality while reacting other functional groups of the molecule. The term "protected (monosubstituted)amino" means there is an amino-protecting group on the
25 monosubstituted amino nitrogen atom.

Examples of such amino-protecting groups include the formyl ("For") group, the trityl group, the phthalimido group, the trichloroacetyl group, the trifluoroacetyl group, the chloroacetyl, bromoacetyl, and iodoacetyl groups, urethane-type protecting groups, such as t-butoxycarbonyl ("Boc"), 2-(4-biphenyl)propyl-2-


oxycarbonyl ("Bpoc"), 2-phenylpropyl-2-oxycarbonyl ("Poc"), 2-(4-xenyl)isopropoxycarbonyl, 1,1-diphenylethyl-1-oxycarbonyl, 1,1-diphenylpropyl-1-oxycarbonyl, 2-(3,5-dimethoxyphenyl)propyl-2-oxycarbonyl ("Ddz"), 2-(*p*-toluyl)propyl-2-oxycarbonyl, cyclopentanyloxycarbonyl, 1-methylcyclopentanyl-oxycarbonyl, cyclohexanyloxy-carbonyl, 1-methyl-cyclohexanyloxycarbonyl, 2-methylcyclohexanyl-oxycarbonyl, 2-(4-toluylsulfonyl)ethoxycarbonyl, 2-(methylsulfonyl)ethoxycarbonyl, 2-(triphenylphosphino)-ethoxycarbonyl, 9-fluorenylmethoxycarbonyl ("Fmoc"), 2-(trimethylsilyl)ethoxycarbonyl, allyloxycarbonyl, 1-(trimethylsilylmethyl)prop-1-enyloxycarbonyl, 5-benzisoxazylmethoxycarbonyl, 4-acetoxybenzyl-oxycarbonyl, 2,2,2-trichloroethoxycarbonyl, 2-ethynyl-2-propoxycarbonyl, cyclopropylmethoxycarbonyl, isobornyloxycarbonyl, 1-piperidyloxycarbonyl, benzyloxycarbonyl ("Cbz"), 4-phenylbenzyloxycarbonyl, 2-methylbenzyloxycarbonyl, α -2,4,5,-tetramethylbenzyl-oxycarbonyl ("Tmz"), 4-methoxybenzyloxycarbonyl, 4-fluorobenzyloxycarbonyl, 4-chlorobenzyloxycarbonyl, 3-chlorobenzyloxycarbonyl, 2-chlorobenzyloxycarbonyl, 2,4-dichlorobenzyloxycarbonyl, 4-bromobenzyloxycarbonyl, 3-bromobenzyloxycarbonyl, 4-nitrobenzyloxycarbonyl, 4-cyanobenzyloxycarbonyl, 4-(decyloxy)benzyloxycarbonyl and the like; the benzoylmethylsulfonyl group, the 2,2,5,7,8-pentamethylchroman-6-sulfonyl group ("PMC"), the dithiasuccinoyl ("Dts") group, the 2-(nitro)phenyl-sulfenyl group ("Nps"), the diphenylphosphine oxide group, and like amino-protecting groups. The species of amino-protecting group employed is not critical so long as the derivatized amino group is stable to the conditions of the subsequent reaction(s) and can be removed at the appropriate point without disrupting the remainder of the molecule. Preferred amino-protecting groups are Boc, Cbz and Fmoc. Further examples of amino-protecting groups embraced by the above term are well known in organic synthesis and the peptide art and are described by, for example, T.W. Greene and P.G.M. Wuts, "Protective Groups in Organic Synthesis," 2nd ed., John Wiley and Sons, New York, NY, 1991, Chapter 7, M. Bodanzsky, "Principles of Peptide Synthesis," 1st and 2nd revised Ed., Springer-Verlag, New York, NY, 1984 and 1993, and J.M. Stewart and J.D. Young, "Solid Phase Peptide Synthesis," 2nd Ed.,

Pierce Chemical Co., Rockford, IL, 1984, E. Atherton and R.C. Shephard, "Solid Phase Peptide Synthesis - A Practical Approach" IRL Press, Oxford, England (1989), each of which is incorporated herein by reference. The related term "protected amino" defines an amino group substituted with an amino-protecting group discussed above.

5 The terms "natural and unnatural amino acid" refers to both the naturally occurring amino acids and other non-proteinogenic α -amino acids commonly utilized by those in the peptide chemistry arts when preparing synthetic analogues of naturally occurring peptides, including D and L forms. The naturally occurring amino acids are glycine, alanine, valine, leucine, isoleucine, serine, methionine, threonine, 10 phenylalanine, tyrosine, tryptophan, cysteine, proline, histidine, aspartic acid, asparagine, glutamic acid, glutamine, γ -carboxyglutamic acid, arginine, ornithine and lysine. Examples of unnatural alpha-amino acids include hydroxylysine, citrulline, kynurenine, (4-aminophenyl)alanine, 3-(2'-naphthyl)alanine, 3-(1'-naphthyl)alanine, methionine sulfone, (t-butyl)alanine, (t-butyl)glycine, 4-hydroxyphenyl-glycine, 15 aminoalanine, phenylglycine, vinylalanine, propargyl-glycine, 1,2,4-triazolo-3-alanine, thyonine, 6-hydroxytryptophan, 5-hydroxytryptophan, 3-hydroxy-kynurenine, 3-aminotyrosine, trifluoromethylalanine, 2-thienylalanine, (2-(4-pyridyl)ethyl)cysteine, 3,4-dimethoxy-phenylalanine, 3-(2'-thiazolyl)alanine, ibotenic acid, 1-amino-1-cyclopentane-carboxylic acid, 1-amino-1-cyclohexanecarboxylic acid, quisqualic acid, 20 3-(trifluoromethylphenyl)alanine, (cyclohexyl)glycine, thiohistidine, 3-methoxytyrosine, norleucine, norvaline, alloisoleucine, homoarginine, thioproline, dehydro-proline, hydroxyproline, homoproline, indoline-2-carboxylic acid, 1,2,3,4-tetrahydroisoquinoline-3-carboxylic acid, 1,2,3,4-tetrahydroquinoline-2-carboxylic acid, α -amino-n-butyric acid, cyclohexylalanine, 2-amino-3-phenylbutyric acid, 25 phenylalanine substituted at the ortho, meta, or para position of the phenyl moiety with one or two of the following groups: a (C₁ to C₄)alkyl, a (C₁ to C₄)alkoxy, a halogen or a nitro group, or substituted once with a methylenedioxy group; β -2- and 3-thienylalanine; β -2- and 3-furanylalanine; β -2-, 3- and 4-pyridylalanine; β -(benzothienyl-2- and 3-yl)alanine; β -(1- and 2-naphthyl)alanine; O-alkylated 30 derivatives of serine, threonine or tyrosine; S-alkylated cysteine, S-alkylated

homocysteine, the O-sulfate, O-phosphate and O-carboxylate esters of tyrosine; 3-(sulfo)tyrosine, 3-(carboxy)tyrosine, 3-(phospho)tyrosine, the 4-methane-sulfonic acid ester of tyrosine, 4-methanephosphonic acid ester of tyrosine, 3,5-diiodotyrosine, 3-nitrotyrosine, ϵ -alkyllysine, and delta-alkyl ornithine. Any of these α -amino acids may 5 be substituted with a methyl group at the alpha position, a halogen at any position of the aromatic residue on the α -amino side chain, or an appropriate protective group at the O, N, or S atoms of the side chain residues. Appropriate protective groups are discussed above.

Depending on the choice of solvent and other conditions known to the 10 practitioner skilled in the art, compounds of this invention may also take the ketal or acetal form, which forms are included in the instant invention. In particular, compounds of Formula I in which R³ is a hydrogen atom (*i.e.*, Formula Ia) may exist in the cyclic ketal or acetal form Formula Ia' shown below:



In addition, it should be understood that the equilibrium forms of the compounds of this invention may include tautomeric forms. All such forms of these compounds are expressly included in the present invention.

The compounds of this invention may be modified by appropriate 20 functionalities to enhance selective biological properties. Such modifications are known in the art and include those which increase biological penetration into a given biological system (*e.g.*, blood, lymphatic system, central nervous system), increase oral availability, increase solubility to allow administration by injection, alter metabolism and alter rate of exertion. In addition, the compounds may be altered to pro-drug form 25 such that the desired compound is created in the body of the patient as the result of the

action of metabolic or other biochemical processes on the pro-drug. Some examples of pro-drug forms include ketal, acetal, oxime, and hydrazone forms of compounds which contain ketone or aldehyde groups, especially where they occur in the group denoted as "A" in Formula I or the modified aspartic acid residue attached to the group denoted as
5 "A".

Compounds of this invention with respect to the groups R¹, R², and X in Formula I, include those wherein:

R¹ is substituted phenyl (such as 2-substituted phenyl), naphthyl, or substituted naphthyl;

10 R² is hydrogen, lower alkyl, (CH₂)_pCO₂R³, (CH₂)_mphenyl, (CH₂)_m(substituted phenyl), (CH₂)_m(1 or 2-naphthyl), or (CH₂)_mtetrazolyl, where p is 1 or 2, m is 1 or 2;

R³ is hydrogen or alkyl;

X is O or NH;

15 q is 1; and

n is 0 or 1.

Other compounds of this invention with respect to the groups R¹, R², and X in Formula I, include those wherein:

20 R¹ is substituted phenyl, naphthyl, or substituted naphthyl;

R₂ is (CH₂)_mtetrazolyl, where m is 1 or 2; and

X is C=ONH.

Compounds of this invention with respect to the group "A" in Formula I, include those of Formula IIa wherein:

25 R⁴ is lower alkyl, cycloalkyl, phenyl, substituted phenyl, (CH₂)_mNH₂, (CH₂)_pOR¹¹, (CH₂)_pSR¹², (CH₂)_mcycloalkyl,

(CH₂)_mphenyl, (CH₂)_m(substituted phenyl), or (CH₂)_m(1 or 2-naphthyl);

R¹¹ is hydrogen, lower alkyl, cycloalkyl, phenyl, substituted phenyl, naphthyl, (CH₂)_mcycloalkyl, (CH₂)_mphenyl, (CH₂)_m(substituted phenyl), or (CH₂)_m(1 or 2-naphthyl);

R¹² is lower alkyl, cycloalkyl, phenyl, substituted phenyl, naphthyl, (CH₂)_mcycloalkyl, (CH₂)_mphenyl, (CH₂)_m(substituted phenyl), or (CH₂)_m(1 or 2-naphthyl); and

m is 1, 2, 3, 4 and p is 1 or 2.

10 Compounds of this invention with respect to the group "A" in Formula I, also include those of Formula IIb wherein:

R⁵ is phenyl, substituted phenyl, (CH₂)_pphenyl, (CH₂)_p(substituted phenyl), cycloalkyl, or 2-indanyl; and

p is 1 or 2.

15 Another group of compounds with respect to the group "A" in Formula I, include those of Formula IIc wherein:

R⁷ is hydrogen, fluorine, cycloalkyl, phenyl, substituted phenyl, naphthyl, (CH₂)_mcycloalkyl, (CH₂)_mphenyl, (CH₂)_m(substituted phenyl), (CH₂)_m(1 or 2-naphthyl), OR¹¹, or SR¹²;

20 R¹¹ and R¹² are independently cycloalkyl, phenyl, substituted phenyl, naphthyl, (CH₂)_mcycloalkyl, (CH₂)_mphenyl, (CH₂)_m(substituted phenyl), or (CH₂)_m(1 or 2-naphthyl); and

m is 1, 2, 3 or 4.

A forth group of compounds with respect to the group "A" in Formula I, 25 include those of Formula IIe wherein:

R⁸ is hydrogen, oxo, cycloalkyl, phenyl, substituted phenyl, or naphthyl; and

Y^1 is CH_2 , $(CH_2)_2$, $(CH_2)_3$, or S.

Another group of compounds with respect to the group "A" in Formula I, include those of Formula IIh wherein:

a is 0 and b is 1 or 2.

5 Compounds of this invention with respect to the group "B" in Formula I, include those wherein:

B is hydrogen, 2-benzoxazolyl, substituted 2-oxazolyl, CH_2ZR^{16} , $CH_2OCO(aryl)$, or $CH_2OPO(R^{17})R^{18}$, where Z is O or S;

10 R^{16} is phenyl, substituted phenyl, naphthyl, substituted naphthyl, heteroaryl, $(CH_2)_m$ phenyl, $(CH_2)_n$ (substituted phenyl), $(CH_2)_m$ (1 or 2-naphthyl), or $(CH_2)_m$ heteroaryl;

R^{17} and R^{18} are independently alkyl, cycloalkyl, phenyl, substituted phenyl, naphthyl, phenylalkyl, substituted phenylalkyl and (cycloalkyl)alkyl.

15 Another group of compounds with respect to the group "B" in Formula I, include those of Formula IIIa-c wherein:

Y^2 is O or NR^{24} ;

Y^3 is CH_2 , O, or NR^{24} ;

20 R^{19} and R^{20} are independently hydrogen, alkyl, phenyl, or R^{19} and R^{20} taken together are $-(CH=CH)_2-$;

R^{21} is hydrogen, alkyl, phenyl, substituted phenyl, $(CH_2)_m$ phenyl, or $(CH_2)_n$ (substituted phenyl);


R^{22} , R^{23} and R^{24} are independently hydrogen or alkyl.

25 The compounds of Formula I may be synthesized using conventional techniques as discussed below. Advantageously, these compounds are conveniently synthesized from readily available starting materials. To this end, in the following





synthetic schemes, q is 1, and corresponding compounds wherein q is 2 may be made in the same manner by employing the corresponding ethylene (-CH₂CH₂-) starting material in place of the methylene (-CH₂-) moiety.

One synthetic route for synthesizing the instant compounds is set forth in
5 the following Scheme 1:

SCHEME 1



In the above Scheme 1, Formula (V), that is $\text{H}_2\text{N}-\text{C}$, is a modified aspartic acid residue of Formulas Va through Vd:



In the above Scheme 1, "PG" stands for an amino protecting group and "A" stands for a natural or unnatural amino acid of formula IIa through IIi, as discussed above. In Formula Vb through Vd, R³ is a carboxyl protecting group as described in the 5 definition of R³ in Formula I with the exception that R³ cannot be a hydrogen atom.

The modified aspartic acids of Formula Va-d can be prepared by methods well known in the art. See, for example, European Patent Application 519,748; PCT Patent Application No. PCT/EP92/02472; PCT Patent Application No. PCT/US91/06595; PCT Patent Application No. PCT/US91/02339; European Patent 10 Application No. 623,592; World Patent Application No. WO 93/09135; PCT Patent Application No. PCT/US94/08868; European Patent Application No. 623,606; European Patent Application No. 618,223; European Patent Application No. 533,226; European Patent Application No. 528,487; European Patent Application No. 618,233; PCT Patent Application No. PCT/EP92/02472; World Patent Application No. WO 15 93/09135; PCT Patent Application No. PCT/US93/03589; and PCT Patent Application No. PCT/US93/00481, all of which are herein incorporated by reference.

The coupling reactions carried out under Step A are performed in the presence of a standard peptide coupling agent such as the combination of the combination of dicyclohexylcarbodiimide(DCC) and 1-hydroxy-benzotriazole(HOBt), 20 as well as the BOP (benzotriazolyloxy-tris-(dimethylamino)phosphonium

hexafluorophosphate) reagent, pyBOP (benzotriazolyloxy-tris(N-pyridinyl)phosphoniumhexafluorophosphate), HBTU (O-benzotriazolytetramethylisouronium-hexafluorophosphate), and EEDQ (1-ethyloxycarbonyl-2-ethoxy-1,2-dihydroquinoline) reagents, the combination of
5 1-ethyl(3,3'-dimethyl-1'-aminopropyl)carbodiimide (EDAC) and HOBr, and the like, as discussed in J. Jones, "Amino Acid and Peptide Synthesis," Steven G. Davis ed., Oxford University Press, Oxford, pp. 25-41 (1992); M. Bodanzky, "Principles of Peptide Synthesis," Hafner *et al.* ed., Springer-Verlag, Berlin Heidelberg, pp. 9-52 and pp. 202-251 (1984); M. Bodanzky, "Peptide Chemistry, A Practical Textbook,"
10 Springer-Verlag, Berlin Heidelberg, pp. 55-73 and pp. 129-180; and Stewart and Young, "Solid Phase Peptide Synthesis," Pierce Chemical Company, (1984), all of which are herein incorporated by reference. The amino protecting group is then removed and the resulting amine is coupled to the (substituted) carboxylic acid of Formula VII (Step B). Again, this coupling reaction uses the standard peptide coupling
15 reactions mentioned above.


Alternatively, the (substituted)carboxylic acid of Formula VII can be coupled to an amino ester of Formula IX (Step D). Again, this coupling reaction uses the standard peptide coupling reactions mentioned above. In Formula IX, the group R is a carboxyl protecting group such as methyl, allyl, benzyl or tert-butyl. After removal of
20 the carboxyl protecting group under standard conditions well known in the art, the resulting carboxylic acid is coupled to amine V using the standard peptide coupling methods described above (Step E).

In the case where the coupling reaction depicted by either Step A or Step E was carried out with the amino alcohol of Formula Vc, the alcohol moiety must be
25 oxidized to the corresponding carbonyl compound prior to removal of the protecting groups. Preferred methods for the oxidation reaction include Swern oxidation (oxalyl chloride-dimethyl sulfoxide, methylene chloride at -78°C followed by triethylamine); and Dess-Martin oxidation (Dess-Martin periodinane, t-butanol, and methylene chloride.) The protecting groups contained in substructures of the Formula Va-d, VII

and A are removed by methods well known in the art. These reactions and removal of some or all of the protecting groups are involved in Step C in the above Scheme 1.

An alternative synthetic route for synthesizing the instant compounds is set forth in the following Scheme 2:

SCHEME 2



In the above Scheme 2, "PG" stands for an amino protecting group and "A" stands for a natural or unnatural amino acid of formula IIa through IIIi, as discussed


above. The group R is a carboxyl protecting group such as trimethylsilyl, methyl, allyl, benzyl or tert-butyl.

The coupling reactions carried out under Step F and Step G are performed in the presence of a standard peptide coupling agent as discussed above. In 5 Step G, the amino protecting group must be removed prior to the coupling step. In Step H the alpha-carboxy protecting group R of the compound of Formula XIII is selectively removed and the resulting mono-carboxylic acid treated sequentially with diazomethane and hydrobromic acid to give the alpha-bromoketone of Formula XIV.

In Step I, the bromoketone of Formula XIV is treated with either 10 $R^{16}Z-H$, $(aryl)-CO_2H$, $(heteroaryl)-CO_2H$, or $R^{17}(R^{18})PO_2H$ in the presence of an inorganic base such as potassium carbonate or potassium fluoride in an inert solvent such as dimethyl formamide to give the corresponding compound of Formula I in which B is CH_2ZR^{16} , $CH_2OCO(aryl)$, $CH_2OCO(heteroaryl)$, or $CH_2OPO(R^{17})R^{18}$, respectively. Compounds of Formula I in which B is a fragment of Formula III may 15 also be prepared in a similar fashion. The protecting groups contained in substructures of the Formula VII, XI and A are removed by methods well known in the art. These reactions and removal of some or all of the protecting groups are involved in Step I in the above Scheme 2.

An alternative method for the preparation of compounds of the instant 20 invention of Formula I in which R^3 and B are both hydrogen (*i.e.*, Formula Ib) is set forth below in Scheme 3:

SCHEME 3



In Scheme 3, Fmoc is the amino protecting group 9-fluorenylmethoxycarbonyl and the shaded circle labeled "PS" represents polystyrene resin.

The coupling of the acid of Formula XV to a primary amine on solid support, preferably aminomethyl polystyrene, is carried out using standard peptide coupling agents, preferably using benzotriazolyloxy-tris(N-pyrrolidinyl)phosphoniumhexafluorophosphate (pyBOP) in a inert solvent such as dimethylformamide or N-methyl pyrrolidone (Step J). After removal of the Fmoc protecting group of XVI by treatment with pyrrolidine-dimethylformamide, the resulting amine is coupled to Fmoc-amino acid of Formula IVa using standard peptide coupling conditions as discussed above (Step K).

In Step L the Fmoc protecting group of the compound of Formula XVII is removed again by treatment with pyrrolidine-dimethylformamide and the resulting amine coupled to the (substituted)carboxylic acid of Formula VII again using standard peptide coupling conditions as discussed above. The tert-butyl ester of the compound of Formula XVIII is removed by treatment with trifluoroacetic acid-methylene chloride in the presence of a trapping agent such as anisole and the resulting acid cleaved from the solid support by treatment with 37% aqueous formaldehyde/acetic acid/tetrahydrofuran/ trifluoroacetic acid, preferably in a ratio of 1/1/5/0.025, to give the aspartyl aldehyde of Formula Ib (Step M).

Pharmaceutical compositions of this invention comprise any of the compounds of the present invention, and pharmaceutically acceptable salts thereof, with any pharmaceutically acceptable carrier, adjuvant or vehicle (hereinafter collectively referred to as "pharmaceutically-acceptable carriers"). Pharmaceutically acceptable carriers, adjuvants and vehicles that may be used in the pharmaceutical compositions of this invention include, but are not limited to, ion exchange, alumina, aluminum stearate, lecithin, serum proteins, such as human serum albumin; buffer substances such as the various phosphates, glycine, sorbic acid, potassium sorbate, partial glyceride mixtures of saturated vegetable fatty acids; water, salts or electrolytes, such as protamine sulfate, disodium hydrogen phosphate, potassium hydrogen phosphate, sodium chloride, and

zinc salts; colloidal silica, magnesium trisilicate, polyvinyl pyrrolidone, cellulose-based substances, polyethylene glycol, sodium carboxymethylcellulose, polyarylates, waxes, polyethylene-polyoxypropylene-block polymers, polyethylene glycol and wool fat, and the like.

5 The pharmaceutical compositions of this invention may be administered orally, parenterally, by inhalation spray, topically, rectally, nasally, buccally, vaginally or by an implanted reservoir. Oral and parenteral administration are preferred. The term "parenteral" as used herein includes subcutaneous, intracutaneous, intravenous, intramuscular, intra-articular, intrasynovial, intrasternal, intrathecal, intralesional and
10 intracranial injection or infusion techniques.

The pharmaceutical compositions may be in the form of a sterile injectable preparation, for example, as a sterile injectable aqueous or oleaginous suspension. This suspension may be formulated according to techniques known in the art using suitable dispersing or wetting agents (such as, for example, Tween 80) and
15 suspending agents. The sterile injectable preparation may also be a sterile injectable solution or suspension in a non-toxic parenterally-acceptable diluent or solvent, for example, as a solution in 1,3-butanediol. Among the acceptable vehicles and solvents that may be employed are mannitol, water, Ringer's solution and isotonic sodium chloride solution. In addition, sterile, fixed oils are conventionally employed as a
20 solvent or suspending medium. For this purpose, any bland fixed oil may be employed including synthetic mono- or diglycerides. Fatty acids, such as oleic acid and its glyceride derivatives are useful in the preparation of injectables, as are natural pharmaceutically-acceptable oils, such as olive oil or castor oil, especially in their polyoxyethylated versions. These oil solutions or suspensions may also contain a
25 long-chain alcohol diluent or dispersant.

30 The pharmaceutical compositions of this invention may be orally administered in any orally acceptable dosage form including, but not limited to, capsules, tablets, and aqueous suspensions and solutions. In the case of tablets for oral use, carrier which are commonly used include lactose and corn starch. Lubricating agents, such as magnesium stearate, are also typically added. For oral administration in

capsule form useful diluents include lactose and dried corn starch. When aqueous suspensions are administered orally, the active ingredient is combined with emulsifying and suspending agents. If desired, certain sweetening and/or flavoring and/or coloring agents may be added.

5 The pharmaceutical compositions of this invention may also be administered in the form of suppositories for rectal administration. These compositions can be prepared by mixing a compound of this invention with a suitable non-irritating excipient which is solid at room temperature but liquid at the rectal temperature. Such materials include, but are not limited to, cocoa butter, beeswax and polyethylene
10 glycols.

Topical administration of the pharmaceutical compositions of this invention is especially useful when the desired treatment involves areas or organs readily accessible to topical application. For application topically to the skin, the pharmaceutical composition should be formulated with a suitable ointment containing
15 the active components suspended or dissolved in a carrier. Carriers for topical administration of the compounds of this invention include, but are not limited to, mineral oil, liquid petroleum, white petroleum, propylene glycol, polyoxyethylene, polyoxypropylene compound, emulsifying wax and water. Alternatively, the pharmaceutical composition can be formulated with a suitable lotion or cream
20 containing the active compound suspended or dissolved in a carrier. Suitable carriers include, but are not limited to, mineral oil, sorbitan monostearate, polysorbate 60, cetyl esters wax, cetearyl alcohol, 2-octyldodecanol, benzyl alcohol and water. The pharmaceutical compositions of this invention may also be topically applied to the lower intestinal tract by rectal suppository formulation or in a suitable enema
25 formulation. Topically-applied transdermal patches are also included in this invention.

The pharmaceutical compositions of this invention may be administered by nasal aerosol or inhalation. Such compositions are prepared according to techniques well-known in the art of pharmaceutical formulation and may be prepared as solutions in saline, employing benzyl alcohol or other suitable preservatives, absorption

promoters to enhance bioavailability, fluorocarbons, and/or other solubilizing or dispersing agents known in the art.

The compounds of this invention may be used in combination with either conventional anti-inflammatory agents or with matrix metalloprotease inhibitors,
5 lipoxygenase inhibitors and antagonists of cytokines other than IL-1 β .

The compounds of this invention can also be administered in combination with immunomodulators (e.g., bropirimine, anti-human alpha interferon antibody, IL-2, GM-CSF, methionine enkephalin, interferon alpha, diethyldithiocarbamate, tumor necrosis factor, naltrexons and rEPO) or with
10 prostaglandins, to prevent or combat IL-1-mediated disease symptoms such as inflammation.

When the compounds of this invention are administered in combination therapies with other agents, they may be administered sequentially or concurrently to the patient. Alternatively, pharmaceutical compositions according to this invention
15 may be comprised of a combination of a compound of Formula I and another therapeutic or prophylactic agent mentioned above.

The disease states which may be treated or prevented by the instant pharmaceutical compositions include, but are not limited to, inflammatory diseases, autoimmune diseases and neurodegenerative diseases, and for inhibiting unwanted
20 apoptosis involved in ischemic injury, such as ischemic injury to the heart (e.g., myocardial infarction), brain (e.g., stroke), and kidney (e.g., ischemic kidney disease). As a consequence of their ability to inhibit apoptosis, the present pharmaceutical compositions are also useful for the repopulation of hematopoietic cells of a patient following chemotherapy. Methods of administering an effective amount of the
25 above-described pharmaceutical compositions to mammals, also referred to herein as patients, in need of such treatment (that is, those suffering from inflammatory diseases, autoimmune diseases, neurodegenerative diseases and for the repopulation of hematopoietic cells in cancer patients who have undergone chemotherapy) are another aspect of the instant invention. Finally, as a further consequence of their ability to

inhibit apoptosis, the instant pharmaceutical compositions may be used in a method to prolong the viability of organs to be used in transplantations.

Inflammatory disease which may be treated or prevented include, for example, septic shock, septicemia, and adult respiratory distress syndrome. Target 5 autoimmune diseases include, for example, rheumatoid, arthritis, systemic lupus erythematosus, scleroderma, chronic thyroiditis, Graves' disease, autoimmune gastritis, insulin-dependent diabetes mellitus, autoimmune hemolytic anemia, autoimmune neutropenia, thrombocytopenia, chronic active hepatitis, myasthenia gravis and multiple sclerosis. Target neurodegenerative diseases include, for example, 10 amyotrophic lateral sclerosis, Alzheimer's disease, Parkinson's disease, and primary lateral sclerosis. The pharmaceutical compositions of this invention may also be used to promote wound healing. Target diseases associated with harmful, apoptosis, in other words, those associated with ischemic injury, includes myocardial infarction, stroke, and ischemic kidney disease. The pharmaceutical compositions of this invention may 15 also be used to treat infectious diseases, especially those involved with viral infections.

The term "effective amount" refers to dosage levels of the order of from about 0.05 milligrams to about 140 milligrams per kilogram of body weight per day for use in the treatment of the above-indicated conditions (typically about 2.5 milligrams to about 7 grams per patient per day). For example, inflammation may be effectively 20 treated by the administration of from about 0.01 to 50 milligrams of the compound per kilogram of body weight per day (about 0.5 milligrams to about 3.5 grams per patient per day).

The amount of the compounds of Formula I that may be combined with the carrier materials to produce a single dosage form will vary depending upon the host 25 treated and the particular mode of administration. For example, a formulation intended for the oral administration of humans may contain from 0.5 milligrams to 5 grams of a compound of Formula I combined with an appropriate and convenient amount of a pharmaceutically-acceptable carrier which may vary from about 5 to about 95 percent of the total composition. Dosage unit forms will generally contain between from about 30 1 milligram to about 500 milligrams of an active compound of Formula I.


It will be understood, however, that the specific "effective amount" for any particular patient will depend upon a variety of factors including the activity of the specific compound employed, the age, body weight, general health, sex, diet, time of administration, route of administration, rate of excretion, drug combination and the 5 severity of the particular disease undergoing prevention or therapy.

Although this invention focuses on the use of the compounds disclosed herein for preventing and treating IL-1-mediated diseases, the compounds of this invention can also be used as inhibitory agents for other cysteine proteases.

The compounds of this invention are also useful as commercial reagents 10 which effectively bind to the ICE/ced-3 family of cysteine protease or other cysteine proteases. As commercial reagents, the compounds of this invention, and their derivatives, may be used to block proteolysis of a target peptide or may be derivatized to bind to a stable resin as a tethered substrate for affinity chromatography applications. These and other uses which characterize commercial cysteine protease inhibitors will be 15 evident to those of ordinary skill in the art.

In order that this invention be more fully understood, the following examples are set forth. These examples are for the purpose of illustration only and are not to be construed as limiting the scope of the invention in any way.

In the following Examples, proton NMR spectra were obtained at 300 20 MHz; chemical shifts are quoted downfield from internal tetramethylsilane.

PREPARATION 1

**Preparation of (3S)-Amino-4-Oxobutanoic Acid
tert-Butyl Ester Semicarbazone, p-Toluenesulfonate Salt**

5 Part A: N-(Benzoyloxycarbonyl)-L-(N'-Methyl-N'-Methoxy)aspartamide β-(tert-Butyl) Ester

To a solution of N-(benzyloxycarbonyl)-L-aspartic acid-β-(tert-butyl) ester (14.65 g, 45.3 mmol, Bachem) in CH₂Cl₂ (150 mL) at 0°C (ice bath) under a nitrogen atmosphere was added 1-hydroxybenzotriazole hydrate (7.29 g, 47.6 mmol, 10 Aldrich) followed by 1-ethyl-3-(3',3'-dimethyl-1'-aminopropyl)carbodiimide hydrochloride (9.55 g, 49.8 mmol, Sigma). After stirring at 0°C for 15 min., N,O-dimethylhydroxylamine hydrochloride (5.10 g, 52.3 mmol, Aldrich) and N-methylmorpholine (5.8 mL, 53 mmol, Aldrich) were added. The mixture was allowed to warm to room temperature over 3 hours then stirred at room temperature for 16 15 hours. The solution was concentrated under vacuum and the residue partitioned between ethyl acetate-5% KHSO₄ (200 mL each). The organic phase was washed in turn with 5% KHSO₄, saturated sodium bicarbonate and saturated sodium chloride solutions; dried over anhydrous sodium sulfate and evaporated to an oil. The oil was crystallized from hexane to give the title product (16.10 g, 97% yield) as a fluffy white 20 crystalline solid. TLC (ethyl acetate), single spot (UV and PMA): R_f=0.37.

A similar procedure to the one above, starting with 29.3 g of N-(benzyloxycarbonyl)-L-aspartic acid-β-(tert-butyl)ester (2-fold scale up) gave 31.18 g (94% yield) of the title product.

Part B: (3S)-(Benzylloxycarbonyl)Amino-4-Oxobutanoic Acid tert-Butyl Ester Semicarbazone

To a solution of N-(benzylloxycarbonyl)-L-(N'-methyl-N'-methoxy)aspartamide- β -(tert-butyl) ester (15.50 g, 42.3 mmol) in anhydrous ether (400 mL) at 0°C (ice bath) under a nitrogen atmosphere was added dropwise to a 1.0 M solution of LiAlH₄ in ether (22.0 mL, 22.0 mmol, Aldrich) at such a rate as to keep the reaction solution temperature between 0-5°C (addition time 15-20 min). After the addition of the lithium aluminum hydride reagent was complete, the mixture was stirred at 0-5°C for 1 hr, then quenched by the dropwise addition of 0.3 N KHSO₄ solution (100 mL). The resultant mixture was transferred to a separatory funnel adding sufficient 5% KHSO₄ solution (75 mL) to dissolve the solids. The organic phase was separated and the combined aqueous washes back-extracted with ether (100 mL). The combined ether extracts were washed with saturated NaCl solution, dried over anhydrous sodium sulfate and concentrated in vacuo with minimal heating. TLC (ethyl acetate): streaky spot (UV and PMA) R_f=0.48. TLC (methanol/methylene chloride, 1:9) major spot (UV and PMA): R_f=0.75.

The crude aldehyde was immediately taken up in aqueous ethanol (45 mL water/105 mL alcohol), placed in an ice bath and treated with sodium acetate (3.82 g, 46.6 mmol) and semicarbazide hydrochloride (5.20 g, 46.6 mmol, Aldrich). The mixture was stirred at 0°C (ice bath) under a nitrogen atmosphere for 3 hrs, allowed to warm to room temperature, and stirred overnight (16 hrs). Most of the ethanol was removed under vacuum and the residue partitioned between ethyl acetate and water (100 mL each). The organic phase was washed sequentially with 5% KHSO₄, saturated sodium bicarbonate and saturated sodium chloride solutions; dried over anhydrous sodium sulfate and evaporated to dryness. The crude product of this reaction was combined with that of two similar procedures starting with 15.40 g and 4.625 g of N-(benzylloxycarbonyl)-L-(N'-methyl-N'-methoxy)aspartamide- β -(tert-butyl) ester (total: 35.525 g, 97 mmol) and these combined products were purified by flash chromatography on silica gel eluting with acetone/methylene chloride (3:7) then methanol-acetone-methylene chloride (0.5:3:7) to give pure title product (27.73 g,

78.5%) as a colorless foam. TLC (MeOH-CH₂Cl₂, 1:9): single spot (UV and PMA), Rf=0.51.

Part C: (3S)-Amino-4-Oxobutanoic Acid tert-Butyl Ester Semicarbazone, p-Toluenesulfonate Salt

5 To a solution of (3S)-(benzyloxycarbonyl)amino-4-oxobutanoic acid tert-butyl ester semicarbazone (13.84 g, 38.0 mmol) in absolute ethanol (250 mL) was added 10% Pd/C (1.50 g, Aldrich) and the resulting mixture stirred under an atmosphere of hydrogen (balloon) until TLC (methanol/methylene chloride, 1:9) indicated complete consumption of the starting material (60 min). Note: It is important
10 to follow this reaction closely since the product can be over-reduced. The mixture was filtered through Celite and evaporated to an oil. The oil was chased with methylene chloride (2 x 75mL) then with methylene chloride/toluene (1:1, 75 mL) to give the crude amine as a white crystalline solid. TLC (EtOAc-pyridine-AcOH-H₂O; 60:20:5:10) single spot (UV and PMA) Rf=0.24. Note: In this TLC system, any over-reduced product will show up immediately below the desired product, Rf=0.18 (PMA only).


15

The crude amine was taken up in CH₃CN (60 mL) and treated with a solution of p-toluenesulfonic acid monohydrate (7.22 g, 38.0 mmol) in acetonitrile (60 mL). The crystalline precipitate was collected, washed with acetonitrile and ether, and air-dried to give the title compound (13.95 g, 92% yield) as a white, crystalline solid.

20

The optical purity of this material was checked by conversion to the corresponding Mosher amide [1.05 equiv (R)-(-)- α -methoxy- α -(trifluoromethyl)phenylacetyl chloride, 2.1 equivalents of i-Pr₂NEt in CH₂Cl₂, room temperature, 30 min]. The desired product has a doublet at 7.13 ppm (1H, d, J=2.4 Hz, CH=N) while the corresponding signal for its diastereomer is at 7.07 ppm. The optical purity of the title compound obtained from the above procedure is typically > 95:5.

25

PREPARATION 2

**Preparation of (3S)-3-(9-Fluorenylmethoxycarbonyl)Amino-4-Oxobutanoic Acid
tert-Butyl Ester Semicarbazonyl-4-[2'-(4-Ethyl-Phenoxyacetic Acid)]**

5 Part A: 4-[2'-(N-t-Butoxycarbonyl)Aminoethyl]Phenoxyacetic Acid, Methyl
Ester

To a suspension 4-hydroxy-phenethylamine (7.00 g, 51.1 mmol, Aldrich) in dry dimethylformamide (50 mL) at room temperature under nitrogen was added di-tert-butyl dicarbonate (11.0 g, 50.5 mmol). After stirring at room temperature 10 for 1 hr, the resulting clear solution was treated with methyl bromoacetate (7.5 mL, 79 mmol) and cesium carbonate (17.5 g, 53.7 mmol). After stirring at room temperature for 16 hrs, TLC ($\text{Et}_2\text{O-toluene}$; 2:8) shows some unalkylated material remained ($R_f = 0.43$) and a second portion of methyl bromoacetate (2.0 mL, 21 mmol) and cesium carbonate (4.5 g, 14 mmol) were added. After stirring for an additional 24 hrs, the 15 mixture was partitioned between EtOAc-water (250 mL each), organic phase washed successively with water (3X), 5% potassium bisulfate and saturated NaCl solutions, dried over anhydrous Na_2SO_4 and evaporated to dryness. Trituration of the residue with hexane gave 15.87 g of a tan solid. Filtration of the crude product through a pad of silica gel eluting with EtOAc-hexane (2:8) and crystallization from hexane gave the 20 title compound (14.75, 93%) as a white granular, crystalline solid. TLC ($\text{Et}_2\text{O-toluene}$; 2:8) $R_f = 0.53$.

Part B: 4-(2'-Aminoethyl)Phenoxyacetic Acid, Methyl Ester, Hydrochloride

To a solution 4-[2'-(N-t-butoxycarbonyl)aminoethyl]phenoxyacetic acid, methyl ester (18.31 g, 59.3 mmol) in dioxane (55 mL) at room temperature was added

4.0 N HCl in dioxane (55 mL). After stirring at room temperature for 16 hrs, the mixture was diluted with Et₂O, the precipitate collected, washed thoroughly with Et₂O and dried in vacuo to give the title compound (14.55 g, 94%) was a fluffy white, crystalline solid.

5 Part C: 1-tert-Butoxycarbonyl-Semicarbazidyl-4-[2'-(4-Ethyl-Phenoxyacetic Acid)] Methyl Ester

A solution of t-butyl carbazate (6.60 g, 50 mmol) in dimethylformamide (50 mL) was added dropwise to a solution carbonyldiimidazole (8.10 g, 50 mmol) in dimethylformamide (80 mL) over 40 min at room temperature under nitrogen. After 10 stirring at room temperature for an additional 30 min, 4-(2'-aminoethyl)phenoxyacetic acid, methyl ester, hydrochloride (12.3 g, 50 mmol) was added as a solid in one portion followed by a triethylamine (8.0 ml., 58 mmol) added dropwise over 30 min. After stirring at room temperature for 18 hrs, the mixture was partitioned between EtOAc-water (300 mL each). The organic phase was washed successively with water (3X), 5% 15 potassium bisulfate, saturated sodium bicarbonate, and saturated NaCl solutions, dried over anhydrous Na₂SO₄ and evaporated to dryness. Crystallization of the residue from EtOAc-hexane gave the title compound (15.50, 84%) as an off-white crystalline solid. TLC (MeOH-CH₂Cl₂; 1:9) Rf = 0.45.

20 Part D: 1-tert-Butoxycarbonyl-Semicarbazidyl-4-[2'-(4-Ethyl-Phenoxyacetic Acid)]

A solution of 1-tert-butoxycarbonyl-semicarbazidyl-4-[2'-(4-ethyl-phenoxyacetic acid)] methyl ester (14.68 g, 40 mmol) in dioxane (50 mL) at room temperature under nitrogen was added 1.0 N LiOH solution (50 mL). After stirring at room temperature for 1 hr, the mixture was acidified with conc. HCl and extracted with 25 EtOAc (100 mL). The organic phase was washed with saturated NaCl solution, dried over anhydrous Na₂SO₄ and evaporated to a white solid. Recrystallization of the crude product from THF-EtOAc-hexane gave the title compound (13.44, 95%) as a white crystalline solid. TLC (AcOH-MeOH-CH₂Cl₂; 1:1:8) Rf = 0.31.

Part E: Semicarbazidyl-4-[2'-(4-Ethyl-Phenoxyacetic Acid)] Hydrochloride

To a solution of 1-tert-butoxycarbonyl-semicarbazidyl-4-[2'-(4-ethyl-phenoxyacetic acid)] (13.43 g, 38.0 mmol) in dioxane (80 mL)-anisole (15 mL) at room temperature was added 4.0 N HCl in dioxane (35 mL). After stirring at room 5 temperature for 18 hrs, additional 4.0 N HCl in dioxane (15 mL) was added. After an additional 6 hrs, the precipitate was collected, washed thoroughly with dioxane then Et₂O and dried in vacuo to give the title compound (11.67 g, 100%) was a white, crystalline solid.

Part F: N-(9-Fluorenylmethoxycarbonyl)-L-(N'-Methyl-N'-
10 Methoxy)aspartamide β-(tert-Butyl) Ester

To a solution of N-(9-fluorenylmethoxycarbonyl)-L-aspartic acid-β-(tert-butyl) ester (16.48 g, 40 mmol) in CH₂Cl₂ (80 mL)-tetrahydrofuran (20 mL) at 0°C (ice bath) under a nitrogen atmosphere was added 1-hydroxybenzotriazole hydrate (7.12 g, 46.5 mmol) followed by 1-ethyl-3-(3',3'-dimethyl-1'-aminopropyl)carbodiimide 15 hydrochloride (9.20 g, 48 mmol). After stirring at 0°C for 15 min., N,O-dimethylhydroxylamine hydrochloride (4.68 g, 48 mmol) and N-methylmorpholine (5.2 mL, 47 mmol) were added. The mixture was allowed to warm to room temperature over 2 hours then stirred at room temperature for 16 hours. The solution was concentrated under vacuum and the residue partitioned between ethyl acetate-5% 20 KHSO₄ (200 mL each). The organic phase was washed successively with 5% KHSO₄, saturated sodium bicarbonate and saturated sodium chloride solutions; dried over anhydrous sodium sulfate and evaporated to an oil. Purification of the crude product by flash chromatography on silica gel eluting with EtOAc-hexane (30:70 then 35:65) gave the title product (17.75 g, 98% yield) as a colorless foam. TLC (EtOAc-hexane; 1:1)
25 R_f=0.35.

Part G: (3S)-3-(9-Fluorenylmethoxycarbonyl)Amino-4-Oxobutanoic Acid tert-
Butyl Ester Semicarbazonyl-4-[2'-(4-Ethyl-Phenoxyacetic Acid)]

To a solution of N-(9-fluorenylmethoxycarbonyl)-L-(N'-methyl-N'-methoxy)aspartamide-β-(tert-butyl) ester (13.20 g, 29 mmol) in anhydrous ether (250

mL) at 0°C (ice bath) under a nitrogen atmosphere was added dropwise to a 1.0 M solution of LiAlH₄ in ether (14.5 mL, 14.5 mmol) at such a rate as to keep the reaction solution temperature between 0-5°C (addition time 15-20 min). After the addition of the lithium aluminum hydride reagent was complete, the mixture was stirred at 0-5°C
5 for 1 hr, then quenched by the dropwise addition of 0.3 N KHSO₄ solution (100 mL). After adding sufficient 0.3 N KHSO₄ solution to dissolve most of the inorganic salts, the mixture was transferred to a separatory funnel. The organic phase was separated and the aqueous phase back-extracted with ether (100 mL). The combined ether extracts were washed with saturated NaCl solution, dried over anhydrous sodium
10 sulfate and concentrated in vacuo with minimal heating. TLC (EtOAc-hexane): Rf=0.40.

The crude aldehyde was immediately taken up in ethanol (105 mL)-water(45 mL)-tetrahydrofuran(75 mL), placed in an ice bath and treated with sodium acetate (3.20 g, 39 mmol) and semicarbazidyl-4-[2'-(4-ethyl-phenoxyacetic acid)]
15 hydrochloride (8.65 g, 30 mmol). The mixture was stirred at 0°C (ice bath) under a nitrogen atmosphere for 3 hrs, allowed to warm to room temperature, and stirred overnight (16 hrs). The mixture was concentrated on a rotovap, diluted with water and resulting precipitate collected by suction. The material was dried in vacuo to give 18.36 g of crude product as a white solid. The crude product of this reaction was combined
20 with that of a smaller scale reaction (6.34 g) starting with 4.55 g (10 mmol) of N-(9-fluorenylmethoxycarbonyl)-L-(N'-methyl-N'-methoxy)aspartamide-β-(tert-butyl ester) and partitioned between ethyl acetate-tetrahydrofuran(1:1) and 5% KHSO₄. The organic phase was washed with 5% KHSO₄ and saturated sodium chloride solutions, dried over anhydrous sodium sulfate and evaporated to dryness. The residue was
25 purified by filtration through a pad of silica gel eluting with tetrahydrofuran/methylene chloride (1:1). The combined product-containing fractions were evaporated to dryness and recrystallized from tetrahydrofuran-Et₂O to give pure title product (17.01 g, 69%) as a white solid. TLC (AcOH-MeOH-CH₂Cl₂, 1:1:40): Rf=0.19.

PREPARATION 3

Assay for Inhibition of ICE/ced-3 Protease Family Activity

A. Determination of IC₅₀ Values

Fluorescence enzyme assays detecting the activity of the compounds of Formula 1 utilizing the recombinant ICE and CPP32 enzymes are performed essentially according to Thornberry *et al.* (*Nature*, 356:768:774 (1992)) and Nicholson *et al.* (*Nature*, 376:37-43 (1995)) respectively, (herein incorporated by reference) in 96 well microtiter plates. The substrate is Acetyl-Tyr-Val-Ala-Asp-amino-4-methylcoumarin (AMC) for the ICE assay and Acetyl-Asp-Glu-Val-Asp-amino-4-methylcoumarin for the CPP32, Mch2, Mch3 and Mch5 assays. Enzyme reactions are run in ICE buffer (25 mM HEPES, 1 mM EDTA, 0.1% CHAPS, 10% sucrose, pH 7.5) containing 2 mM DTT at room temperature in duplicate. The assays are performed by mixing the following components:

15 50 µL ICE, Mch2, Mch5, CPP32 (18.8, 38, 8.1 and 0.153 nM concentrations, respectively) or Mch3 (1 unit) enzyme in ICE buffer containing either 8.0 (ICE, Mch2, Mch3, CPP32) or 20 (Mch5) mM DTT;

50 µL compound of Formula 1 or ICE buffer (control); and

100 µL of 20 µM substrate.

20 The enzyme and the compound of Formula I to be assayed are allowed to preincubate in the microtitre plate wells for 30 minutes at room temperature prior to the addition of substrate to initiate the reaction. Fluorescent AMC product formation is monitored for one hour at room temperature by measuring the fluorescence emission at 460 nm using an excitation wavelength of 360 nm. The fluorescence change in duplicate (control) wells are averaged and the mean values are plotted as a function of inhibitor concentration to determine the inhibitor concentration producing 50% inhibition (IC₅₀). The results of this assay are set forth below in Table 1 and in Table 3 (for Table 3, see Examples 11 through 52).

The reference compound for this assay was Cbz-ValAlaAsp-H and the values are denoted in Table 1 as "Reference".

Table 1

Ex. No.	mICE IC ₅₀ (μM)	CPP32 IC ₅₀ (μM)	MCH-2 IC ₅₀ (μM)	MCH-3 IC ₅₀ (μM)	MCH-5 IC ₅₀ (μM)
1	0.535	0.141	0.995	1.56	0.680
2	0.336	0.355	>10	2.10	1.20
3	2.55	0.021	0.015	0.587	0.012
4	4.86	0.0038	0.0035	0.130	0.031
5	2.96	0.401	3.61	10.9	0.733
6	0.385	0.054	1.43	1.65	0.048
7	1.89	0.731	1.90	17.0	0.200
8	0.033	0.013	0.037	1.32	0.0076
9	0.087	0.512	0.310	7.24	0.017
10	6.34	0.241	13.1	2.32	6.34
179	0.204	14.0	3.53	>50	1.55
186	0.298	25.3	>50	>50	39.8
188	0.127	0.207	1.01	11.0	0.615
reference	0.064	47.0	>10	>10	2.96

5 B. Determination of the dissociation constant K_i and irreversible rate constant k₃ for irreversible inhibitors

For the irreversible inhibition of a ICE/ced-3 Family Protease enzyme with a competitive irreversible inhibitor; using the model represented by the following formulas:



The product formation at time t may be expressed as:

$$[P]_t = [E]^T \left(\frac{[S]K_i}{[I]K_s} \right) \left(\frac{k_3}{k_3} \right) \left[1 - e^{-k_3 t / (1 + \frac{K_i}{[I]} (1 + \frac{[S]}{K_s}))} \right]$$

Equation 1

where E, I, EI and E-I denote the active enzyme, inhibitor, non-covalent enzyme-inhibitor complex and covalent enzyme-inhibitor adduct, respectively. The K_i value is 5 the overall dissociation constant of the reversible binding steps, and k_3 is the irreversible rate constant. The $[S]$ and K_s values are the substrate concentration and dissociation constant of the substrate bound to the enzyme, respectively. $[E]^T$ is the total enzyme concentration.

The above equations were used to determine the K_i and k_3 values of a 10 given inhibitor bound to a ICE/ced-3 family protease. Thus, a continuous assay was run for sixty minutes at various concentrations of the inhibitor and the substrate. The assay was formulated essentially the same as described above for generating the data in Table 1, except that the reaction was initiated by adding the enzyme to the substrate-inhibitor mixture. The K_i and k_3 values were obtained by simulating the 15 product AMC formation as a function of time according to Equation 1. The results of this second assay are set forth below in Table 2.

The reference compound for this assay was Cbz-ValAlaAsp-CH₂F and the values are denoted in Table 2 as "Reference". The K_i values in Table 2 are in micromolar (μM). The k_3/K_i values are in moles⁻¹ seconds⁻¹ ($M^{-1}s^{-1}$).

20


Table 2

Ex.No.	mICE		CPP32		MCH-2		MCH-5	
	Ki	k_3/Ki	Ki	k_3/Ki	Ki	k_3/Ki	Ki	k_3/Ki
53	0.053	129,000	0.079	207,000	0.038	36,800	0.040	71,700
54	1.09	8,280	0.209	59,300	0.057	64,400	0.059	32,300
55	0.246	33,200	0.186	41,300	0.039	59,400	0.056	20,400
56	0.324	15,400	0.138	105,000	0.053	50,000	0.085	12,800
57	0.120	37,400	0.042	177,000	0.030	91,000	0.066	15,900
59	0.184	46,300	0.942	14,400	0.071	10,100	0.090	17,600
60	0.373	33,500	0.758	8,440	ND	ND	0.467	5.780

Ex.No.	mICE		CPP32		MCH-2		MCH-5	
	Ki	k ₃ /Ki						
61	0.148	93,200	0.360	28,300	ND	ND	0.217	10,100
62	0.253	45,400	0.052	169,000	0.042	44,000	0.048	18,200
63	0.079	52,100	0.012	725,000	0.012	56,900	0.012	17,000
64	0.262	3,630	0.062	19,200	0.153	2,400	0.235	4,260
65	0.305	6,020	0.102	26,800	0.336	0	0.354	230
66	0.442	2,700	0.121	17,800	0.344	48	0.406	460
67	0.218	9,120	0.033	8,560	0.203	0	0.255	700
68	0.355	14,800	0.110	28,800	0.383	1,610	0.821	200
69	0.615	8,400	0.092	21,700	0.951	0	1.30	630
70	0.399	12,100	0.104	49,000	0.357	1,330	0.760	480
71	0.193	53,900	0.039	200,000	0.038	9,980	0.120	9,100
72	0.718	1,620	0.090	6,460	1.16	90	1.04	120
73	0.592	2,170	0.106	9,240	0.862	110	1.03	150
74	0.280	11,900	0.135	35,800	1.25	250	1.08	770
75	0.147	14,700	0.061	60,100	0.221	1,510	0.794	1,470
76	0.090	47,100	0.063	188,000	0.058	81,700	0.081	17,000
77	0.262	11,500	0.123	24,400	0.526	630	1.50	670
78	0.137	20,700	0.038	114,000	0.081	5,140	0.202	9,080
79	0.091	77,500	0.042	268,000	0.006	78,900	0.034	30,200
80	0.926	14,700	0.099	56,600	0.023	13,600	0.146	8,040
103	0.063	143,000	0.038	351,000	0.038	39,700	0.025	59,300
104	0.133	50,600	0.054	151,000	0.037	50,200	0.059	15,500
105	0.413	18,000	0.341	44,900	0.233	6,090	0.160	3,700
106	0.167	42,500	0.048	155,000	0.080	52,900	0.134	10,500
107	0.066	106,000	0.014	424,000	0.021	187,000	0.048	27,800
108	0.147	37,900	0.041	140,000	0.037	60,400	0.105	9,890
109	0.453	15,500	0.136	48,300	0.119	16,800	0.219	4,070
110	0.059	64,900	0.035	272,000	0.015	150,000	0.043	18,800
111	0.308	6,500	0.220	21,900	2.16	230	2.87	170
115	0.324	8,740	0.046	127,000	0.054	0	4.67	0
121	0.242	24,800	0.047	114,000	0.120	5,150	0.276	3,200
128	0.213	5,480	0.254	5,240	2.41	83	4.48	0
143	0.205	28,300	0.050	121,000	0.028	8,500	0.037	14,500

	mICE		CPP32		MCH-2		MCH-5	
Ex.No.	Ki	k ₃ /Ki						
144	0.126	42,500	0.054	144,000	0.070	5,800	0.155	6,340
150	0.263	43,700	0.016	698,000	0.009	400,000	0.127	9,340
151	0.349	29,600	0.032	257,000	0.023	88,100	0.270	5,900
152	0.191	29,300	0.029	241,000	0.011	191,000	0.066	16,600
155	0.168	59,800	0.047	206,000	0.015	166,000	0.136	7,910
156	0.438	20,200	0.148	49,700	0.052	14,900	0.293	3,990
157	0.225	39,300	0.257	53,300	0.022	72,000	0.072	11,600
158	0.168	34,300	0.109	98,200	0.022	103,000	0.264	1,610
159	1.37	4,580	1.18	11,700	0.113	15,000	10.7	86
160	1.18	11,400	0.132	33,000	0.093	36,600	0.351	3,680
161	0.098	86,400	0.019	319,000	0.030	149,000	0.105	15,200
162	0.319	22,200	0.044	246,000	0.029	104,000	0.128	5,290
163	0.415	37,800	0.023	308,000	0.012	110,000	0.252	7,960
164	0.467	24,000	0.063	137,000	0.023	91,700	0.223	6,190
165	0.396	25,500	0.020	335,000	0.008	116,000	0.089	13,100
166	0.042	149,000	0.028	317,000	0.011	146,000	0.028	80,000
167	0.501	21,300	0.089	56,200	0.042	52,500	0.126	13,600
174	0.779	6,320	1.15	8,210	0.222	7,720	1.19	1,260
175	2.34	4,000	1.10	10,900	0.149	20,600	0.377	4,090
176	0.480	11,100	3.08	4,330	1.26	1,330	1.16	684
177	0.225	45,600	0.086	89,700	0.047	21,100	0.439	4,370
refer.	0.015	214,000	0.820	12,200	0.594	2,950	0.018	83,300

The following are examples of compounds of the invention.

EXAMPLE 1

**(3S)-3-[N-((1-Naphthoxy)Acetyl)Leucinyl]
Amino-4-Oxobutanoic Acid**

5 Part A: (3S)-3-[(N-Benzylloxycarbonyl)Leucinyl]Amino-4-Oxobutanoic Acid
tert-Butyl Ester Semicarbazone

To a solution of (N-benzyloxycarbonyl)leucine N-hydroxysuccinimide ester (1.81 g, 5.0 mmol) in CH_2Cl_2 (30 mL) at room temperature under nitrogen was added (3S)-amino-4-oxobutanoic acid tert-butyl ester semicarbazone, p-toluenesulfonate salt (2.58 g, 6.4 mmol) followed by diisopropyl ethylamine (1.2 mL, 6.9 mmol). After stirring at room temperature for 16 hrs, the mixture was concentrated and the residue partitioned between EtOAc -5% KHSO_4 . The organic phase was washed with 5% KHSO_4 , saturated NaHCO_3 and saturated NaCl solutions, dried over anhydrous Na_2SO_4 and evaporated to give the title compound (2.798 g) as a pale yellow foam. TLC($\text{MeOH}-\text{CH}_2\text{Cl}_2$; 1:9) $R_f = 0.52$.

15 Part B: (3S)-3-(Leucinyl)Amino-4-Oxobutanoic Acid tert-Butyl Ester
Semicarbazone

To a solution of crude (3S)-[(N-benzyloxycarbonyl)leucinyl]amino-4-oxobutanoic acid tert-butyl ester semicarbazone (2.798 g, ca. 5.0 mmol) in absolute EtOH (40 mL) was added 10% Pd-C (0.40 g) and resulting mixture stirred under a hydrogen atmosphere (balloon) for 1.5 hrs. The mixture was filtered through Celite washing the filter cake with CH_2Cl_2 and the combined filtrates evaporated to dryness. The residue was chased with CH_2Cl_2 (2X 20 mL) to give the title product (2.113 g) as a colorless foam. TLC($\text{MeOH}-\text{CH}_2\text{Cl}_2$; 1:9) $R_f = 0.23$.

Part C: (3S)-3-[N-((1-Naphthyoxy)Acetyl)Leucinyl]Amino-4-Oxobutanoic Acid tert-Butyl Ester Semicarbazone

To a solution of (1-naphthyoxy)acetic acid (0.150 g, 0.74 mmol) and (3S)-3-(leucinyl)amino-4-oxobutanoic acid tert-butyl ester semicarbazone (0.360 g, ca 5 0.83 mmol) in N-methylpyrrolidone(2.0 mL)-CH₂Cl₂(2.0 mL) at 0°C (ice bath) under nitrogen was added hydroxybenzotriazole hydrate (0.130 g) followed by 1-ethyl-3-(3',3'-dimethyl-1'-aminopropyl)carbodiimide hydrochloride (0.195 g, 1.02 mmol). After stirring at 0°C for 1 hrs and at room temperature for 5 hrs, the mixture was partitioned between EtOAc-water. The organic phase was washed with water, 5% KHSO₄, 10 saturated NaHCO₃ and saturated NaCl solutions, dried over anhydrous Na₂SO₄ and evaporated to dryness. The crude product was purified by flash chromatography eluting with MeOH-CH₂Cl₂ (2:100 then 5:100) to give the title compound (0.366 g, 94%) as a colorless foam. TLC(MeOH-CH₂Cl₂; 5:95) Rf = 0.20.

Part D: (3S)-3-[N-((1-Naphthyoxy)Acetyl)Leucinyl]Amino-4-Oxobutanoic Acid Semicarbazone


To a solution of (3S)-3-[N-((1-naphthyoxy)acetyl)leucinyl]amino-4-oxobutanoic acid tert-butyl ester semicarbazone (0.366 g, 0.69 mmol) in CH₂Cl₂(2.0 mL)-anisole(0.5 mL) at room temperature under nitrogen was added trifluoroacetic acid (2.0 mL). The resulting solution was stirred at room temperature for 3 hrs, evaporated 20 to dryness and chased with toluene-CH₂Cl₂ (1:1). The residue was triturated with Et₂O to give the title compound (0.354 g, 100%) as an off-white solid. TLC(AcOH-MeOH-CH₂Cl₂; 1:1:20) Rf = 0.25. TLC(EtOAc-pyridine-AcOH-H₂O; 60:20:5:10) Rf = 0.48.

Part E: (3S)-3-[N-((1-Naphthyoxy)Acetyl)Leucinyl]Amino-4-Oxobutanoic Acid

25 A solution of (3S)-3-[N-((1-naphthyoxy)acetyl)leucinyl]amino-4-oxobutanoic acid semicarbazone (0.320 g, 0.68 mmol) in 37% aqueous formaldehyde(1.0 mL)-acetic acid(1.0 mL)-methanol(3.0 mL) was stirred at room temperature under nitrogen for 3.5 hrs. The resulting solution was diluted with water and extracted with EtOAc. The extract was washed with water and saturated NaCl

solution, dried over anhydrous Na_2SO_4 and evaporated to dryness. The residue was taken up in EtOAc, filtered through Celite and evaporated to dryness. The product was taken up in a small amount of dioxane, diluted with water, frozen and lyophilized to give the title compound (0.222 g, 79%) as a fluffy white solid. TLC(EtOAc-pyridine-
5 AcOH-H₂O; 60:20:5:10) R_f = 0.65.

EXAMPLE 2



(3S)-3-[N-((1-Naphthyl)Acetyl)Valinyl]Amino-4-Oxobutanoic Acid


10 Part A: (3S)-3-[(N-Benzylloxycarbonyl)Valinyl]Amino-4-Oxobutanoic Acid
tert-Butyl Ester Semicarbazone

To a solution of (N-benzyloxycarbonyl)valine (2.035 g, 8.10 mmol) in CH_2Cl_2 (80 mL) at 0°C (ice bath) under nitrogen was added hydroxybenzotriazole hydrate (1.15 g) followed by 1-ethyl-3-(3',3'-dimethyl-1'-aminopropyl)carbodiimide hydrochloride (2.33 g, 12.2 mmol). After stirring at 0°C for 10 min, (3S)-amino-4-oxobutanoic acid tert-butyl ester semicarbazone, p-toluenesulfonate salt (3.26 g, 8.10 mmol) followed by N-methylmorpholine (0.89 mL, 8.10 mmol) was added. After stirring at 0°C for 2 hrs and at room temperature for 20 hrs, the mixture was partitioned between EtOAc-water. The organic phase was washed with water, 5% KHSO_4 , saturated NaHCO_3 and saturated NaCl solutions, dried over anhydrous Na_2SO_4 and evaporated to dryness. The crude product was purified by flash chromatography eluting with MeOH- CH_2Cl_2 (2:100 then 5:100) to give the title compound (3.50 g, 93%) as a colorless foam. TLC(MeOH- CH_2Cl_2 ; 1:9) R_f = 0.59.
15
20

Part B: (3S)-3-[N-((1-Naphthyl)Acetyl)Valinyl]Amino-4-Oxobutanoic Acid
25 Starting with (3S)-3-[(N-benzyloxycarbonyl)valinyl]-amino-4-oxobutanoic acid tert-butyl ester semicarbazone and following the general method

described in Example 1, Parts B through E, the title compound was also prepared. TLC(AcOH-MeOH-CH₂Cl₂; 1:1:20) R_f = 0.20. MS(ES) for C₂₁H₂₄N₂O₆ (MW 400.61): positive 401(M+H); negative 399(M-H).

5

EXAMPLE 3

**(3S,2'S)-3-[N-((2'-(1-Naphthyoxy)-4'-Carboxy)Butyryl)Leucinyl]
Amino-4-Oxobutanoic Acid**

Part A: (2R)-2-Bromo-4-Carbobenzoyloxy-Butyric Acid Methyl Ester

10 To a solution of D-glutamic acid γ -benzyl ester (5.00 g, 21 mmol) and KBr (7.5 g, 63 mmol) in 2.5N H₂SO₄ (35 mL) at 0°C (ice bath) was added NaNO₂ (2.45 g, 35.5 mmol) in small portions over 1.5 hrs keeping the internal temperature below 5°C. The resulting mixture was stirred at 0°C for 1 hr and at room temperature for 45 min. The mixture was extracted with Et₂O, extract washed with water and saturated
15 NaCl solution, dried over anhydrous Na₂SO₄ and evaporated to dryness. The residue was taken up in CH₂Cl₂, re-dried over Na₂SO₄ and evaporated to dryness to give crude (2R)-2-bromo-4-carbobenzoyloxy-butyric acid (5.52 g) as a colorless oil.

20 A portion of the crude acid (3.05 g) was taken up in Et₂O (35 mL) and treated with excess diazomethane (prepared from 3.2 g of 1-methyl-3-nitro-1-nitrosoguanidine, 10 mL 40% KOH/35 mL Et₂O at 0°C) in portions at 0°C (ice bath). When TLC indicated consumption of the acid material, the excess diazomethane was discharged with a few drops of acetic acid and the mixture was evaporated to a colorless oil. The crude product was purified by flash chromatography on silica gel

eluting with Et₂O-hexane(1:9) to give the title compound (1.87 g, 51% overall) as a colorless liquid. TLC(Et₂O-hexane; 35:65) Rf=0.50.

Part B: (2S)-2-(1-Naphthyoxy)-4-Carbobenzoyloxy-Butyric Acid Methyl Ester

To a solution of (2R)-2-bromo-4-carbobenzoyloxy-butyric acid methyl ester (1.00 g, 3.17 mmol) and 1-naphthol (0.500 g, 3.47 mmol) in dimethylformamide (4.0 mL) at room temperature under nitrogen was added powdered anhydrous K₂CO₃ (0.560 g, 4.7 mmol). After stirring at room temperature for 3.5 hrs, the mixture was partitioned between EtOAc-water. The organic phase was washed with water, 5% KHSO₄ and saturated NaCl solutions, dried over anhydrous Na₂SO₄ and evaporated to a yellow oil. The crude product was purified by flash chromatography on silica gel eluting with Et₂O-hexane(1:4) to give the title compound (1.105 g, 92%) as a pale yellow oil. TLC(Et₂O-hexane; 3:7; 2 developments) Rf=0.33 (bromide Rf=0.52; 1-naphthol Rf=0.41).

Part C: (2S)-2-(1-Naphthyoxy)-4-Carbo(tert-Butoxy)-Butyric Acid Methyl Ester

A solution of (2S)-2-(1-naphthyoxy)-4-carbobenzoyloxy-butyric acid methyl ester (1.09 g, 2.88 mmol) in MeOH (10 mL) was treated with 10% Pd-C (0.13 g) and stirred under a hydrogen atmosphere (balloon) for 1.5 hrs. The mixture was filtered through Celite washing the filter cake with CH₂Cl₂ and the combined filtrates evaporated to dryness. The residue was chased with toluene (10 mL) and CH₂Cl₂ (2X 20 mL) to give the monoacid (0.889 g) as a colorless, viscous oil. TLC(MeOH-CH₂Cl₂; 5:95) Rf = 0.25.

A solution of the crude acid (0.889 g, ca 2.88 mmol) in dry tetrahydrofuran (18 mL) at room temperature under nitrogen was treated with triethylamine (0.64 mL, 4.6 mmol) and 2,4,6-trichlorobenzoyl chloride (0.605 mL, 3.87 mmol). After stirring at room temperature for 18 hrs, the mixture was diluted with Et₂O, filtered through sintered glass and evaporated to dryness. The crude mixed anhydride was taken up in CH₂Cl₂ (12 mL) and tert-butanol (3.5 mL), and treated with 4-dimethylaminopyridine (0.445 g, 3.65 mmol). After stirring at room temperature

under nitrogen for 3.5 hrs, the mixture was concentrated and partitioned between EtOAc-5% KHSO₄. The organic phase was washed with 5% KHSO₄, saturated NaHCO₃ and saturated NaCl solutions, dried over anhydrous Na₂SO₄ and evaporated to an oil. The crude product was purified by flash chromatography eluting with Et₂O-hexane (1:9) to give the title compound (0.817 g, 82% overall) as a colorless, viscous oil. TLC(Et₂O-hexane; 3:7) Rf=0.30.

5 Part D: (3S,2'S)-3-[N-((2'-(1-Naphthyoxy)-4'-Carboxy)Butyryl)

Leucinyl]Amino-4-Oxobutanoic Acid Semicarbazone Di-tert-Butyl Ester

10 To a solution of (2S)-2-(1-naphthyoxy)-4-carbo(tert-butoxy)-butyric acid methyl ester (0.136 g, 0.395 mmol) in dioxane(1.5 mL)-water(0.5 mL) at 0°C (ice bath) under nitrogen, was added 1.0N LiOH solution (0.52 mL, 0.52 mmol). After stirring at 0°C for 30 min and at room temperature for 1.25 hrs, the mixture was acidified with 1.0N HCl and extracted with EtOAc. The extract was washed with 15 saturated NaCl solution, dried over anhydrous Na₂SO₄ and evaporated to a colorless, viscous oil (0.143 g, theory:0.130 g). TLC(MeOH-CH₂Cl₂; 1:9) Rf = 0.26.


20 To a solution of the crude acid (0.143 g, ca 0.395 mmol) and (3S)-3-(leucinyl)amino-4-oxobutanoic acid tert-butyl ester semicarbazone (see Example 1, Part B, 0.184 g, ca 0.41 mmol) in N-methylpyrrolidone(1.0 mL)-CH₂Cl₂(1.0 mL) at 0°C (ice bath) under nitrogen was added hydroxybenzotriazole hydrate (0.077 g) followed by 1-ethyl-3-(3',3'-dimethyl-1'-aminopropyl)carbodiimide hydrochloride (0.120 g, 0.626 mmol). After stirring at 0°C for 1.5 hrs and at room temperature for 3.5 hrs, the mixture was partitioned between EtOAc-water. The organic phase was washed with water, 5% KHSO₄, saturated NaHCO₃ and saturated NaCl solutions, dried over anhydrous Na₂SO₄ and evaporated to give the title compound (0.270 g, 100%) as an off-white foam. TLC(MeOH-CH₂Cl₂; 1:9) Rf = 0.45. ¹H-NMR(300 MHz, CDCl₃) reveals that the product is a 82:18 mixture of 2'S (d, 0.91 ppm, 6.3 Hz; d, 0.95 ppm, 6.0 Hz) and 2'R (d, 0.56 ppm, 6.3 Hz; d, 0.67 ppm, 6.3 Hz) diastereomers due to racemization which occurred at some point in the synthesis.

Part E: (3S,2'S)-3-[N-((2'-(1-Naphthyoxy)-4'-Carboxy)Butyryl)Leucinyl]Amino-4-Oxobutanoic Acid Semicarbazone

To a solution of (3S,2'S)-3-[N-((2'-(1-naphthyoxy)-4'-carboxy)butyryl)leucinyl]amino-4-oxobutanoic acid semicarbazone di-tert-butyl ester (0.270 g, ca 0.395 mmol) in CH₂Cl₂(2.0 mL)-anisole(0.5 mL) at room temperature under nitrogen was added trifluoroacetic acid (2.5 mL). The resulting solution was stirred at room temperature for 4.5 hrs, evaporated to dryness and chased with CH₂Cl₂ and toluene-CH₂Cl₂ (1:1). The residue was triturated with EtOAc to give the title compound (0.171 g, 80%) as an off-white solid. Evaporation of the mother liquor and trituration of the residue with Et₂O gave an additional 0.035 g of the title compound (total: 0.206 g, 96%). TLC(EtOAc-pyridine-AcOH-H₂O; 60:20:5:10) R_f = 0.33. ¹H-NMR(300 MHz, CD₃OD) of the 1st crop of material indicates that the product is a 82:18 mixture of 2'S (d, 0.88 ppm, 6.3 Hz; d, 0.95 ppm, 6.0 Hz) and 2'R (d, 0.62 ppm, 6.6 Hz; d, 0.68 ppm, 6.3 Hz) diastereomers.

15 Part F: (3S,2'S)-3-[N-((2'-(1-Naphthyoxy)-4'-Carboxy)Butyryl)Leucinyl]Amino-4-Oxobutanoic Acid

A suspension of (3S,2'S)-3-[N-((2'-(1-naphthyoxy)-4'-carboxy)butyryl)leucinyl]amino-4-oxobutanoic acid semicarbazone (0.159 g, 0.29 mmol) in 37% aqueous formaldehyde(1.0 mL)-acetic acid(1.0 mL)-methanol(3.0 mL) was stirred at room temperature under nitrogen for 18 hrs. The resulting clear solution was diluted with water and extracted with EtOAc. The extract was washed with water and saturated NaCl solution, dried over anhydrous Na₂SO₄ and evaporated to dryness. The residue was taken up in tetrahydrofuran, filtered through Celite and evaporated to dryness. The product was taken up in a small amount of tetrahydrofuran and precipitated with Et₂O-hexane to give the title compound (0.121 g, 85%) as a white solid. TLC(EtOAc-pyridine-AcOH-H₂O; 60:20:5:10) R_f = 0.62. ¹H-NMR(300 MHz, CD₃OD) indicates that the product is a 78:22 mixture of 2'S (d, 0.88 ppm, 5.7 Hz; d, 0.95 ppm, 6.0 Hz) and 2'R (d, 0.57 ppm, 6.6 Hz; 2d's, 0.659 ppm, 6.6 Hz and 0.663 ppm, 6.6 Hz) diastereomers.


EXAMPLE 4

(3S,2'R)-3-[N-((2'-(1-Naphthyoxy)-4'-Carboxy)Butyryl)Leucinyl]

5

Amino-4-Oxobutanoic Acid

Starting with L-glutamic acid γ -benzyl ester following the method set forth in Example 3, Parts A through F, the title compound was similarly prepared. ^1H -NMR(300 MHz, CD₃OD) indicates that the product is a 67:33 mixture of 2'R (d, 0.57 ppm, 6.6 Hz; 2d's, 0.659 ppm, 6.6 Hz and 0.663 ppm, 6.6 Hz) and 2'S (d, 0.88 ppm, 10 5.7 Hz; d, 0.95 ppm, 6.0 Hz) diastereomers.

EXAMPLE 5

(3S)-3-[N-((1'-Carboxy-2'-Naphthyoxy)Acetyl)Valinyl]

15

Amino-4-Oxobutanoic Acid

Part A: (1-Carbomethoxy-2-Naphthyoxy)Acetic Acid

To a solution of 1-carbomethoxy-2-naphthol (0.382 g, 1.90 mmol) in dimethylformamide (9.4 mL) at room temperature under nitrogen was added tert-butyl bromoacetate (0.28 mL, 1.90 mmol) and powdered anhydrous potassium carbonate 20 (0.783 g, 5.7 mmol). After stirring at room temperature for 18 hrs, the mixture was partitioned between EtOAc-water. The organic phase was washed with water (2X) and

saturated NaCl solution, dried over anhydrous sodium sulfate and evaporated to an oil. TLC(EtOAc-hexane; 1:10) Rf = 0.18.

The crude product (ca 1.90 mmol) was taken up in CH₂Cl₂ (20 mL) and treated with anisole (0.1 mL) and trifluoroacetic acid-water (9:1, 3.0 mL) at room temperature under nitrogen. After stirring at room temperature for 16 hrs, the mixture was concentrated and chased with toluene. Trituration of the residue with Et₂O-hexane gave the title compound (0.455 g, 92%) as a white solid.

Part B: (3S)-3-[N-((1'-Carbomethoxy-2'-Naphthyl)Acetyl)Valinyl]Amino-4-Oxobutanoic Acid tert-Butyl Ester Semicarbazone

To a solution of (1-carbomethoxy-2-naphthyl)acetic acid (0.260 g, 1.0 mmol) in CH₂Cl₂ (10 mL) at 0°C (ice bath) under nitrogen was added hydroxybenzotriazole hydrate (0.184 g) followed by 1-ethyl-3-(3',3'-dimethyl-1'-aminopropyl)carbodiimide hydrochloride (0.288 g, 1.50 mmol). After stirring for 15 min, the mixture was treated with (3S)-N-(valinyl)amino-4-oxobutanoic acid tert-butyl ester semicarbazone (0.329 g, 1.0 mmol, prepared by a method analogous to that described for N-(leucinyl)amino-4-oxobutanoic acid tert-butyl ester semicarbazone, see Example 1, Part B and Example 2, Part A) and N-methylmorpholine (0.13 mL, 1.2 mmol). After stirring at 0°C for 2 hrs and at room temperature for 16 hrs, the mixture was partitioned between EtOAc-water. The organic phase was washed with water, 5% KHSO₄, saturated NaHCO₃ and saturated NaCl solutions, dried over anhydrous Na₂SO₄ and evaporated to give the title compound (0.571 g, 99%) as a viscous oil. TLC(MeOH-CH₂Cl₂; 1:9) Rf = 0.63.

Part C: (3S)-3-[N-((1'-Carboxy-2'-Naphthyl)Acetyl)Valinyl]Amino-4-Oxobutanoic Acid tert-Butyl Ester Semicarbazone

To a solution of (3S)-3-[N-((1'-carbomethoxy-2'-naphthyl)acetyl)valinyl]amino-4-oxobutanoic acid tert-butyl ester semicarbazone (0.571 g, 1.0 mmol) in dioxane-water (3.0 mL, 3:1, v:v) at room temperature was added 1.0 N LiOH solution (1.1 mL, 1.1 mmol). After stirring at room temperature for 4 hrs, the mixture was partitioned between EtOAc-5% KHSO₄. The organic phase

was washed with saturated NaCl solution, dried over anhydrous Na₂SO₄ and evaporated to dryness. Trituration with Et₂O-hexane gave the title compound (0.461 g, 83%) as a white solid. TLC(MeOH-CH₂Cl₂; 1:9) R_f = 0.09.


Part D: (3S)-3-[N-((1'-Carboxy-2'-Naphthyloxy)Acetyl)Valinyl]Amino-4-Oxobutanoic Acid Semicarbazone

To a solution of (3S)-3-[N-((1'-carboxy-2'-naphthyloxy)acetyl)valinyl]amino-4-oxobutanoic acid tert-butyl ester semicarbazone (0.279 g, 0.50 mmol) in CH₂Cl₂(5.0 mL)-anisole(0.1 mL) at room temperature under nitrogen was added trifluoroacetic acid (0.85 mL). The resulting clear solution was 10 stirred at room temperature for 16 hr, evaporated to dryness and chased with toluene-CH₂Cl₂ (1:1). The residue was triturated with Et₂O to give the title compound (0.241 g, 96%) as an off-white solid.

Part E: (3S)-3-[N-((1'-Carboxy-2'-Naphthyloxy)Acetyl)Valinyl]Amino-4-Oxobutanoic Acid


A solution of (3S)-3-[N-((1'-carboxy-2'-naphthyloxy)acetyl)valinyl]amino-4-oxobutanoic acid semicarbazone (0.100 g, 0.20 mmol) in MeOH-acetic acid-37% aqueous formaldehyde (4.0 mL, 3:1:1, v:v:v), was stirred at room temperature under nitrogen for 16 hrs. The mixture was concentrated, diluted with water, frozen and lyophilized. The residue was taken up in methanol, 20 filtered and evaporated to dryness. The residue was triturated with Et₂O to give the title compound (0.070 g, 79%) as an off-white solid. MS(ES) for C₂₂H₂₄N₂O₈ (MW 444.44): positive 445(M+H); negative 443(M-H).

EXAMPLE 6



Amino-4-Oxobutanoic Acid

Starting with 2-carbomethoxy-1-naphthol and following the general methods described in Example 5, Parts A through E, the title compound was also prepared. MS(ES) for $C_{22}H_{24}N_2O_8$ (MW 444.44): positive 445(M+H); negative 443(M-H).

EXAMPLE 7


(3S)-3-[N-((3'-Carboxy-2'-Naphthoxy)Acetyl)Valinyl]

10

Amino-4-Oxobutanoic Acid

Starting with 3-carbomethoxy-2-naphthol and following the general methods described in Example 5, Parts A through E, the title compound was also prepared. MS(ES) for $C_{22}H_{24}N_2O_8$ (MW 444.44): positive 445(M+H), 483(M+K); negative 443(M-H).

15

EXAMPLE 8

(3S)-3-[N-((1-Naphthylamino)Acetyl)Leucinyl]Amino-4-Oxobutanoic Acid

Part A: (1-Naphthylamino)Acetic Acid

20

To a solution of 1-aminonaphthalene (1.43 g, 10 mmol) and triethylamine (1.5 mL, 10.8 mmol) in dimethylformamide (5.0 mL) at room

temperature under nitrogen was added methyl bromoacetate (1.5 mL, 15.8 mmol). After stirring at room temperature for 60 hrs, the mixture was partitioned between EtOAc-water. The organic phase was washed with water, 5% KHSO₄, saturated NaHCO₃ and saturated NaCl solutions, dried over anhydrous Na₂SO₄ and evaporated to a purple oil
5 (1.55 g). TLC(Et₂O-hexane; 2:3) major spot(UV and PMA) Rf=0.41 (1-aminonaphthalene Rf=0.33).

The crude methyl ester (1.55 g) was taken up in dioxane (10 mL) and treated with 1.0N LiOH (12 mL, 12 mmol). After stirring at room temperature for 1 hr, the mixture was washed with Et₂O, the Et₂O washes discarded, and the aqueous phase
10 acidified with 1.0N HCl (15 mL.). The resulting precipitate was collected by suction, washed with water and air-dried to give 1.35 g of crude product as a tan solid. Recrystallization from EtOAc-hexane gave the title compound (1.03 g, 51% overall) as an off-white crystalline solid. TLC(MeOH-CH₂Cl₂; 1:9) Rf = 0.16.

Part B: (3S)-3-[N-((1-Naphthylamino)Acetyl)Leucinyl]Amino-4-Oxobutanoic Acid tert-Butyl Ester Semicarbazone

To a solution of (1-naphthylamino)acetic acid (0.076 g, 0.38 mmol) and (3S)-3-(leucinyl)amino-4-oxobutanoic acid tert-butyl ester semicarbazone (see Example 1, Part B, 0.180 g, ca 0.41 mmol) in N-methylpyrrolidone(1.0 mL)-CH₂Cl₂(1.0 mL) at 0°C (ice bath) under nitrogen was added hydroxybenzotriazole hydrate (0.075 g)
20 followed by 1-ethyl-3-(3',3'-dimethyl-1'-aminopropyl)carbodiimide hydrochloride (0.100 g, 0.52 mmol). After stirring at 0°C for 3 hrs and at room temperature for 16 hrs, the mixture was partitioned between EtOAc-water. The organic phase was washed with water, 5% KHSO₄, saturated NaHCO₃ and saturated NaCl solutions, dried over anhydrous Na₂SO₄ and evaporated to dryness. The crude product was purified by flash
25 chromatography eluting with MeOH-CH₂Cl₂ (1:30 then 1:15) to give the title compound (0.201 g, 100%) as a pale yellow foam. TLC(MeOH-CH₂Cl₂; 5:95) Rf = 0.29.

Part C: (3S)-3-[N-((1-Naphthylamino)Acetyl)Leucinyl]Amino-4-Oxobutanoic Acid Semicarbazone


To a solution of (3S)-3-[N-((1-naphthylamino)acetyl)leucinyl]amino-4-oxobutanoic acid tert-butyl ester semicarbazone (0.201 g, 0.38 mmol) in CH₂Cl₂(2.0 mL)-anisole(0.5 mL) at room temperature under nitrogen was added trifluoroacetic acid (2.0 mL). The resulting solution was stirred at room temperature for 5 hrs, evaporated to dryness and chased with CH₂Cl₂ and toluene-CH₂Cl₂ (1:1). The resulting solid was triturated with CH₂Cl₂-Et₂O to give the title compound (0.176 g, 98%) as a pale gray solid. TLC(EtOAc-pyridine-AcOH-H₂O; 60:20:5:10) Rf = 0.45.

10 Part D: (3S)-3-[N-((1-Naphthylamino)Acetyl)Leucinyl]Amino-4-Oxobutanoic Acid

A solution of (3S)-3-[N-((1-naphthylamino)acetyl)leucinyl]amino-4-oxobutanoic acid semicarbazone (0.167 g, 0.36 mmol) in 37% aqueous formaldehyde(1.0 mL)-acetic acid(1.0 mL)-methanol(3.0 mL) was stirred at room temperature under nitrogen for 4 hrs. The resulting solution was diluted with water, the resulting white precipitate collected by suction and washed with water. The solid was air-dried, triturated with Et₂O and then dried in vacuo to give the title compound (0.110 g, 75%) as a light gray solid. TLC(EtOAc-pyridine-AcOH-H₂O; 60:20:5:10) Rf = 0.54 (streaky spot). TLC(AcOH-MeOH-CH₂Cl₂; 1:1:8) Rf = 0.25 (streaky spot).

20

EXAMPLE 9



**(3S,2'RS)-3-[N-(2'-(1-Naphthylamino)Propionyl)Leucinyl]
Amino-4-Oxobutanoic Acid**

Part A: 2-(1-Naphthylamino)Propionic Acid

To a solution of 1-aminonaphthalene (1.43 g, 10 mmol) and triethylamine (1.5 mL, 10.8 mmol) in dimethylformamide (3.0 mL) at room temperature under nitrogen was added ethyl 2-bromopropionate (1.4 mL, 10.8 mmol).

5 After stirring at 60°C (bath temperature) 18 hrs, the mixture was partitioned between EtOAc-water. The organic phase was washed with water, 5% KHSO₄, saturated NaHCO₃ and saturated NaCl solutions, dried over anhydrous Na₂SO₄, and evaporated to a brown oil. Purification of the crude product by flash chromatography on silica gel eluting with Et₂O-hexane (5:95) to give ethyl 2-(1-naphthylamino)propionate (1.726 g, 10 73%) as a white crystalline solid after trituration with cold hexane. TLC(Et₂O-hexane; 2:3) Rf=0.43.

The ethyl ester (1.644 g, 6.76 mmol) was taken up in dioxane (10 mL) and treated with 1.0N LiOH (10 mL, 10 mmol). After stirring at room temperature for 1.5 hrs, the mixture was acidified with 1.0N HCl (12 mL). The resulting precipitate was 15 collected by suction, washed with water and dried in vacuo to give the title compound (1.387 g, 95%) as a white crystalline solid. TLC(MeOH-CH₂Cl₂; 1:9) Rf = 0.38.

Part B: (3S,2'RS)-3-[N-(2'-(1-Naphthylamino)Propionyl)Leucinyl]Amino-4-Oxobutanoic Acid tert-Butyl Ester Semicarbazone

To a solution of 2-(1-naphthylamino)propionic acid (0.081 g, 0.38 mmol) and (3S)-3-(leucinyl)amino-4-oxobutanoic acid tert-butyl ester semicarbazone (see Example 1, Part B, 0.180 g, ca 0.41 mmol) in N-methylpyrrolidone(1.0 mL)-CH₂Cl₂(1.0 mL) at 0°C (ice bath) under nitrogen was added hydroxybenzotriazole hydrate (0.075 g) followed by 1-ethyl-3-(3',3'-dimethyl-1-aminopropyl)carbodiimide hydrochloride (0.100 g, 0.52 mmol). After stirring at 0°C 25 for 2 hrs and at room temperature for 6 hrs, the mixture was partitioned between EtOAc-water. The organic phase was washed with water, 5% KHSO₄, saturated NaHCO₃ and saturated NaCl solutions, dried over anhydrous Na₂SO₄ and evaporated to dryness. The crude product was purified by flash chromatography eluting with MeOH-

CH₂Cl₂ (1:30 then 1:15) to give the title compound (0.197 g, 97%) as a white foam. TLC(MeOH-CH₂Cl₂; 5:95) Rf = 0.35.

Part C: (3S,2'R'S)-3-[N-(2'-(1-Naphthylamino)Propionyl)Leucinyl]Amino-4-Oxobutanoic Acid Semicarbazone


5 To a solution of (3S,2'R'S)-3-[N-(2'-(1-naphthylamino)-propionyl)-leucinyl]-amino-4-oxobutanoic acid tert-butyl ester semicarbazone (0.184 g, 0.34 mmol) in CH₂Cl₂(2.0 mL)-anisole(0.5 mL) at room temperature under nitrogen was added trifluoroacetic acid (2.5 mL). The resulting solution was stirred at room temperature for 6.5 hrs, evaporated to dryness and chased with CH₂Cl₂ and toluene-10 CH₂Cl₂ (1:1). The resulting solid was triturated with CH₂Cl₂-Et₂O to give the title compound (0.148 g, 90%) as a pale gray solid. TLC(EtOAc-pyridine-AcOH-H₂O; 60:20:5:10) two spots (diastereomers) Rf = 0.36 and 0.39. TLC(AcOH-MeOH-CH₂Cl₂; 1:1:20) two spots (diastereomers) Rf = 0.13 and 0.16.

15 Part D: (3S,2'R'S)-3-[N-(2'-(1-Naphthylamino)Propionyl)Leucinyl] Amino-4-Oxobutanoic Acid

A solution of (3S,2'R'S)-3-[N-(2'-(1-naphthoxy)propionyl)leucinyl] amino-4-oxobutanoic acid semicarbazone (0.138 g, 0.28 mmol) in 37% aqueous formaldehyde(0.5 mL)-acetic acid(0.5 mL)-methanol(1.5 mL) was stirred at room temperature under nitrogen for 5.5 hrs. The resulting solution was diluted with water (15 mL) and extracted with EtOAc. The extract was washed with water and saturated NaCl solution, dried over anhydrous Na₂SO₄ and evaporated to dryness. The residue was taken up in methanol (0.5 mL) and applied directly to a 3 mL Supelco™ LC-18 reverse phase extraction tube which had been pre-conditioned with water, and eluted successively with 10 mL each of water, 30% MeOH-water, 60% MeOH-water, 80% MeOH-water and 90% MeOH-water. The product-containing fractions (TLC) were combined, concentrated and the resulting aqueous mixture extracted with EtOAc. The extract was washed with saturated NaCl solution, dried over anhydrous Na₂SO₄ and evaporated to dryness. Trituration with EtOAc-Et₂O gave the title compound (0.098 g,

80%) as an off-white solid. TLC(EtOAc-pyridine-AcOH-H₂O; 60:20:5:10) R_f = 0.50 (streaky spot).

EXAMPLE 10



5

(3S)-3-[N-((2,3-Dihydro-2,2-Dimethyl-Benzofuranyloxy)Acetyl)Leucinyl]

Amino-4-Oxobutanoic Acid

Part A: (3S)-3-[N-(9-Fluorenylmethoxycarbonyl)Leucinyl]Amino-4-
Oxobutanoic Acid tert-Butyl Ester Semicarbazonyl-4-[2'-(4-Ethyl-
Phenoxyacetyl)] Aminomethylpolystrene

Aminomethylpolystyrene resin (10.0 g, 100-200 mesh, 0.71 meq/g) was placed in a 200 mL filter tube equipped with a vacuum stopcock and glass frit and washed successively with CH₂Cl₂(50 mL)/dimethylformamide(50 mL), diisopropylethylamine(5 mL)/dimethylformamide(30 mL), dimethylformamide (2 X 40 mL) and tetrahydrofuran (30 mL). The resin was suspended in tetrahydrofuran(20 mL)/N-methylpyrrolidinone(20 mL) with nitrogen agitation through the bottom of the frit and treated with diisopropylethylamine (1.9 mL, 10.9 mmol) and (3S)-3-(9-fluorenylmethoxycarbonyl)amino-4-oxobutanoic acid tert-butyl ester semicarbazonyl-4-[2'-(4-ethyl-phenoxyacetic acid)] (2.24 g, 3.56 mmol). After all of the solid had dissolved (approx. 10 min), the mixture was treated with pyBOP [benzotriazolyloxy-tris(N-pyrrolidinyl)phosphonium hexafluorophosphate, 2.78 g, 5.34 mmol) in one portion. After mixing by nitrogen agitation for 3 hrs, the supernatant was removed by suction and the resin washed successively with tetrahydrofuran (2 X 50 mL), dimethylformamide (3 X 50 mL) and CH₂Cl₂ (2 X 50 mL). Unreacted amine groups were capped by treatment with a mixture of acetic anhydride(10 mL)/

dimethylformamide(30 mL)/diisopropylethylamine(1.0 mL). After mixing by nitrogen agitation for 1 hr, the supernatant was removed by suction and the resin washed with dimethylformamide(4 X 50 mL).

5 The resin was treated with piperidine(10 mL)/ dimethylformamide(40 mL) and mixed by nitrogen agitation for 45 min. The supernatant was removed by suction and the resin washed with dimethylformamide(4 X 50 mL) and tetrahydrofuran (50 mL).


10 The resin was suspended in tetrahydrofuran(20 mL)/N-methylpyrrolidinone(20 mL), treated with N-(9-fluorenylmethoxycarbonyl)leucine (2.52 g, 7.12 mmol), diisopropylethylamine (3.8 mL, 21.8 mmol) and pyBOP (5.56 g, 10.7 mmol) and mixed by nitrogen agitation for 2.5 hrs. The supernatant was removed by suction and the resin washed successively with dimethylformamide (3 X 40 mL) and CH₂Cl₂ (3 X 40 mL), methanol (2 X 40 mL) and Et₂O (2 X 40 mL). The resin was dried in vacuo to give the title product (12.98 g, quantitative). Based on the starting 15 semicarbazone-acid, the resin loading was calculated as approximately 0.27 meq/g.

Part B: (3S)-3-[N-((2,3-Dihydro-2,2-Dimethyl-7-Benzofuranyloxy)Acetyl)Leucinyl] Amino-4-Oxobutanoic Acid

20 An aliquot of the Part A resin (0.120 g, ca 0.032 mmol) was placed in a 6 mL Supelco™ filtration tube equipped with a 20μm polyethylene frit, treated with piperidine-dimethylformamide (1.0 mL, 1:4 v/v) and mixed on an orbital shaker for 1 hr. The supernatant was removed by suction and the resin washed with dimethylformamide (4 X 1.0 mL) and CH₂Cl₂ (3 X 1.0 mL). The resin was treated with 0.5M iPr₂NEt in N-methylpyrrolidinone (0.40 mL, 0.20 mmol), (2,3-dihydro-2,2-dimethyl-7-benzofuranyloxy)acetic acid (0.026 g, 0.12 mmol) and 0.25M pyBOP in N-25 methylpyrrolidinone (0.40 mL, 0.10 mmol). The mixture was mixed on an orbital shaker under an nitrogen atmosphere for 16 hrs. The supernatant was removed by suction and the resin washed succesively with dimethylformamide (3 X 1.0 mL) and CH₂Cl₂ (3 X 1.0 mL), methanol (2 X 1.0 mL) and Et₂O (2 X 1.0 mL).

The resin was treated with 1.0 mL of CH₂Cl₂ and allowed to re-swell for 15 min. The solvent was removed by suction and the resin treated with trifluoroacetic acid-CH₂Cl₂-anisole (1.0 mL, 4:3:1 v/v/v). After mixing on an orbital shaker under nitrogen for 6 hrs, the supernatant was removed by suction and the resin washed with 5 CH₂Cl₂ (4 X 1.0 mL). The resin was treated with 37% aqueous formaldehyde-acetic acid-tetrahydrofuran-trifluoroacetic acid (1.0 mL, 1:1:5:0.025 v/v/v/v) and mixed on an orbital shaker under nitrogen for 4 hrs. The supernatant was collected by suction, the resin washed with tetrahydrofuran (3 X 0.5 mL). The combined filtrates were blown down under nitrogen. The residue was taken up in methanol (0.5 mL), filtered and 10 applied directly to a 3 mL Supelco™ LC-18 reverse phase extraction tube which had been pre-conditioned with water, and eluted successively with 3 mL each of 10% MeOH-water, 30% MeOH-water, 60% MeOH-water and 90% MeOH-water. The product-containing fractions (TLC) were combined and evaporated to dryness to give the title compound (0.0084 g, 60%) as a colorless glass. TLC(AcOH-MeOH-CH₂Cl₂; 15 1:1:20) R_f = 0.29.

EXAMPLES 11-52




Following the general procedure set forth in Example 10, Part B; the 20 compounds of Formula Ib (Examples 11 through 52) shown in Table 3 below are also prepared. IC₅₀'s were determined by the method set forth in Preparation 3A:

Table 3

Ex. No.	R¹	X	n	R²	mICE I ₅₀ (μM)	CPP32 I ₅₀ (μM)	MCH2 I ₅₀ (μM)	MCH3 I ₅₀ (μM)	MCH5 I ₅₀ (μM)
------------	----	---	---	----	------------------------------	-------------------------------	------------------------------	------------------------------	------------------------------

Ex. No.	R ¹	X	n	R ²	mICE I ₅₀ (μM)	CPP32 I ₅₀ (μM)	MCH2 I ₅₀ (μM)	MCH3 I ₅₀ (μM)	MCH5 I ₅₀ (μM)
11	1-naphthyl	CH ₂	0	H	1.86	1.59	4.19	8.78	12.2
12	1-naphthyl	O	0	H	0.597	0.139	0.846	1.95	0.821
13	2-naphthyl	O	0	H	2.57	0.944	18.6	8.87	>10
14	1-naphthyl	O	0	CH ₃	3.99	0.376	1.28	1.32	2.43
15	6-Br-1-naphthyl	O	0	CH ₃	6.84	4.81	13.8	32.4	29.1
16	1-naphthyl	S	0	H	2.75	0.195	1.43	1.74	7.42
17	2-naphthyl	S	0	H	0.792	0.269	3.16	2.52	11.0
18	2-naphthyl	CH ₂	1	H	1.80	2.76	14.5	18.2	>50
19	1-naphthyl	C=O	1	H	0.408	0.967	11.8	11.3	11.2
20	1-naphthyl	C=O	1	CH ₃	4.55	9.88	24.9	29.8	3.25
21	2-naphthyl	C=O	1	H	0.543	1.42	10.3	7.43	5.23
22	1-naphthyl	O	1	H	0.686	0.059	0.305	1.37	9.81
23	2-naphthyl	O	1	H	1.32	0.910	5.90	9.65	15.2
24	1-naphthyl	S	1	H	0.563	0.412	2.72	3.60	16.3
25	2-naphthyl	S	1	H	0.611	0.837	1.62	5.89	15.0
26	2-Me-1-naphthyl	O	0	H	0.843	0.375	32.4	4.16	4.14
27	4-MeO-1-naphthyl	O	0	H	0.831	0.263	22.6	4.08	1.45
28	4-Cl-1-naphthyl	O	0	H	0.429	0.231	12.0	3.38	1.69
29	2,4-diCl-1-naphthyl	O	0	H	0.141	0.357	21.4	3.61	3.04
30	1-isoquinoliny	O	0	H	44.2	1.57	>50	34.7	>50
31	4-quinoliny	O	0	H	35.3	0.232	>50	4.57	>50
32	5-quinoliny	O	0	H	5.25	0.412	>50	3.85	4.02
33	5-isoquinoliny	O	0	H	5.14	0.407	42.7	3.48	3.64
34	8-quinoliny	O	0	H	13.7	0.147	12.5	1.51	2.24
35	phenyl	CH ₂	0	H	>10	9.74	ND	>10	>10
36	phenyl	O	0	CH ₃	20.4	1.77	>10	8.27	>10
37	phenyl	O	1	H	9.42	0.419	>50	6.04	>10
38	phenyl	O	0	H	>10	3.40	>50	>10	>10
39	2-biphenyl	O	0	H	0.636	0.095	0.717	2.02	1.71
40	3-biphenyl	O	0	H	1.10	0.311	14.5	3.75	3.86
41	4-biphenyl	O	0	H	1.90	0.763	20.5	12.0	7.53
42	(2-benzyl)phenyl	O	0	H	0.521	0.490	10.1	3.36	6.05
43	(4-benzyl)phenyl	O	0	H	1.80	0.346	18.9	4.41	4.72

Ex. No.	R ¹	X	n	R ²	mICE I ₅₀ (μM)	CPP32 I ₅₀ (μM)	MCH2 I ₅₀ (μM)	MCH3 I ₅₀ (μM)	MCH5 I ₅₀ (μM)
44	(4-phenoxy)phenyl	O	0	H	2.21	0.545	21.2	6.82	9.28
45	(2-benzyloxy)phenyl	O	0	H	2.40	0.222	9.75	2.20	4.34
46	(4-benzyloxy)phenyl	O	0	H	2.51	0.570	33.4	7.25	8.60
47	(2-cyclo-pentyl)-phenyl	O	0	H	0.538	0.197	3.37	1.49	1.86
48	(4-cyclo-pentyl)-phenyl	O	0	H	2.20	0.319	51.2	5.23	5.90
49	[2-(1-adamantanyl)-4-Me]phenyl	O	0	H	1.43	0.474	5.86	2.79	3.87
50	4-(1-adamantanyl)-phenyl	O	0	H	1.83	0.528	32.5	8.24	4.35
51	5,6,7,8-tetrahydro-1-naphthyl	O	0	H	1.81	0.324	11.8	2.74	1.75
52	5,6,7,8-tetrahydro-2-naphthyl	O	0	H	2.57	0.162	28.6	2.31	4.95

EXAMPLE 53

(3RS)-3-[N-((1-Naphthoxy)Acetyl)Valinyl]

5 **Amino-5-Fluoro-4-Oxopentanoic Acid**

Part A: (3RS,4RS)-3-[(N-Benzylloxycarbonyl)Valinyl]Amino-5-Fluoro-4-Hydroxypentanoic Acid, tert-Butyl Ester

To a solution of (N-benzyloxycarbonyl)valine (0.332 g, 1.32 mmol) in CH₂Cl₂(7.0 mL) at 0°C (ice bath) under nitrogen was added hydroxybenzotriazole hydrate (0.219 g) followed by 1-ethyl-3-(3',3'-dimethyl-1'-aminopropyl)carbodiimide hydrochloride (0.317 g, 1.65 mmol). After stirring at 0°C for 10 min, the mixture was treated with (3RS,4RS)-3-amino-5-fluoro-4-hydroxypentanoic acid, tert-butyl ester (0.228 g, 1.1 mmol, prepared as described in *Tetrahedron Letters* 1994,35, 9693-9696)

and the reacton allowed to warm to room temperature. After stirring at room temperature for 24 hrs, the mixture was partitioned between EtOAc-water. The organic phase was washed with water, 5% KHSO₄, saturated NaHCO₃ and saturated NaCl solutions, dried over anhydrous Na₂SO₄ and evaporated to dryness. The residue was
5 purified by flash chromatography eluting with EtOAc-hexane (1:1) to give the title compound (0.423 g, 87%) as colorless glass. TLC(MeOH-CH₂Cl₂; 5:95) Rf = 0.17.

Part B: (3RS,4RS)-3-(Valinyl)Amino-5-Fluoro-4-Hydroxypentanoic Acid, tert-Butyl Ester

To a solution of (3RS,4RS)-3-[N-benzyloxycarbonyl]valinyl]amino-5-fluoro-4-hydroxypentanoic acid, tert-butyl ester (1.00 g, 2.30 mmol) in EtOH (130 mL)
10 was added 10% Pd-C (0.120 g) and resulting mixture stirred under a hydrogen atmosphere (balloon) for 1 hr. The mixture was filtered through Celite washing the filter cake with CH₂Cl₂ and the combined filtrates evaporated to dryness. The residue was chased with CH₂Cl₂ to give the title product (0.707 g, quantitative) as a colorless
15 oil. TLC(MeOH-CH₂Cl₂; 1:9) Rf = 0.50.

Part C: (3RS,4RS)-3-[N-((1-Naphthyoxy)Acetyl)Valinyl]Amino-5-Fluoro-4-Hydroxypentanoic Acid, tert-Butyl Ester

To a solution of (1-naphthyoxy)acetic acid (0.202 g, 1.0 mmol) in dimethylformamide(4.0 mL)-CH₂Cl₂(6.0 mL) at 0°C (ice bath) under nitrogen was
20 added hydroxybenzotriazole hydrate (0.168 g) followed by 1-ethyl-3-(3',3'-dimethyl-1'-aminopropyl)carbodiimide hydrochloride (0.249 g, 1.3 mmol). After stirring for 10 min, the mixture was treated with a solution of (3RS,4RS)-3-(valinyl)amino-5-fluoro-4-hydroxypentanoic acid, tert-butyl ester (0.319 g, 1.04 mmol) in CH₂Cl₂(8.0 mL). After stirring at 0°C for 1 hr and at room temperature for 3 hrs, the mixture was partitioned
25 between EtOAc-water. The organic phase was washed with water, 5% KHSO₄, saturated NaHCO₃ and saturated NaCl solutions, dried over anhydrous Na₂SO₄ and evaporated to dryness. The residue was purified by flash chromatography on silica gel eluting with EtOAc-hexane (3:2) to give the title compound (0.307 g, 63%) as a white solid. TLC(MeOH-CH₂Cl₂; 1:9) Rf = 0.69.

Part D: (3RS)-3-[N-((1-Naphthyoxy)Acetyl)Valinyl]Amino-5-Fluoro-4-Oxopentanoic Acid, tert-Butyl Ester


To a solution of (3RS,4RS)-3-[N-((1-naphthyoxy)acetyl)valinyl]amino-5-fluoro-4-hydroxypentanoic acid, tert-butyl ester (0.163 g, 0.315 mmol) and N-methylmorpholine N-oxide (0.144 g, 0.98 mmol) in CH₂Cl₂ (5.0 mL) at room temperature was added activated 4Å molecular sieves. After stirring at room temperature for 20 min, the mixture was treated with tetra(n-propyl)ammonium perruthenate (0.011 g). After stirring at room temperature for 3.5 hrs, the mixture through Celite and evaporated to dryness. The residue was purified by flash chromatography on silica gel eluting with EtOAc-hexane (3:4) to give the title compound (0.124 g, 40%) as a pale yellow oil. TLC(MeOH-CH₂Cl₂; 1:9) R_f = 0.71. ¹H NMR (CDCl₃): δ 8.27-8.23 (m, 1 H), 7.86-7.83 (m, 1 H), 7.59-7.51 (m, 3 H), 7.42-7.36 (m, 1 H), 7.23-7.19 (m, 1H), 7.05-6.95 (m, 1H), 6.84 (d, 1H, J = 7.7 Hz), 5.26-4.97 (m, 2 H), 4.93-4.89 (m, 1 H), 4.76 (s, 2 H), 4.45-4.35 (m, 1H), 3.05-2.76 (m, 2H), 1.42 (d, 15 9H, J = 4.1 Hz), 1.02-0.87 (m, 6H).

Part E: (3RS)-3-[N-((1-Naphthyoxy)Acetyl)Valinyl]Amino-5-Fluoro-4-Oxopentanoic Acid


To a solution of (3RS)-3-[N-((1-naphthyoxy)acetyl)valinyl]amino-5-fluoro-4-oxopentanoic acid, tert-butyl ester (0.113 g, 0.23 mmol) in CH₂Cl₂(2.0 mL)-anisole(0.5 mL) at room temperature under nitrogen was added trifluoroacetic acid (1.0 mL). The resulting clear solution was stirred at room temperature for 1 hr, evaporated to dryness and chased with toluene-CH₂Cl₂ (1:1). The residue was purified by flash chromatography on silica gel eluting with AcOH-MeOH-CH₂Cl₂ (0.5:2:100) to give the title compound (0.069 g, 69%) as a white solid. TLC(AcOH-MeOH-CH₂Cl₂; 1:1:20) R_f = 0.38. MS(ES) for C₂₂H₂₅FN₂O₆ (MW 432.45): positive 433(M+NH); negative 431(M-H). ¹H NMR (CD₃OD): δ 8.32-8.29 (m, 1H), 7.82-7.79 (m, 1H), 7.49-7.46 (m, 3H), 7.38-7.32 (m, 1H), 6.88 (d, 1H, J = 7.7 Hz), 4.78-4.73 (m, 2H), 4.55-4.26 (m, 2H), 2.82-2.76 (m, 2H), 2.16-2.03 (m, 1H), 0.94-0.85 (m, 6H).

EXAMPLES 54-56

Starting with (3RS,4RS)-3-(valinyl)amino-5-fluoro-4-hydroxypentanoic acid, tert-butyl ester (see Example 53, Part B) and following the methods described in Example 53, Parts C through E, the compounds shown below in Table 4 were also prepared:

Table 4

Ex.	R ¹	X	n	R ²	Formula	MW	MS(ES)	
							pos.	neg.
54	2-naphthyl	O	0	H	C ₂₂ H ₂₃ FN ₂ O ₆	432.45	433(M+H) 455(M+Na) 471(M+K)	431(M-H) 545(M+TFA)
55	1-naphthyl	O	1	H	C ₂₃ H ₂₇ FN ₂ O ₆	446.47	447(M+H) 489(M+Na)	445(M-H) 559(M+TFA)
56	(2-Ph)Ph	O	0	H	C ₂₄ H ₂₇ FN ₂ O ₆	458.49	481(M+Na) 497(M+K)	457(M-H) 571(M+TFA)

EXAMPLE 57

(3RS)-3-[N-((2-Phenylphenoxy)Acetyl)Leucinyl]

Amino-5-Fluoro-4-Oxopentanoic Acid

5 Part A: (3RS,4RS)-3-[(N-Benzylloxycarbonyl)Leucinyl]Amino-5-Fluoro-4-Hydroxypentanoic Acid, tert-Butyl Ester

To a solution of (3RS,4RS)-3-amino-5-fluoro-4-hydroxypentanoic acid, tert-butyl ester (0.230 g, 1.1 mmol) in CH₂Cl₂ (2.0 mL) at room temperature under nitrogen was added (N-benzylloxycarbonyl)leucine, N-hydroxysuccinimide ester (0.402 g, 1.1 mmol). After stirring at room temperature for 16 hrs, the mixture was evaporated to dryness and the residue purified by flash chromatography on silica gel eluting with EtOAc-hexane (1:2) to give the title compound (0.332 g, 66%) as a colorless, viscous oil. TLC(EtOAc-hexane; 2:1) R_f = 0.51.


15 Part B: (3RS,4RS)-3-(Leucinyl)Amino-5-Fluoro-4-Hydroxypentanoic Acid, tert-Butyl Ester, p-Toluenesulfonate Salt

To a solution of (3RS,4RS)-3-[(N-benzylloxycarbonyl)Leucinyl]amino-5-fluoro-4-hydroxypentanoic acid, tert-butyl ester (0.332 g, 0.734 mmol) in MeOH (100 mL) was added p-toluenesulfonic acid hydrate (0.140 g, 0.737 mmol) and 10% Pd-C (0.033 g) and resulting mixture stirred under a hydrogen atmosphere (balloon) for 2 hrs. The mixture was filtered through Celite washing the filter cake with CH₂Cl₂ and the combined filtrates evaporated to dryness. The residue was chased with CH₂Cl₂ to give the title product (0.371 g) as a colorless foam.

Part C: (3RS)-3-[N-((2-Phenylphenoxy)Acetyl)Leucinyl]Amino-5-Fluoro-4-Oxopentanoic Acid

Starting with (3RS,4RS)-3-(leucinyl)amino-5-fluoro-4-hydroxypentanoic acid, tert-butyl ester, p-toluenesulfonate salt and following the methods described in Example 53, Parts C through E utilizing (2-phenylphenoxy)acetic acid in place of (1-naphthyoxy)acetic acid in Part C, gave the title compound as a white solid. MS(ES) for $C_{25}H_{29}FN_2O_6$ (MW 472.51): positive 495(M+Na), 511(M+K); negative 471(M-H), 585(M+TFA).


10

EXAMPLE 58

**(3RS)-3-[N-(3-(1'-Naphthyoxy)Propionyl)Leucinyl]
Amino-5-Fluoro-4-Oxopentanoic Acid**


Starting with (3RS,4RS)-3-(leucinyl)amino-5-fluoro-4-hydroxypentanoic acid, tert-butyl ester, p-toluenesulfonate salt and following the methods described in Example 53, Parts C through E utilizing 3-(1'-naphthyoxy)propionic acid in place of (1-naphthyoxy)acetic acid in Part C, gave the title compound as a white solid. MS(ES) for $C_{24}H_{29}FN_2O_6$ (MW 460.50): positive 479(M+Na); negative 569(M+TFA).

20

EXAMPLE 59


**(S,3RS)-3-[N-(1-Naphthyl)Acetyl]Homoprolinyl
Amino-5-Fluoro-4-Oxopentanoic Acid**

Following the general methods described in Example 53, Parts A through E, and utilizing N-(benzyloxycarbonyl)-homoproline in place of N-(benzyloxycarbonyl)valine in Part A, the title compound was also prepared.
TLC(CH₂Cl₂/MeOH/AcOH, 20:1:1): R_f = 0.50. ¹H NMR (CD₃OD): δ 8.34-8.31 (m, 1H), 7.82-7.79 (m, 1H), 7.49-7.34 (m, 4H), 6.91-6.89 (m, 1H), 5.20-3.93 (m, 6H), 3.06-2.50 (m, 2H), 2.36-2.14 (m, 2H), 1.80-1.22 (m, 6H). MS(ES) for C₂₃H₂₅FN₂O₆ (MW 444.46): positive 445(M+H); negative 443(M-H).

EXAMPLE 60

(2'S,3RS)-3-[N-(1-Naphthyl)Acetyl]-1,2,3,4-Tetrahydroisoquinoline-2'-Carbonyl Amino-5-Fluoro-4-Oxopentanoic Acid

Following the general methods described in Example 53, Parts A through E, and utilizing (2S)-N-(benzyloxycarbonyl)-1,2,3,4-tetrahydroisoquinoline-2-carboxylic acid in place of N-(benzyloxycarbonyl)valine in Part A, the title compound was also prepared. MS(ES) for C₂₇H₂₅FN₂O₆ (MW 492.50): positive 493(M+H); negative 491(M-H).

EXAMPLE 61

(2'S,3RS)-3-[N-((1-Naphthyoxy)Acetyl)Indoline-2'-Carbonyl]

5 **Amino-5-Fluoro-4-Oxopentanoic Acid**

Part A: (2S)-N-[(1-Naphthyoxy)Acetyl]Indoline-2'-Carboxylic Acid, Methyl Ester

To a solution of (1-naphthyoxy)acetic acid (1.119 g, 5.53 mmol) in ether (30 mL) at 0°C was treated with phosphorus pentachloride (1.267 g, 6.08 mmol).

10 After stirring at 0°C for 20 min and at room temperature for 30 min, the mixture was evaporated to dryness and the residue chased with toluene (2X) to give a light-yellow oil. The crude acid chloride was taken up in toluene (10 mL) and added to a vigorously stirring mixture of methyl (S)-indoline-2-carboxylate hydrochloride (1.182 g, 5.53 mmol) in toluene (10 mL)/aqueous NaHCO₃ solution (2.1 g in 18 mL of H₂O) under N₂ at 0°C. The mixture was stirred for 30 min then partitioned between EtOAc and 5% KHSO₄. The organic phase was washed with 5% KHSO₄, sat'd NaHCO₃ (2x) and saturated NaCl solutions, dried (Na₂SO₄), and evaporated to dryness to give the title compound (1.986 g, 99%) as a white foam.

Part B: (2S)-N-[(1-Naphthyoxy)Acetyl]Indoline-2-Carboxylic Acid

20 To a solution of (2S)-N-[(1-naphthyoxy)acetyl]indoline-2-carboxylic acid methyl ester (1.0 g, 2.77 mmol) in tetrahydrofuran (3.3 mL) at 0°C was added 1.0 N LiOH solution (3.3 mL, 3.3 mmol). After stirring at 0°C for 2 hours the mixture was concentrated, diluted with water, acidified to pH 3, and extracted with EtOAc. The EtOAc extract was washed with saturated NaCl, dried (Na₂SO₄), and evaporated to give

the title compound (0.918 g, 96%) as an off-white solid. ^1H NMR (CD_3OD): δ 8.36-8.33 (m, 1H), 8.15 (d, 1H, J = 7.8 Hz), 7.81-7.78 (m, 1H), 7.49-7.18 (m, 7H), 7.10-7.04 (m, 1H), 6.92 (d, 1H, J = 7.5 Hz), 5.32-4.94 (m, 5H), 3.69-3.34 (m, 2H).

Part C: (2'S,3RS,4RS)-N-[((1-Naphthyloxy)Acetyl)Indoline-2'-

5 Carbonyl]Amino-5-Fluoro-4-Hydroxypentanoic Acid t-Butyl Ester

To a solution of (2S)-N-[(1-naphthyloxy)acetyl]-indoline-2-carboxylic acid (0.278 g, 0.8 mmol) in CH_2Cl_2 (2.0 mL)-dimethylformamide (0.5 mL) at 0°C under nitrogen was added hydroxybenzotriazole hydrate (0.129 g) followed by 1-ethyl-3-(3',3'-dimethyl-1'-aminopropyl)carbodiimide hydrochloride (0.184 g, 0.96 mmol).

10 After stirring at 0°C for 10 min, a solution of (3RS,4RS)-3-amino-5-fluoro-4-hydroxypentanoic acid, tert-butyl ester (0.166 g, 0.8 mmol) in CH_2Cl_2 (3.0 mL) was added. After stirring at 0°C for 1 hr and at room temperature for 3 hrs, the reaction mixture was partitioned between EtOAc and 5% KHSO_4 . The organic phase was washed with 5% KHSO_4 , saturated NaHCO_3 (2x) and saturated NaCl solutions, dried 15 (Na_2SO_4), and evaporated to dryness to give the crude title compound (255 mg) as an off-white solid. TLC(CH_2Cl_2 -MeOH, 9:1): R_f = 0.60.

Part D: (2'S,3RS)-N-[((1-Naphthyloxy)Acetyl)Indoline-2'-Carbonyl]Amino-5-

Fluoro-4-Oxopentanoic Acid t-Butyl Ester

20 To a solution of 2.0 M oxalyl chloride- CH_2Cl_2 (0.3 mL, 0.6 mmol) at -78°C under nitrogen was added dimethylsulfoxide (0.09 mL, 1.2 mmol). After stirring at -78°C for 10 min, a solution of (2'S,3RS,4RS)-N-[(1-naphthyloxy)acetyl]indoline-2'-carbonyl]amino-5-fluoro-4-hydroxypentanoic acid t-butyl ester (0.255 g, 0.48 mmol) in dry CH_2Cl_2 (3.0 mL) was added dropwise. After stirring at -78°C for 15 min, triethylamine (0.27 mL, 2.5 mmol) was added dropwise, the mixture stirred for 10 min, 25 then allowed to warm to room temperature. After an additional 1 hr, the mixture was partitioned between EtOAc and 5% KHSO_4 . The organic phase was washed with 5% KHSO_4 and saturated NaCl solutions, dried (Na_2SO_4), and evaporated to a yellow oil. The crude product was purified by flash chromatography on silica gel eluting with


EtOAc/hexane (1:2) to give the title compound (0.214 g, 83%) as a pale yellow solid.
TLC(EtOAc/hexane, 1:1): R_f = 0.50.

Part E: (2'S,3RS)-N-[((1-Naphthyloxy)Acetyl)Indoline-2'-Carbonyl]Amino-5-Fluoro-4-Oxopentanoic Acid

5 To a solution of (2'S,3RS)-N-[((1-naphthyloxy)acetyl)indoline-2'-carbonyl]amino-5-fluoro-4-oxopentanoic acid t-butyl ester (0.107 g, 0.20 mmol) in anisole (0.2 mL)-CH₂Cl₂ (2.0 mL) at room temperature under nitrogen was added trifluoroacetic acid (1.0 mL). After stirring at room temperature for 1.5 hrs, the mixture was concentrated then chased with CH₂Cl₂ and toluene. The residue was triturated with
10 ether-hexane to give the title compound (0.065 g, 68%) as an off-white solid. ¹H NMR (CD₃OD): δ 8.32-8.17 (m, 2H), 7.81-7.79 (m, 1H), 7.54-6.80 (m, 8H), 5.38-4.29 (m, 6H), 3.25-2.32 (m, 4H). MS(ES) for C₂₆H₂₃FN₂O₆ (MW 478.48): positive 479 (M+H); negative 477 (M-H).

15

EXAMPLE 62



(3S)-3-[N-((1-Naphthyloxy)Acetyl)Valinyl]

Amino-5-(1',2',3'-Benzotriazin-4'(3H)-on-3'-yloxy)-4-Oxopentanoic Acid

Part A: [(N-Benzoyloxycarbonyl)Valinyl]Aspartic Acid, β-tert-Butyl, α-Methyl Ester

20 To a solution of (N-benzyloxycarbonyl)valine (2.10 g, 8.36 mmol) in CH₂Cl₂ (20 mL) at 0°C (ice bath) under nitrogen was added hydroxybenzotriazole hydrate (1.74 g) followed by 1-ethyl-3-(3',3'-dimethyl-1'-aminopropyl)carbodiimide hydrochloride (2.40 g, 12.5 mmol). After stirring at 0°C for 10 min, the mixture was
25 treated with aspartic acid, β-tert-butyl, α-methyl ester hydrochloride (2.00 g, 8.34 mmol) and N-methylmorpholine 1.1 mL, 10 mmol), and the reaction allowed to warm

to room temperature. After stirring at room temperature for 2.5 hrs, the mixture was concentrated and the residue partitioned between EtOAc-water. The organic phase was washed with water, 5% KHSO₄, saturated NaHCO₃ and saturated NaCl solutions, dried over anhydrous Na₂SO₄ and evaporated to give the title compound (3.55 g, 97%) as a white solid after tituration with Et₂O-hexane. TLC(EtOAc-hexane; 1:1) R_f = 0.48.

5 **Part B:** N-(Valinyl)Aspartic Acid, β-tert-Butyl, α-Methyl Ester

To a solution of [(N-benzyloxycarbonyl)valinyl]aspartic acid, β-tert-butyl, α-methyl ester (2.14 g, 4.90 mmol) in EtOH (200 mL) was added 10% Pd-C (0.21 g) and resulting mixture stirred under a hydrogen atmosphere (balloon) for 2 hrs.

10 The mixture was filtered through Celite washing the filter cake with CH₂Cl₂ and the combined filtrates evaporated to dryness. The residue was chased with CH₂Cl₂ to give the title product (1.48 g, quantitative) as a viscous oil. The crude product was used immediately for the next step.

15 **Part C:** [N-((1-Naphthyoxy)Acetyl)Valinyl]Aspartic Acid, β-tert-Butyl, α-Methyl Ester

To a solution of (1-naphthyoxy)acetic acid (0.936 g, 4.90 mmol) in CH₂Cl₂(45 mL) at 0°C (ice bath) under nitrogen was added hydroxybenzotriazole hydrate (0.851 g) followed by 1-ethyl-3-(3',3'-dimethyl-1'-aminopropyl)carbodiimide hydrochloride (1.33 g, 6.94 mmol). After stirring for 15 min, the mixture was treated with N-(valinyl)aspartic acid, β-tert-butyl, α-methyl ester (1.48 g, ca 4.90 mmol) and N-methylmorpholine (0.61 mL, 5.55 mmol). After stirring at 0°C for 2 hrs and at room temperature for 16 hrs, the mixture was partitioned between EtOAc-water. The organic phase was washed with water, 5% KHSO₄, saturated NaHCO₃ and saturated NaCl solutions, dried over anhydrous Na₂SO₄ and evaporated to dryness. The residue was purified by flash chromatography on silica gel eluting with EtOAc-hexane (1:2) to give the title compound (1.89 g, 79%) as a viscous oil. TLC(EtOAc-hexane; 1:1) R_f = 0.57.

25 **Part D:** [N-((1-Naphthyoxy)Acetyl)Valinyl]Aspartic Acid, β-tert-Butyl Ester

To a solution of [N-((1-naphthyoxy)acetyl)valinyl] aspartic acid, β-tert-butyl, α-methyl ester (1.88 g, 3.87 mmol) in dioxane (9.0 mL)-water (3.0 mL) was

added 1.0 N LiOH solution (4.3 mL, 4.3 mmol). After stirring at room temperature for 1 hr, the mixture was acidified with 1.0 N HCl and extracted with EtOAc. The extract was washed with saturated NaCl solution, dried over anhydrous Na₂SO₄ and evaporated to give the title compound (1.82 g, quantitative) as a white solid. TLC(AcOH-MeOH-CH₂Cl₂; 1:1:20) Rf = 0.65.

Part E: (3S)-3-[N-((1-Naphthyoxy)Acetyl)Valinyl]Amino-5-Bromo-4-Oxopentanoic Acid tert-Butyl Ester

To a solution of [N-((1-naphthyoxy)acetyl)valinyl] aspartic acid, β-tert-butyl ester (3.96 g, 8.40 mmol) and N-methylmorpholine (1.48 mL, 13.5 mmol) in tetrahydrofuran (37 mL) at -10°C (NaCl/ice bath) under nitrogen was added isobutyl chloroformate (1.63 mL, 12.6 mmol). After stirring at -10°C for 0.5 hrs, the mixture was filtered into another ice-cooled flask and the filter cake washed with cold tetrahydrofuran (approx. 15 mL). The resulting mixed anhydride solution was treated at -10°C with excess diazomethane/Et₂O solution (prepared from 3.09 g, 21 mmol of 1-methyl-3-nitro-1-nitrosoguanidine, 15 mL 40% KOH/28 mL Et₂O). After stirring at -10°C for 30 min and at room temperature for 15 min, the mixture was cooled to 0°C (ice bath) and treated with 48% aqueous HBr (19.0 mL, 170 mmol). Gas evolution was observed. After 15 min, the mixture was partitioned between EtOAc-saturated NaHCO₃, the organic phase washed with saturated NaCl solution, dried over anhydrous Na₂SO₄ and evaporated. Trituration of the residue with Et₂O gave the title compound (3.29 g, 71%) as a white solid. TLC(EtOAc-hexane; 1:1) Rf = 0.51. ¹H NMR (CDCl₃): δ 8.26-8.22 (m, 1H), 7.86-7.83 (m, 1H), 7.59-7.51 (m, 3H), 7.41-7.36 (m, 1H), 7.27-7.20 (m, 2H), 6.83 (d, 1H, J = 7.8 Hz), 5.00-4.95 (m, 1H), 4.76 (s, 2H), 4.48-4.43 (m, 1H), 4.12 (s, 2H), 2.95-2.74 (dd, 2H), 2.26-2.19 (m, 1H), 1.41 (s, 9H), 0.99 (d, 3H, J = 6.9 Hz), 0.92 (d, 3H, J = 6.9 Hz).

Part F: (3S)-3-[N-((1-Naphthyoxy)Acetyl)Valinyl]Amino-5-(1',2',3'-Benzotriazin-4'(3H)-on-3'-yloxy)-4-Oxopentanoic Acid, tert-Butyl Ester

To a solution of (3S)-3-[N-((1-naphthyoxy)acetyl) valinyl]amino-5-bromo-4-oxopentanoic acid tert-butyl ester (0.165 g, 0.30 mmol) and 3-hydroxy-1,2,3-

benzotriazin-4(3H)-one (0.059 g, 0.36 mmol) in dimethylformamide (2.0 mL) at room temperature under nitrogen was added potassium fluoride (0.061 g, 1.05 mmol). After stirring at room temperature for 5 hrs, the mixture was partitioned between EtOAc-water. The organic phase was washed with water, 5% KHSO₄, saturated NaHCO₃, and 5 saturated NaCl solutions, dried over anhydrous Na₂SO₄ and evaporated to dryness. Trituration of the residue with Et₂O-hexane gave the title compound (0.171 g, 90%) as pale yellow solid. TLC(MeOH-CH₂Cl₂; 1:9) R_f = 0.40.

Part G: (3S)-3-[N-((1-Naphthyoxy)Acetyl)Valinyl]Amino-5-(1',2',3'-Benzotriazin-4'(3H)-on-3'-yloxy)-4-Oxopentanoic Acid


10 To a solution of (3S)-3-[N-((1-naphthyoxy)acetyl) valinyl]amino-5-(1',2',3'-benzotriazin-4'(3H)-on-3'-yloxy)-4-oxopentanoic acid, tert-butyl ester (0.143 g, 0.23 mmol) in CH₂Cl₂(2.0 mL)-anisole(0.2 mL) at room temperature under nitrogen was added trifluoroacetic acid (1.0 mL). The resulting clear solution was stirred at room temperature for 2 hr, evaporated to dryness and chased with toluene-CH₂Cl₂ (1:1). The 15 residue was triturated with Et₂O-hexane to give the title compound (0.099 g, 76%) as an off-white solid. ¹H NMR (CD₃OD): δ 8.33-7.24 (m, 10H), 6.92-6.77 (m, 1H), 5.38-5.27 (m, 1H), 4.80-4.31 (m, 5H), 3.08-2.60 (m, 2H), 2.18-2.04 (m, 1H), 1.11-0.83 (m, 6H). MS(ES) for C₂₉H₃₉N₃O₈ (MW 575.58): positive 576(M+H); negative 574(M-H).

20

EXAMPLES 63-149

Starting with (3S)-3-[N-((1-naphthyoxy)acetyl)valinyl]amino-5-bromo-4-oxopentanoic acid tert-butyl ester (see Example 62, Part E) and following the methods described in Example 62, Parts F through G, the compounds shown below in Table 5 were also prepared:

25

Table 5

Ex.	B	Formula	MW	MS(ES)	
				pos.	neg.
63	CH ₂ OCO(2,6-diCl-Ph)	C ₂₉ H ₂₈ Cl ₂ N ₂ O ₈	603.45	603/605 (M+H)	601/603 (M-H)
64	CH ₂ OPh	C ₂₈ H ₃₀ N ₂ O ₇	506.55	507(M+H) 529(M+Na) 545(M+K)	505(M-H)
65	CH ₂ O(2-F-Ph)	C ₂₈ H ₂₉ FN ₂ O ₇	524.54	525(M+H)	523(M-H)
66	CH ₂ O(3-F-Ph)	C ₂₈ H ₂₉ FN ₂ O ₇	524.54	525(M+H)	523(M-H)
67	CH ₂ O(4-F-Ph)	C ₂₈ H ₂₉ FN ₂ O ₇	524.54	547(M+Na)	523(M-H)
68	CH ₂ O(2,3-diF-Ph)	C ₂₈ H ₂₉ F ₂ N ₂ O ₇	542.54	543(M+H) 565(M+Na)	541(M-H) 655(M+TFA)
69	CH ₂ O(2,4-diF-Ph)	C ₂₈ H ₂₉ F ₂ N ₂ O ₇	542.54	543(M+H) 565(M+Na) 581(M+K)	541(M-H)
70	CH ₂ O(2,5-diF-Ph)	C ₂₈ H ₂₉ F ₂ N ₂ O ₇	542.54	543(M+H) 565(M+Na) 581(M+K)	541(M-H)
71	CH ₂ O(2,6-diF-Ph)	C ₂₈ H ₂₉ F ₂ N ₂ O ₇	542.54	543(M+H) 565(M+Na)	541(M-H)
72	CH ₂ O(3,4-diF-Ph)	C ₂₈ H ₂₉ F ₂ N ₂ O ₇	542.54	543(M+H) 581(M+K)	541(M-H)
73	CH ₂ O(3,5-diF-Ph)	C ₂₈ H ₂₉ F ₂ N ₂ O ₇	542.54	543(M+H) 565(M+Na) 581(M+K)	541(M-H)
74	CH ₂ O(2,3,4-triF-Ph)	C ₂₈ H ₂₇ F ₃ N ₂ O ₇	560.53	561(M+H) 583(M+Na) 599(M+K)	559(M-H)
75	CH ₂ O(2,3,5-triF-Ph)	C ₂₈ H ₂₇ F ₃ N ₂ O ₇	560.53	561(M+H) 583(M+Na) 599(M+K)	559(M-H) 673(M+TFA)
76	CH ₂ O(2,3,6-triF-Ph)	C ₂₈ H ₂₇ F ₃ N ₂ O ₇	560.53	561(M+H) 583(M+Na) 599(M+K)	559(M-H) 673(M+TFA)

Ex.	B	Formula	MW	MS(ES)	
				pos.	neg.
77	CH ₂ O(2,4,5-triF-Ph)	C ₂₈ H ₂₇ F ₃ N ₂ O ₇	560.53	561(M+H) 583(M+Na) 599(M+K)	559(M-H)
78	CH ₂ O(2,4,6-triF-Ph)	C ₂₈ H ₂₇ F ₃ N ₂ O ₇	560.53	561(M+H) 583(M+Na)	559(M-H)
79	CH ₂ O(2,3,5,6-tetraF-Ph)	C ₂₈ H ₂₆ F ₄ N ₂ O ₇	578.52	579(M+H) 601(M+Na) 617(M+K)	577(M-H)
80	CH ₂ O(2,3,4,5,6-pentaF-Ph)	C ₂₈ H ₂₅ F ₅ N ₂ O ₇	596.51	619(M+Na)	595(M-H)
81	CH ₂ O(2-CF ₃ -Ph)	C ₂₉ H ₂₉ F ₃ N ₂ O ₇	574.55	597(M+Na)	573(M-H)
82	CH ₂ O(3-CF ₃ -Ph)	C ₂₉ H ₂₉ F ₃ N ₂ O ₇	574.55	597(M+Na)	573(M-H)
83	CH ₂ O(4-CF ₃ -Ph)	C ₂₉ H ₂₉ F ₃ N ₂ O ₇	574.55	597(M+Na)	573(M-H)
84	CH ₂ O(3,5-diCF ₃ -Ph)	C ₃₀ H ₂₈ F ₆ N ₂ O ₇	642.55	643(M+H) 665(M+Na) 681(M+K)	641(M-H)
85	CH ₂ O(2-F,3-CF ₃ -Ph)	C ₂₉ H ₂₈ F ₄ N ₂ O ₇	592.54	593(M+H) 615(M+Na) 631(M+K)	591(M-H)
86	CH ₂ O(2,6-diCl-Ph)	C ₂₈ H ₂₈ Cl ₂ N ₂ O ₇	575.44	575/577 (M+H)	573/575 (M-H)
87	CH ₂ O(2-NO ₂ -Ph)	C ₂₈ H ₂₉ N ₃ O ₉	551.55	552(M+H) 574(M+Na) 590(M+K)	550(M-H)
88	CH ₂ O(4-NO ₂ -Ph)	C ₂₈ H ₂₉ N ₃ O ₉	551.55	552(M+H) 574(M+Na)	550(M-H)
89	CH ₂ O(2-F,4-NO ₂ -Ph)	C ₂₈ H ₂₈ FN ₃ O ₉	569.54	570(M+H) 592(M+Na)	568(M-H)
90	CH ₂ O(4-CN-Ph)	C ₂₉ H ₂₉ N ₃ O ₇	531.56	554(M+Na)	530(M-H)
91	CH ₂ O(4-CF ₃ O-Ph)	C ₂₉ H ₂₉ F ₃ N ₂ O ₈	590.55	591(M+H)	589(M-H) 703(M+TFA)
92	CH ₂ O(4-H ₂ NCO-Ph)	C ₂₉ H ₃₁ N ₃ O ₈	549.58	550(M+H) 572(M+Na)	548(M-H) 662(M+TFA)
93	CH ₂ O(4-PhCO-Ph)	C ₃₅ H ₃₄ N ₂ O ₈	610.66	611(M+H) 633(M+Na)	609(M-H)
94	CH ₂ O(4-Ph-Ph)	C ₃₄ H ₃₄ N ₂ O ₇	582.65	583(M+H) 605(M+Na) 621(M+K)	581(M-H) 695(M+TFA)
95	CH ₂ O(4-C ₆ F ₅ -2,3,5,6-tetraF-Ph)	C ₃₄ H ₂₅ F ₉ N ₂ O ₇	744.57	745(M+H) 767(M+Na) 783(M+K)	743(M-H)


Ex.	B	Formula	MW	MS(ES)	
				pos.	neg.
96	CH ₂ O(4-PhO-Ph)	C ₃₄ H ₃₄ N ₂ O ₈	598.65	599(M+H) 621(M+Na)	597(M-H)
97	CH ₂ O[4-(4'-CF ₃ -PhO)Ph]	C ₃₅ H ₃₃ F ₃ N ₂ O ₈	666.65	667(M+H) 689(M+Na)	665(M-H)
98	CH ₂ O(3-AcNH-Ph)	C ₃₀ H ₃₃ N ₃ O ₈	563.61	564(M+H) 586(M+Na)	562(M-H)
99	CH ₂ O(3,4-OCOS-Ph)	C ₂₉ H ₂₈ N ₂ O ₉ S	580.61	581(M+H) 603(M+Na) 619(M+K)	693(M+TFA)
100	CH ₂ O(2-pyridinyl)	C ₂₇ H ₂₉ N ₃ O ₇	507.54	508(M+H)	506(M-H)
101	CH ₂ O(4,5-diCl-3-pyridazinyl)	C ₂₆ H ₂₆ Cl ₂ N ₄ O ₇	577.42	577/579 (M+H)	575/577 (M-H) 689/691 (M+TFA)
102	CH ₂ O(2-naphthyl)	C ₃₂ H ₃₂ N ₂ O ₇	556.61	557(M+H)	555(M-H)
103	CH ₂ OPOPh ₂	C ₃₄ H ₃₅ N ₂ O ₈ P	630.63	631(M+H) 653(M+Na)	629(M-H)
104	CH ₂ OPO(Me)Ph	C ₂₉ H ₃₃ N ₂ O ₈ P	568.56	569(M+H)	567(M-H)
105	CH ₂ OPOMe ₂	C ₂₄ H ₃₁ N ₂ O ₈ P	506.49	529(M+Na)	505(M-H)
106	CH ₂ OPO(n-hexyl)Ph	C ₃₄ H ₄₃ N ₂ O ₈ P	638.28	639(M+H) 661(M+Na) 677(M+K)	637(M-H) 751(M+TFA)
107	CH ₂ OPO(PhCH ₂)Ph	C ₃₅ H ₃₇ N ₂ O ₈ P	644.66	645(M+H) 667(M+Na) 683(M+K)	643(M-H) 757(M+TFA)
108	CH ₂ OPO(Me)(4-F-Ph)	C ₂₉ H ₃₂ FN ₂ O ₈ P	586.55	587(M+H) 609(M+Na)	585(M-H) 699(M+TFA)
109	CH ₂ OPO(n-hexyl)(4-F-Ph)	C ₃₄ H ₄₂ FN ₂ O ₈ P	656.69	679(M+Na)	655(M-H)
110	CH ₂ OPO(Me)(1-naphthyl)	C ₃₃ H ₃₅ N ₂ O ₈ P	618.62	619(M+H) 641(M+Na)	731(M+TFA)
111	CH ₂ O(6-Me-2-pyron-4-yl)	C ₂₈ H ₃₀ N ₂ O ₉	538.55	539(M+H)	
112	CH ₂ O(4-coumarinyl)	C ₃₁ H ₃₀ N ₂ O ₉	574.59	575(M+H) 597(M+Na)	537(M-H) 687(M+TFA)
113	CH ₂ O(2-Me-4-pyron-3-yl)	C ₂₈ H ₃₀ N ₂ O ₉	538.55	539(M+H) 561(M+Na)	537(M-H) 651(M+TFA)
114	CH ₂ O[1,2-diMe-4(1H)-pyridon-3-yl]	C ₂₉ H ₃₃ N ₃ O ₈	551.59	552(M+H)	550(M-H)
115	CH ₂ O(3-flavonyl)	C ₃₇ H ₃₄ N ₂ O ₉	650.68	651(M+H)	649(M-H)
116	CH ₂ O(4,6-diMe-2-pyrimidinyl)	C ₂₈ H ₃₂ N ₄ O ₇	536.58	537(M+H)	535(M-H)
117	CH ₂ O(4-CF ₃ -2-pyrimidinyl)	C ₂₇ H ₂₇ F ₃ N ₄ O ₇	576.53	577(M+H)	575(M-H)

Ex.	B	Formula	MW	MS(ES)	
				pos.	neg.
118	CH ₂ S(4,6-diMe-2-pyrimidinyl)	C ₂₈ H ₃₂ N ₄ O ₆ S	552.64	553(M+H) 575(M+Na)	551(M-H) 665(M+TFA)
119	CH ₂ O(2,6-diMe-4-pyrimidinyl)	C ₂₈ H ₃₂ N ₄ O ₇	536.58	537(M+H)	535(M-H)
120	CH ₂ O(6-CF ₃ -4-pyrimidinyl)	C ₂₇ H ₂₇ F ₃ N ₄ O ₇	576.53	577(M+H)	575(M-H)
121	CH ₂ O(2-CF ₃ -4-pyrimidinyl)	C ₂₇ H ₂₇ F ₃ N ₄ O ₇	576.53	577(M+H)	575(M-H)
122	CH ₂ S(2-imidazolyl)	C ₂₅ H ₂₈ N ₄ O ₆ S	512.58	513(M+H)	511(M-H) 625(M+TFA)
123	CH ₂ S(1-Me-2-imidazolyl)	C ₂₆ H ₃₀ N ₄ O ₆ S	526.61	527(M+H)	525(M-H)
124	CH ₂ S(1H-1,2,4-triazol-3-yl)	C ₂₄ H ₂₇ N ₃ O ₆ S	513.57	514(M+H)	512(M-H)
125	CH ₂ S(4-Me-4H-1,2,4-triazol-3-yl)	C ₂₅ H ₂₉ N ₃ O ₆ S	527.59	528(M+H)	526(M-H) 640(M+TFA)
126	CH ₂ S(1-Me-5-tetrazolyl)	C ₂₄ H ₂₈ N ₆ O ₆ S	528.58	529(M+H)	527(M-H)
127	CH ₂ S(1-Ph-5-tetrazolyl)	C ₂₉ H ₃₀ N ₆ O ₆ S	590.65	591(M+H)	589(M-H)
128	CH ₂ S(5-Me-1,3,4-thiadiazol-2-yl)	C ₂₅ H ₂₈ N ₄ O ₆ S ₂	544.64	545(M+H)	543(M-H)
129	CH ₂ S(5-Ph-1,3,4-oxadiazol-2-yl)	C ₃₀ H ₃₀ N ₄ O ₇ S	590.65	591(M+H) 613(M+Na)	589(M-H) 703(M+TFA)
130	CH ₂ S(3-Ph-1,2,4-oxadiazol-5-yl)	C ₃₀ H ₃₀ N ₄ O ₇ S	590.65	591(M+H)	589(M-H)
131	CH ₂ S(4-Ph-2-thiazolyl)	C ₃₁ H ₃₁ N ₃ O ₆ S ₂	605.72	606(M+H) 628(M+Na)	604(M-H)
132	CH ₂ S(4,5-diPh-2-imidazolyl)	C ₃₇ H ₃₆ N ₄ O ₆ S	664.77	665(M+H)	663(M-H)
133	CH ₂ O(2-benzothiazolyl)	C ₂₉ H ₂₉ N ₃ O ₆ S	563.62	564(M+H) 586(M+Na)	562(M-H)
134	CH ₂ O(2-benzimidazolyl)	C ₂₉ H ₃₀ N ₄ O ₇	546.58	547(M+H) 569(M+Na)	545(M-H)
135	CH ₂ S(2-benzothiazolyl)	C ₂₉ H ₂₉ N ₃ O ₆ S ₂	579.68	580(M+H)	578(M-H)
136	CH ₂ S(2-benzimidazolyl)	C ₂₉ H ₃₀ N ₄ O ₆ S	562.64	563(M+H)	561(M-H) 675(M+TFA)
137	CH ₂ O(2-quinolinyl)	C ₃₁ H ₃₁ N ₃ O ₇	557.60	558(M+H) 580(M+Na)	556(M-H) 670(M+TFA)
138	CH ₂ O(3-isoquinolinyl)	C ₃₁ H ₃₁ N ₃ O ₇	557.60	558(M+H)	556(M-H)
139	CH ₂ O(1-isoquinolinyl)	C ₃₁ H ₃₁ N ₃ O ₇	557.60	558(M+H) 580(M+Na)	556(M-H) 670(M+TFA)
140	CH ₂ O(4-quinazolinyl)	C ₃₀ H ₃₀ N ₄ O ₇	558.59	559(M+H)	557(M-H)
141	CH ₂ O(8-quinolinyl)	C ₃₁ H ₃₁ N ₃ O ₇	557.60	558(M+H)	556(M-H) 670(M+TFA)
142	CH ₂ O(3-Me-4-CO ₂ Et-isoxazol-5-yl)	C ₂₉ H ₃₃ N ₃ O ₁₀	583.59	584(M+H)	582(M-H)
143	CH ₂ O(1-Ph-3-CF ₃ -pyrazol-5-yl)	C ₃₂ H ₃₁ F ₃ N ₄ O ₇	640.61	641(M+H)	639(M-H)

Ex.	B	Formula	MW	MS(ES)	
				pos.	neg.
144	CH ₂ O(5-CO ₂ Me-isoxazol-3-yl)	C ₂₇ H ₂₉ N ₃ O ₁₀	555.54	556(M+H) 578(M+Na)	554(M-H)
145	CH ₂ O(5-iPr-isoxazol-3-yl)	C ₂₈ H ₃₃ N ₃ O ₈	539.58	540(M+H)	538(M-H)
146	CH ₂ O(3-benzoisoxazolyl)	C ₂₉ H ₂₉ N ₃ O ₈	547.56	548(M+H)	546(M-H)
147	CH ₂ O(1-Me-5-CF ₃ -pyrazol-3-yl)	C ₂₇ H ₂₉ F ₃ N ₄ O ₇	578.54	579(M+H) 601(M+Na)	577(M-H)
148	CH ₂ O(1-benzotriazolyl)	C ₂₈ H ₂₉ N ₅ O ₇	547.57	548(M+H)	660(M+TFA)
149	CH ₂ O(N-phthalimidyl)	C ₃₀ H ₂₉ N ₃ O ₉	575.57	576(M+H)	574(M+H) 688(M+TFA)

EXAMPLES 150-154


Starting from N-(valinyl)aspartic acid, β -tert-butyl, α -methyl ester (see Example 62, Part B), following the general methods described in Example 62, Parts C through G and utilizing (2-phenylphenoxy)acetic acid in place of (1-naphthyloxy)acetic acid in Part C, and the appropriate acid or phenol in place of 3-hydroxy-1,2,3-benzotriazin-4(3H)-one in Part F, the compounds shown below in Table 6 were also prepared:

Table 6

Ex.	B	Formula	MW	MS(ES)	
				pos.	neg.
150	CH ₂ OCO(2,6-di-Cl-Ph)	C ₃₁ H ₃₀ Cl ₂ N ₂ O ₈	629.49	629/631(M+H) 651/653(M+Na) 667/669(M+K)	627/629(M-H) 741/743(M+TFA)
151	CH ₂ O(2,4,6-triF-Ph)	C ₃₀ H ₂₉ F ₃ N ₂ O ₇	586.57	587(M+H) 609(M+Na) 625(M+K)	585(M-H) 699(M+TFA)
152	CH ₂ O(2,3,5,6-tetraF-Ph)	C ₃₀ H ₂₈ F ₄ N ₂ O ₇	604.56	605(M+H)	603(M-H) 717(M+TFA)
153	CH ₂ OPOPh ₂	C ₃₆ H ₃₇ N ₂ O ₈ P	656.67	679(M+Na) 695(M+K)	655(M-H) 769(M+TFA)
154	CH ₂ OPO(Me)Ph	C ₃₁ H ₃₅ N ₂ O ₈ P	594.60	617(M+Na) 633(M+K)	593(M-H) 707(M+TFA)

EXAMPLES 155-157


Starting from N-(valinyl)aspartic acid, β -tert-butyl, α -methyl ester (see Example 62, Part B), following the general methods described in Example 62, Parts C through G and utilizing (2-naphthyoxy)acetic acid in place of (1-naphthyoxy)acetic acid in Part C, and the appropriate acid or phenol in place of 3-hydroxy-1,2,3-benzotriazin-4(3H)-one in Part F, the compounds shown below in Table 7 were also prepared:

Table 7


Ex.	B	Formula	MW	MS(ES)	
				pos.	neg.
155	CH ₂ OCO(2,6-di-Cl-Ph)	C ₂₉ H ₂₈ Cl ₂ N ₂ O ₈	603.45	603/605(M+H) 625/627(M+Na)	601/603(M-H) 715/717(M+TFA)
156	CH ₂ O(2,4,6-triF-Ph)	C ₂₈ H ₂₇ F ₃ N ₂ O ₇	560.53	583(M+Na)	559(M-H) 673(M+TFA)
157	CH ₂ O(2,3,5,6-tetraF-Ph)	C ₂₈ H ₂₆ F ₄ N ₂ O ₇	578.52	601(M+Na)	577(M-H) 891(M+TFA)

EXAMPLES 158-159

Starting from N-(valinyl)aspartic acid, β -tert-butyl, α -methyl ester (see Example 62, Part B), following the general methods described in Example 62, Parts C through G and utilizing 3-(1-naphthyoxy)propionic acid in place of (1-naphthyoxy)acetic acid in Part C, and the appropriate acid or phenol in place of 3-hydroxy-1,2,3-benzotriazin-4(3H)-one in Part F, the compounds shown below in Table 8 were also prepared:

Table 8


Ex.	B	Formula	MW	MS(ES)	
				pos.	neg.
158	CH ₂ OCO(2,6-di-Cl-Ph)	C ₃₀ H ₃₀ Cl ₂ N ₂ O ₈	617.48	617/619(M+H) 639/641(M+Na)	615/617(M-H) 729/731(M+TFA)
159	CH ₂ O(1-Ph-5-CF ₃ -pyrazol-3-yl)	C ₃₃ H ₃₃ F ₃ N ₄ O ₇	654.64	677(M+Na)	653(M-H) 767(M+TFA)

EXAMPLE 160

(3S)-3-[N-(3'-(Phenoxy)Propionyl)Valinyl]

Amino-5-(2,3,5,6-Tetrafluorophenoxy)-4-Oxopentanoic Acid

Starting from N-(valinyl)aspartic acid, β -tert-butyl, α -methyl ester (see Example 62, Part B), following the general methods described in Example 62, Parts C through G and utilizing 3-(phenoxy)propionic acid in place of (1-naphthylloxy)acetic acid in Part C, and 2,3,5,6-tetrafluorophenol in place of 3-hydroxy-1,2,3-benzotriazin-4(3H)-one in Part F, the title compound was also prepared. MS(ES) for $C_{25}H_{26}F_4N_2O_7$, (MW 542.48): positive 543($M+H$), 565($M+Na$), 581($M+K$); negative 541($M-H$).

EXAMPLE 161

(3S)-3-[N-((2-Phenoxyphenyl)Acetyl)Leucinyl]

Amino-5-(Diphenylphosphinyloxy)-4-Oxopentanoic Acid

Part A: [(N-Benzylloxycarbonyl)Leucinyl]Aspartic Acid, β -tert-Butyl, α -Methyl Ester

To a solution of (N-benzyloxycarbonyl)leucine, N-hydroxysuccinimide ester (4.54 g, 12.5 mmol) and aspartic acid, β -tert-butyl, α -methyl ester hydrochloride (3.00 g, 12.5 mmol) in CH_2Cl_2 (20 mL) at room temperature under nitrogen was added N-methylmorpholine (1.65 mL, 15 mmol). After stirring at room temperature for 18


hrs, the mixture was partitioned between EtOAc-water. The organic phase was washed with 5% KHSO₄, saturated NaHCO₃ and saturated NaCl solutions, dried over anhydrous Na₂SO₄ and evaporated to give the title compound (5.56 g, 99%) as viscous oil. TLC(EtOAc-hexane; 1:1) R_f = 0.48.

5 Part B: (3S)-3-[N-((2-Phenoxyphenyl)Acetyl)Leucinyl]Amino-5-(Diphenylphosphinyloxy)-4-Oxopentanoic Acid


Starting with [(N-benzyloxycarbonyl)leucinyl]aspartic acid, β -tert-butyl, α -methyl ester and following the methods described in Example 62, Parts B through G, utilizing (2-phenylphenoxy)acetic acid in place of (1-naphthoxy)acetic acid in Part C, 10 and the diphenylphosphinic acid in place of 3-hydroxy-1,2,3-benzotriazin-4(3H)-one in Part F, the title compound was also prepared. MS(ES) for C₃₇H₃₉N₂O₈P (MW 670.70): positive 671(M+H), 693(M+Na); negative 669(M-H), 783(M+TFA).

EXAMPLES 162-164

15 Starting with [(N-benzyloxycarbonyl)leucinyl]aspartic acid, β -tert-butyl, α -methyl ester (see Example 161, Part A) and following the methods described in Example 62, Parts B through G, utilizing (2-phenylphenoxy)acetic acid in place of (1-naphthoxy)acetic acid in Part C, and the appropriate acid or phenol in place of 3-hydroxy-1,2,3-benzotriazin-4(3H)-one in Part F, the compounds shown in Table 9 were 20 also prepared.

Table 9

				MS(ES)	
Ex.	B	Formula	MW	pos.	neg.
162	CH ₂ OCO(2,6-di-Cl-Ph)	C ₃₂ H ₃₂ Cl ₂ N ₂ O ₈	643.52	665/667(M+Na)	641/643(M-H) 755/757(M+TFA)
163	CH ₂ O(2,4,6-triF-Ph)	C ₃₁ H ₃₁ F ₃ N ₂ O ₇	600.60	623(M+Na)	599(M-H) 713(M+TFA)
164	CH ₂ O(2,3,5,6-tetraF-Ph)	C ₃₁ H ₃₀ F ₄ N ₂ O ₇	618.59	641(M+Na)	731(M+TFA)

EXAMPLE 165

5

(3S)-3-[N-((2'-Carboxy-1'-Naphthyoxy)Acetyl)Leucinyl]-Amino-5-(2',6'-Dichlorobenzoyloxy)-4-Oxopentanoic Acid

Part A: (2-Carbo-tert-Butoxy-1-Naphthyoxy)Acetic Acid

To a suspension of 1-hydroxy-2-naphthoic acid (4.91 g, 26.1 mmol) in toluene (40 mL) at 80°C (bath temp) under nitrogen was added dimethylformamide di-tert-butyl acetal (25.0 mL, 104.3 mmol) dropwise over 10 min. After stirring at 80°C for an additional 30 min, the cooled mixture was diluted with Et₂O, washed successively with water, saturated NaHCO₃ and saturated NaCl solutions, dried over anhydrous Na₂SO₄ and concentrated. The crude product was combined with that of a smaller run starting with 0.196 g of 1-hydroxy-2-naphthoic acid (total: 5.106 g, 27

mmol) and purified by flash chromatography on silica gel eluting with EtOAc-hexane (5:95) to give 2-carbo-tert-butoxy-1-naphthol (5.52 g, 83%) as a colorless oil. TLC(EtOAc-hexane; 1:9) R_f = 0.68.

To a solution of 2-carbo-tert-butoxy-1-naphthol (4.00 g, 16.4 mmol) in 5 dimethylformamide (16 mL) at room temperature under nitrogen was added methyl bromoacetate (1.7 mL, 18 mmol) and potassium fluoride (2.85 g, 49 mmol). After stirring at room temperature for 16 hrs, TLC showed the reaction was still incomplete. Potassium carbonate (3.0 g, 21.7 mmol) and additional methyl bromoacetate (1.5 mL, 15.8 mmol) were added and the mixture heated to 60°C (bath temp). After heating at 10 60°C for 1 hr, the mixture was partitioned between EtOAc-water. The organic phase was washed with water (2X) and saturated NaCl solution, dried over anhydrous sodium sulfate and evaporated to an oil (6.17 g). TLC(EtOAc-hexane; 5:95) R_f = 0.18.


The above crude product (6.17 g, ca 16.4 mmol) was taken up in dioxane (100 mL) and treated with 1.0 N LiOH solution (33 mL, 33 mmol). After stirring at 15 room temperature for 1 hr, 100 mL of 1.0 N NaOH was added and the mixture washed with Et₂O. The aqueous phase was acidified (pH 2) with conc HCl and extracted with EtOAc. The EtOAc extract was washed with saturated NaCl solution, dried over anhydrous sodium sulfate and evaporated to give the title compound as a viscous oil (6.02 g). The crude product is used without further purification.

20 Part B: (3S)-3-[N-((2'-Carboxy-1'-Naphthyoxy)Acetyl)-Leucinyl]Amino-5-(2',6'-Dichlorobenzoyloxy)-4-Oxopentanoic Acid

Starting with [(N-benzyloxycarbonyl)leucinyl] aspartic acid, b-tert-butyl, a-methyl ester (see Example 161, Part A) and following the methods described in Example 62, Parts B through G, utilizing (2-carbo-tert-butoxy-1-naphthyoxy)acetic acid in place of (1-naphthyoxy)acetic acid in Part C, and 2,6-dichlorobenzoic acid in place of 3-hydroxy-1,2,3-benzotriazin-4(3H)-one in Part F, the title compound was prepared. MS(ES) for C₃₁H₃₀Cl₂N₂O₁₀ (MW 661.49): positive 661/663(M+H), 683/685(M+Na), 699/701(M+Na); negative 659/661(M-H).


EXAMPLES 166-167

Starting with [(N-benzyloxycarbonyl)leucinyl]aspartic acid, β -tert-butyl, α -methyl ester (see Example 161, Part A) and following the methods described in Example 62, Parts B through G, utilizing (2-carbo-tert-butoxy-1-naphthyoxy)acetic acid in place of (1-naphthyoxy)acetic acid in Part C, and the appropriate acid or phenol in place of 3-hydroxy-1,2,3-benzotriazin-4(3H)-one in Part F, the compounds shown in Table 10 were also prepared.

Table 10

Ex.	B	Formula	MW	MS(ES)	
				pos.	neg.
166	CH ₂ OPOPh ₂	C ₃₆ H ₃₇ N ₂ O ₁₀ P	688.67	689(M+H)	687(M-H)
167	CH ₂ O(2,3,5,6-tetraF-Ph)	C ₃₀ H ₂₈ F ₄ N ₂ O ₉	636.55	637(M+H) 659(M+Na) 675(M+K)	635(M-H)

10

EXAMPLE 168

**(3S)-3-[N-((2'-Carboxy-1'-Naphthyoxy)Acetyl)Valinyl]
Amino-5-(2'-Fluorophenoxy)-4-Oxopentanoic Acid**

15 Part A: N-((2-Carbo-tert-Butoxy-1-Naphthyoxy)Acetyl)Valine Methyl Ester

To a solution of (2-carbo-tert-butoxy-1-naphthyoxy)acetic acid (1.20 g, 3.97 mmol, see Example 165, Part A) and valine methyl ester hydrochloride (0.932 g, 5.56 mmol) in N-methylpyrrolidone(7.5 mL)-CH₂Cl₂(7.5 mL) at room temperature

under nitrogen was added O-(7-azabenzotriazol-1-yl)-N,N,N',N'-tetramethyluronium hexafluorophate (2.11 g, 5.56 mmol) and diisopropylethylamine (2.42 mL, 13.9 mmol).

After stirring at room temperature for 3.5 hrs, the mixture was partitioned between EtOAc-water. The organic phase was washed with water, 5% KHSO₄, saturated

5 NaHCO₃ and saturated NaCl solutions, dried over anhydrous Na₂SO₄ and evaporated to dryness. The residue was purified by flash chromatography on silica gel eluting with EtOAc-hexane (1:9 to 3:7) to give the title compound (1.40 g, 85%) as a colorless oil.

TLC(EtOAc-hexane; 1:1) R_f = 0.76.

Part B: N-[N'-(2-Carbo-tert-Butoxy-1-Naphthyoxy)Acetyl]Valinyl]Aspartic acid, β-tert-Butyl, α-Methyl Ester

10 To a solution of N-((2-carbo-tert-butoxy-1-naphthyoxy)acetyl)valine methyl ester (1.39 g, 3.34 mmol) in dioxane (15 mL) at room temperature was added 1.0 N LiOH solution (5.0 mL, 5.0 mmol). After stirring at room temperature for 2 hrs, the mixture was acidified (pH 2) with conc HCl and extracted with EtOAc. The EtOAc extract was washed with saturated NaCl solution, dried over anhydrous sodium sulfate and evaporated to give the mono-carboxylic acid as a gummy solid (1.50 g). The crude product is used without further purification.

15 To a solution of the above crude acid (1.50 g, ca 3.34 mmol) and aspartic acid, β-tert-butyl, α-methyl ester hydrochloride (0.800 g, 3.34 mmol) in N-methylpyrrolidone(7.5 mL)-CH₂Cl₂(7.5 mL) at room temperature under nitrogen was 20 added O-(7-azabenzotriazol-1-yl)-N,N,N',N'-tetramethyluronium hexafluorophate (1.394 g, 3.67 mmol) and diisopropylethylamine (1.75 mL, 10 mmol). After stirring at room temperature for 16 hrs, the mixture was partitioned between EtOAc-water. The organic phase was washed with water, 5% KHSO₄, saturated NaHCO₃, and saturated 25 NaCl solutions, dried over anhydrous Na₂SO₄ and evaporated to dryness. The residue was purified by flash chromatography on silica gel eluting with EtOAc-hexane (1:9 to 1:1) to give the title compound (1.25 g, 64%) as a white foam.

Part C: (3S)-3-[N-((2'-Carboxy-1'-Naphthoxy)Acetyl)-Valinyl]Amino-5-(2'-Fluorophenoxy)-4-Oxopentanoic Acid

Starting with N-[N'-(2-carbo-tert-butoxy-1-naphthoxy)acetyl]valinyl]aspartic acid, β -tert-butyl, α -methyl ester and following the methods described in Example 62, Parts D through G, utilizing 2-fluorophenol in place of 3-hydroxy-1,2,3-benzotriazin-4(3H)-one in Part F, the title compound was prepared.


MS(ES) for $C_{29}H_{29}FN_2O_9$ (MW 568.55): positive 591(M+Na); negative 567(M-H).

EXAMPLES 169-171


Starting with N-[N'-(2-carbo-tert-butoxy-1-naphthoxy)acetyl]valinyl]-aspartic acid, β -tert-butyl, α -methyl ester (see Example 168, Part B) and following the methods described in Example 62, Parts D through G, utilizing the appropriate acid or phenol in place of 3-hydroxy-1,2,3-benzotriazin-4(3H)-one in Part F, the compounds shown in Table 11 were also prepared.

15

Table 11



Ex.	B	Formula	MW	MS(ES)	
				pos.	neg.
169	$CH_3O(2,3,5,6\text{-tetraF-Ph})$	$C_{29}H_{26}F_4N_2O_9$	622.53	645(M+Na)	621(M-H)
170	$CH_2OCO(2,6\text{-diCl-Ph})$	$C_{30}H_{28}Cl_2N_2O_{10}$	647.46	669/671 (M+Na)	645/647 (M-H)
171	CH_3OPOPh_2	$C_{35}H_{35}N_2O_{10}P$	674.64	697(M+Na)	673(M-H)

EXAMPLE 172

(3RS)-3-[N-((1'-Naphthyl)Acetyl)Cyclohexylalaninyl]

Amino-5-(2',3',5',6'-Tetrafluorophenoxy)-4-Oxopentanoic Acid

5 Part A: (3S)-3-(N-Benzylloxycarbonyl)Amino-5-Bromo-4-Oxopentanoic Acid
tert-Butyl Ester

A solution of (N-benzyloxycarbonyl)aspartic acid, β -tert-butyl ester (2.28 g, 7.06 mmol) and N-methylmorpholine (0.85 mL, 7.7 mmol) in tetrahydrofuran (40 mL) at -10°C (NaCl/ice bath) under nitrogen was treated dropwise via syringe with isobutyl chloroformate (1.1 mL, 8.5 mmol). After stirring at -10°C for 20 min, the mixture was filtered (sintered glass) into a pre-cooled receiver (ice bath) washing the filter cake with additional tetrahydrofuran (approx. 10 mL). The combined filtrate was treated with excess diazomethane/Et₂O solution (prepared from 3.10 g, 21 mmol of 1-methyl-3-nitro-1-nitrosoguanidine, 20 mL 40% KOH/10 mL Et₂O) at 0°C (ice bath) under nitrogen. After stirring at 0°C for 15 min and at room temperature for 30 min, the reaction mixture was again cooled to 0°C and treated with 48% HBr(2.0 mL, 12 mmol)/acetic acid(2.0 mL). After stirring at 0°C for 15 min and at room temperature for 15 min, the mixture was partitioned between EtOAc-water. The organic phase was washed with water, saturated NaHCO₃, and saturated NaCl solutions dried over anhydrous Na₂SO₄ and evaporated to a dryness. Trituration with hexane gave the crude title compound (3.32 g) as a yellow oil. TLC(EtOAc-hexane; 1:1) R_f = 0.60 (intermediate diazoketone R_f = 0.52).

Part B: (3S,4RS)-3-(N-Benzylloxycarbonyl)Amino-5-(2',3',5',6'-Tetrafluorophenoxy)-4-Hydroxypentanoic Acid tert-Butyl Ester

To a solution of (3S)-3-(N-benzylloxycarbonyl)amino-5-bromo-4-oxopentanoic acid tert-butyl ester (0.857 g, 2.14 mmol) and 2,3,5,6-tetrafluorophenol (0.410 g, 2.45 mmol) in dimethylformamide (5.0 mL) at room temperature under nitrogen was added potassium fluoride (0.40 g, 6.9 mmol). After stirring at room temperature for 16 hrs, the mixture was diluted with EtOAc, washed with saturated NaHCO₃ and saturated NaCl solutions, dried over anhydrous Na₂SO₄ and evaporated to a to give the crude tetrafluorophenoxy methyl ketone (1.08 g, 98%) as a yellow, viscous oil. TLC(EtOAc-hexane; 1:1) Rf = 0.57.

To a solution of the above crude ketone (1.08 g, ca 2.14 mmol) in ethanol (10 mL) at 0°C under nitrogen was added sodium borohydride (0.057 g, 1.5 mmol). After stirring at 0°C for 1 hr, the excess reducing agent was discharged by treatment with acetone (1.0 mL), the mixture concentrated and the residue partitioned between EtOAc-half saturated NH₄Cl solution. The organic phase was washed with saturated NaHCO₃ and saturated NaCl solutions, dried over anhydrous Na₂SO₄ and evaporated to a dryness. The residue was purified by flash chromatography on silica gel eluting with EtOAc-hexane (1:3) to give the title compound (1.012 g, 94%) as a colorless oil. TLC(EtOAc-hexane; 1:1) Rf = 0.48.

20 Part C: (3S,4RS)-3-[{N-(9-Fluorenylmethoxycarbonyl)Cyclohexylalaninyl}Amino-5-(2',3',5',6'-Tetrafluorophenoxy)-4-Hydroxypentanoic Acid tert-Butyl Ester

To a solution of (3S,4RS)-3-(N-benzylloxycarbonyl)amino-5-(2',3',5',6'-tetrafluorophenoxy)-4-hydroxypentanoic acid tert-butyl ester (1.012 g, 2.08 mmol) in MeOH (25 mL) was added 10% Pd-C (0.30 g) and resulting mixture stirred under a hydrogen atmosphere (balloon) for 4 hrs. The mixture was filtered through Celite washing the filter cake with CH₂Cl₂ and the combined filtrates evaporated to give the crude amine (0.682 g, 93%) as a viscous oil. TLC(MeOH-CH₂Cl₂; 5:95) Rf = 0.21.

To a solution of (N-9-fluorenylmethoxycarbonyl) cyclohexylalanine (0.763 g, 1.94 mmol) in CH₂Cl₂(10 mL) at 0°C (ice bath) under nitrogen was added hydroxybenzotriazole hydrate (0.282 g) followed by 1-ethyl-3-(3',3'-dimethyl-1'-aminopropyl)carbodiimide hydrochloride (0.447 g, 2.33 mmol). After stirring at 0°C
5 for 10 min, the mixture was treated with the above crude amine (0.682 g, ca 1.93 mmol) and the reaction allowed to warm to room temperature. After stirring at room temperature for 3 hrs, the mixture was partitioned between EtOAc-water. The organic phase was washed with water, 5% KHSO₄, saturated NaHCO₃ and saturated NaCl solutions, dried over anhydrous Na₂SO₄ and evaporated to dryness. The residue was
10 purified by flash chromatography eluting with EtOAc-hexane (1:2) to give the title compound (1.028 g, 73%) as yellow foam. TLC(EtOAc-hexane; 1:2) Rf = 0.20.

Part D: (3S,4RS)-3-[Cyclohexylalaninyl]Amino-5-(2',3',5',6'-Tetrafluorophenoxy)-4-Hydroxypentanoic Acid tert-Butyl Ester

A mixture of (3S,4RS)-3-[(N-9-
15 fluorenylmethoxycarbonyl)cyclohexylalaninyl]amino-5-(2',3',5',6'-tetrafluorophenoxy)-4-hydroxypentanoic acid tert-butyl ester (1.028 g, 1.4 mmol) and 10% piperidine/dimethylformamide (3.0 mL) was stirred at room temperature under nitrogen for 2 hrs. The mixture was diluted with CH₂Cl₂, washed with water and saturated NaHCO₃ solution, dried over anhydrous anhydrous Na₂SO₄ and evaporated to dryness. The residue was purified by flash chromatography eluting with isopropanol-CH₂Cl₂ (7:93) to give the title compound (0.561 g, 78%) as a white solid. TLC(MeOH-CH₂Cl₂; 5:95) Rf = 0.43.
20

Part E: (3S,4RS)-3-[N-((1'-Naphthoxy)Acetyl)Cyclohexylalaninyl]-Amino-5-(2',3',5',6'-Tetrafluorophenoxy)-4-Hydroxypentanoic Acid tert-Butyl Ester
25

To a solution of (1-naphthoxy)acetic acid (0.041 g, 0.20 mmol) and (3S,4RS)-3-[cyclohexylalaninyl]amino-5-(2',3',5',6'-tetrafluorophenoxy)-4-hydroxypentanoic acid tert-butyl ester (0.092 g, 0.18 mmol) in CH₂Cl₂(5.0 mL) at 0°C (ice bath) under nitrogen was added hydroxybenzotriazole hydrate (0.050 g) followed

by 1-ethyl-3-(3',3'-dimethyl-1'-aminopropyl)carbodiimide hydrochloride (0.042 g, 0.22 mmol). After stirring at 0°C for 10 min and at room temperature for 18 hrs, the mixture was partitioned between EtOAc-water. The organic phase was washed with water, 5% KHSO₄, saturated NaHCO₃ and saturated NaCl solutions, dried over anhydrous Na₂SO₄ and evaporated to give the crude title compound (0.139 g) as white foam. TLC(EtOAc-hexane; 1:2) R_f = 0.25.

5 Part F: (3RS)-3-[N-((1'-Naphthyoxy)Acetyl)Cyclohexylalaninyl]-Amino-5-
(2',3',5',6'-Tetrafluorophenoxy)-4-Oxopentanoic Acid tert-Butyl
Ester

10 To a solution of crude (3S,4RS)-3-[N-((1'-naphthyoxy)-acetyl)-cyclohexylalaninyl]amino-5-(2',3',5',6'-tetrafluorophenoxy)-4-hydroxypentanoic acid tert-butyl ester (0.139 g, ca 0.18 mmol) in CH₂Cl₂ (5 mL) at room temperature under nitrogen was added Dess-Martin Periodinane (0.099 g, 0.23 mmol). After stirring at room temperature for 1.5 hrs, the mixture was diluted with EtOAc, washed with 1.0 M
15 Na₂S₂O₃, saturated NaHCO₃ and saturated NaCl solutions, dried over anhydrous Na₂SO₄ and evaporated to a dryness. The residue was purified by flash chromatography on silica gel eluting with EtOAc-CH₂Cl₂-hexane (1:1:2) to give the title compound (0.086 g, 69% overall) as a colorless glass. TLC(EtOAc-hexane; 1:2) two spots (diastereomers) R_f = 0.33 and 0.38. Note: racemization of the center alpha to the ketone
20 has apparently occurred at some point in the synthesis.

20 Part G: (3RS)-3-[N-((1'-Naphthyoxy)Acetyl)Cyclohexylalaninyl]-Amino-5-
(2',3',5',6'-Tetrafluorophenoxy)-4-Oxopentanoic Acid

25 To a solution of (3RS)-3-[N-((1'-naphthyoxy)-acetyl)-cyclohexylalaninyl]-amino-5-(2',3',5',6'-tetrafluorophenoxy)-4-oxopentanoic acid, tert-butyl ester (0.086 g, 0.125 mmol) in CH₂Cl₂(2.0 mL) at room temperature under nitrogen was added trifluoroacetic acid (1.0 mL). The resulting clear solution was stirred at room temperature for 1 hr, evaporated to dryness and chased with toluene-CH₂Cl₂ (1:1) to give the title compound (0.066 g, 83%) as an off-white solid. MS(ES)


for $C_{32}H_{32}F_4N_2O_7$ (MW 632.61): positive 633(M+H), 655(M+Na); negative 631(M-H), 745(M+TFA).

EXAMPLES 173-175

Starting with (3S,4RS)-3-[cyclohexylalaninyl]amino-5-(2',3',5',6'-tetrafluorophenoxy)-4-hydroxypentanoic acid tert-butyl ester (see Example 172, Part D) and following the methods described in Example 172, Parts E through G, the compounds shown below in Table 12 were also prepared:

10

Table 12




Ex.	R^1	X	n	R^2	Formula	MW	MS(ES)	
							pos.	neg.
173	2-naphthyl	O	0	H	$C_{32}H_{32}F_4N_2O_7$	632.61	633(M+H) 655(M+Na) 671(M+K)	631(M-H) 745(M+TFA)
174	1-naphthyl	O	1	H	$C_{33}H_{34}F_4N_2O_7$	646.63	647(M+H) 669(M+Na) 685(M+K)	645(M-H) 759(M+TFA)
175	(2-Ph)Ph	O	0	H	$C_{34}H_{34}F_4N_2O_7$	658.65	659(M+H) 681(M+Na) 697(M+K)	657(M-H) 771(M+TFA)

EXAMPLE 176-177

Starting from (N-benzyloxycarbonyl)alanine and following the general methods described in Example 62, Parts A through G, utilizing either (2-phenylphenoxy)acetic acid or (2-naphthyoxy)acetic acid in place of (1-naphthyoxy)acetic acid in Part C, and 2,3,5,6-tetrafluorophenol in place of 3-hydroxy-


1,2,3-benzotriazin-4(3H)-one in Part F, the compounds shown below in Table 13 were also prepared.

Table 13



Ex.	R¹	X	n	R²	Formula	MW	MS(ES)	
							pos.	neg.
176	2-naphthyl	O	0	H	C₂₆H₂₂F₄N₂O₇	550.46	551(M+H) 573(M+Na)	549(M-H) 663(M+TFA)
177	(2-Ph)Ph	O	0	H	C₂₈H₂₄F₄N₂O₇	576.50	577(M+H) 599(M+Na)	575(M-H) 689(M+TFA)

EXAMPLE 178




(3S)-3-[N-α-((2'-Phenylphenoxy)Acetyl)Lysinyl]

10 **Amino-5-(2',6'-Dichlorobenzoyloxy)-4-Oxopentanoic Acid Trifluoroacetate Salt**

Starting from (N-α-benzyloxycarbonyl-N-ε-t-butoxycarbonyl)lysine and following the general methods described in Example 62, Parts A through G, utilizing (2-phenylphenoxy)acetic acid in place of (1-naphthyoxy)acetic acid in Part C, and 2,6-dichlorobenzoic acid in place of 3-hydroxy-1,2,3-benzotriazin-4(3H)-one in Part F, the title compound was also prepared. MS(ES) for C₃₂H₃₃Cl₂N₃O₈ (MW 658.53): positive 658/660(M+H); negative 770/772(M+TFA).

EXAMPLE 179



(3*S*,2'*S*,4'*R*)-3-[3'-(*1*-Naphthoxy)Acetyl]-2'-Phenylthiazolidine-4'-Carboxyl

5 Amino-4-Oxobutanoic Acid

Part A: (2RS,4R)-2-Phenylthiazolidine-4-Carboxylic Acid, Methyl Ester

To a suspension of L-cysteine methyl ester hydrochloride (1.717 g, 10 mmol) in tetrahydrofuran (5.0 mL) at room temperature under nitrogen was added benzaldehyde (1.02 mL, 10 mmol) followed by triethylamine (4.2 mL, 30 mmol). After stirring at room temperature for 3.5 hrs, the resulting mixture was filtered through a pad of silica gel eluting with EtOAc. Evaporation of the filtrate gave the title compound (1.95 g, 88%) as a colorless oil. TLC(EtOAc-hexane; 1:5) R_f = 0.22.

Part B: (2RS,4R)-3-((1-Naphthyloxy)Acetyl)-2-Phenylthiazolidine-4-Carboxylic Acid, Methyl Ester

To a solution of (1-naphthyoxy)acetic acid (3.033 g, 15 mmol) and pyridine (1.46 mL, 18 mmol) in CH_2Cl_2 (50 mL) at room temperature under nitrogen was added cyanuric fluoride (1.52 mL, 18 mmol). After stirring at room temperature for 3 hrs, the mixture was filtered through sintered glass and the filtrate evaporated to a viscous oil. The residue was taken up in CH_2Cl_2 and diluted with CH_2Cl_2 to a total volume of 15.0 mL (ca 1.0 mmol/ml).

To a solution of (2RS,4R)-2-phenylthiazolidine-4-carboxylic Acid, methyl ester (1.953 g, 8.7 mmol) and 2,6-di-tert-butylpyridine (1.95 mL, 8.7 mmol) in CH_2Cl_2 (22 mL) at -30°C (dry ice/acetonitrile bath) under nitrogen was added the above acid fluoride solution (9.0 mL, ca 9.0 mmol). After stirring at -30°C for 6 hrs. the

mixture was allowed to slowly warm to room temperature. After stirring at room temperature for 16 hrs, the mixture was concentrated and the residue partitioned between EtOAc-water. The EtOAc extract was washed with water, 5% KHSO₄, saturated NaHCO₃ and saturated NaCl solutions, dried over anhydrous Na₂SO₄ and evaporated to dryness. The residue was purified by flash chromatography on silica gel eluting with EtOAc-hexane (1:3) to give the title compound (2.672 g, 75%) as a viscous oil.

5
Part C: (2RS,4R)-3-((1-Naphthyoxy)Acetyl)-2-Phenylthiazolidine-4-Carboxylic Acid

10 To a solution of (2RS,4R)-3-((1-naphthyoxy)acetyl)-2-phenylthiazolidine-4-carboxylic acid, methyl ester (2.50 g, 6.14 mmol) in dioxane(15 mL)-water(5.0 mL) at room temperature was added 1.0 N LiOH solution (6.75 mL, 6.75 mmol). After stirring at room temperature for 16 hrs, The mixture was partitioned between EtOAc-5% KHSO₄. The organic phase was washed with saturated NaCl solution, dried over anhydrous Na₂SO₄ and evaporated to give the title compound (2.42 g, 100%) as a viscous oil. TLC(MeOH-CH₂Cl₂; 1:9) R_f = 0.38.

15 Part D: (3S,2'R,S,4'R)-3-[3'-((1-Naphthyoxy)Acetyl)-2'-Phenylthiazolidine-4'-Carbonyl]Amino-4-Oxobutanoic Acid tert-Butyl Ester Semicarbazone

20 To a solution of (2RS,4R)-3-((1-naphthyoxy)acetyl)-2-phenylthiazolidine-4-carboxylic acid (0.393 g, 1.00 mmol) in CH₂Cl₂(10 mL) at 0°C (ice bath) under nitrogen was added hydroxybenzotriazole hydrate (0.161 g) followed by 1-ethyl-3-(3',3'-dimethyl-1'-aminopropyl)carbodiimide hydrochloride (0.288 g, 1.50 mmol). After stirring at 0°C for 10 min, (3S)-amino-4-oxobutanoic acid tert-butyl ester semicarbazone, p-toluenesulfonate salt (0.402 g, 1.0 mmol) followed by N-methylmorpholine (0.12 mL, 1.0 mmol) was added. After stirring at 0°C for 2 hrs and at room temperature for 18 hrs, the mixture was partitioned between EtOAc-water. The organic phase was washed with water, 5% KHSO₄, saturated NaHCO₃ and saturated NaCl solutions, dried over anhydrous Na₂SO₄ and evaporated to dryness. The crude

product was purified by flash chromatography eluting with EtOAc to give the title compound (0.242 g, 40%) as a colorless foam. TLC(EtOAc) Rf = 0.48.

Part E: (3S,2'RS,4'R)-3-[3'-((1-Naphthyloxy)Acetyl)-2'-Phenylthiazolidine-4'-Carbonyl]Amino-4-Oxobutanoic Acid Semicarbazone


5 To a solution (3S,2'RS,4'R)-3-[3'-((1-naphthyloxy)acetyl)-2'-phenylthiazolidine-4'-carbonyl]amino-4-oxobutanoic acid tert-butyl ester semicarbazone (0.240 g, 0.40 mmol) in CH₂Cl₂(2.6 mL)-anisole(0.1 mL) at room temperature under nitrogen was added trifluoroacetic acid (0.61 mL). The resulting solution was stirred at room temperature for 18 hrs, evaporated to dryness and chased 10 with toluene-CH₂Cl₂ (1:1). The residue was triturated with Et₂O to give the title compound (0.195 g, 89%) as an off-white solid. TLC(MeOH-CH₂Cl₂; 1:9) Rf = 0.23.

Part F: (3S,2'RS,4'R)-3-[3'-((1-Naphthyloxy)Acetyl)-2'-Phenylthiazolidine-4'-Carbonyl]Amino-4-Oxobutanoic Acid

A solution of (3S,2'RS,4'R)-3-[3'-((1-naphthyloxy)acetyl)-2'-phenylthiazolidine-4'-carbonyl]amino-4-oxobutanoic acid semicarbazone (0.195 g, 0.355 mmol) in 37% aqueous formaldehyde-acetic acid-methanol (1:1:3; v:v:v; 7.0 mL) was stirred at room temperature under nitrogen for 18 hrs. The resulting solution was concentrated on a rotovap, diluted with water, frozen and lyophilized. The residue was taken up in MeOH, filtered through Celite and evaporated to dryness. The residue was 15 triturated with Et₂O to give the title compound (0.090 g, 51%) as a white solid. TLC(MeOH-CH₂Cl₂; 1:9) Rf = 0.60. MS(ES) for C₂₆H₂₄N₂O₆S (MW 492.55): negative 20 491(M-H).


EXAMPLES 180-184

25 Following the general methods described in Example 179, Parts A through F, utilizing the appropriate aldehyde in place of benzaldehyde in Part A, the compounds shown in Table 14 were also prepared. In the case of Example 184, (4R)-thiazolidine-4-carboxylic acid, methyl ester was prepared by treatment of (4R)-thiazolidine-4-carboxylic acid (Sigma) with HCl(g) in MeOH.

Table 14

Ex.	R ⁸	Formula	MW	MS(ES)	
				pos.	neg.
180	n-propyl	C ₂₃ H ₂₆ N ₂ O ₆ S	458.53	-	457(M-H)
181	n-hexyl	C ₂₆ H ₃₂ N ₂ O ₆ S	500.61	501(M+H) 539(M+Na)	499(M-H)
182	iso-propyl	C ₂₃ H ₂₆ N ₂ O ₆ S	458.53	459(M+H)	457(M-H)
183	cyclo-hexyl	C ₂₆ H ₃₀ N ₂ O ₆ S	498.59	499(M+H)	497(M-H)
184	H	C ₂₀ H ₂₀ N ₂ O ₆ S	416.45	-	415(M-H)

5

EXAMPLE 185

**(3S)-3-[N-((1-Naphthoxy)Acetyl)-4'(trans)-Hydroxyprolinyl]
Amino-4-Oxobutanoic Acid**

Part A: N-((1-Naphthoxy)Acetyl)-4'(trans)-Hydroxyproline, Methyl Ester

10 To a solution of (1-naphthoxy)acetic acid (1.87 g, 9.23 mmol) and 4(trans)-hydroxyproline, methyl ester (1.34 g, 9.23 mmol) in CH₂Cl₂(92 mL) at 0°C (ice bath) under nitrogen was added hydroxybenzotriazole hydrate (1.48 g) followed by 1-ethyl-3-(3',3'-dimethyl-1'-aminopropyl)carbodiimide hydrochloride (2.65 g, 13.8 mmol). After stirring at 0°C for 1 hr and at room temperature for 6 hrs, the mixture was 15 concentrated and the residue partitioned between EtOAc-water. The organic phase was


washed with water, 5% KHSO₄, saturated NaHCO₃ and saturated NaCl solutions, dried over anhydrous Na₂SO₄ and evaporated to give the title compound (2.59 g, 85%) as a colorless oil. TLC(MeOH-CH₂Cl₂; 1:9) R_f = 0.48.

Part B: (3S)-3-[N-((1-Naphthyoxy)Acetyl)-4'(trans)-Hydroxyprolinyl]Amino-4-Oxobutanoic Acid

Starting with N-((1-naphthyoxy)acetyl)-4'(trans)-hydroxypoline, methyl ester and following the general methods described in Example 179, Parts C through F, the title compound was also prepared. MS(ES) for C₂₁H₂₂N₂O₇ (MW 414.41): positive 415(M+H); negative 413(M-H).

10


EXAMPLE 186



(2'S,3S)-3-[N-((1-Naphthyoxy)Acetyl)Indoline-2'-Carbonyl] Amino-4-Oxobutanoic Acid

15 Starting with (2S)-N-[(1-naphthyoxy)acetyl]indoline-2-carboxylic acid (see Example 61, Part B) and following the general methods described in Example 179, Parts D through F, the title compound was also prepared. TLC(AcOH-MeOH-CH₂Cl₂; 1:1:20) R_f = 0.43. MS(ES) for C₂₅H₂₂N₂O₆ (MW 446.46): positive 447(M+H); negative 445(M-H).

20

EXAMPLE 187

**(3S)-3-[N-((3'-Trifluoromethylsulfonylamino-2'-Naphthyloxy)Acetyl)Valinyl]
Amino-4-Oxobutanoic Acid**

5 Part A: (3-Trifluoromethylsulfonylamino-2-Naphthyloxy)Acetic Acid tert-Butyl Ester

To a solution of 3-amino-2-naphthol (0.796 g, 5.0 mmol) in acetone (25 mL) at room temperature under nitrogen was added tert-butyl bromoacetate (0.89 mL, 5.0 mmol) and powdered anhydrous potassium carbonate (2.075 g, 15 mmol). After 10 stirring at room temperature for 18 hrs, the mixture was partitioned between EtOAc-water. The organic phase was washed with water (2X) and saturated NaCl solution, dried over anhydrous sodium sulfate and evaporated to an oil (1.37 g). TLC(EtOAc-hexane; 1:3) R_f = 0.36 (R_f of 3-amino-2-naphthol: 0.17).

To a solution of the crude product (1.37 g, ca 5.0 mmol) in CH₂Cl₂ (17 mL) at -78°C under nitrogen was added triethylamine (0.84 mL, 6.0 mmol) followed by trifluoromethanesulfonic anhydride (1.00 mL, 6.0 mmol). After stirring at -78°C for 30 min, the mixture was allowed to warm to room temperature. After stirring at room temperature for 1 hr, the mixture was partitioned between EtOAc-water. The organic phase was washed with 5% KHSO₄, saturated NaHCO₃ and saturated NaCl solutions, 20 dried over anhydrous Na₂SO₄ and evaporated to dryness. Trituration of the residue with hexane gave the title compound (1.46 g, 72%) as a solid. TLC(EtOAc-hexane; 1:3) R_f = 0.42.

Part B: (3-Trifluoromethylsulfonylamino-2-Naphthyloxy)Acetic Acid

To a solution of (3-trifluoromethylsulfonylamino-2-naphthyloxy)acetic acid tert-butyl ester (1.46 g, 3.60 mmol) in CH₂Cl₂(37 mL)-anisole(0.1 mL)-water(0.57 mL) at room temperature under nitrogen was added trifluoroacetic acid (5.7 mL). After

stirring at room temperature for 16 hrs, the mixture was evaporated to dryness and chased with toluene-CH₂Cl₂ (1:1). The residue was triturated with Et₂O to give the title compound (1.17 g, 92%) as a solid. TLC(MeOH-CH₂Cl₂; 1:9) Rf = 0.04.

5 Part C: (3S)-3-[N-((3'-Trifluoromethylsulfonylamino-2'-Naphthyloxy)Acetyl)
Valinyl]Amino-4-Oxobutanoic Acid tert-Butyl Ester Semicarbazone

To a solution of (3-trifluoromethylsulfonylamino-2-naphthyloxy)acetic acid (0.175 g, 0.5 mmol) in N-methylpyrrolidone(1.0 mL)-CH₂Cl₂(5.0 mL) at 0°C (ice bath) under nitrogen was added hydroxybenzotriazole hydrate (0.092 g) followed by 1-ethyl-3-(3',3'-dimethyl-1'-aminopropyl)carbodiimide hydrochloride (0.144 g, 0.75 mmol). After stirring for 15 min, the mixture was treated with (3S)-N-(valinyl)amino-4-oxobutanoic acid tert-butyl ester semicarbazone (0.165 g, 0.5 mmol, prepared by a method analogous to that described for N-(leucinyl)amino-4-oxobutanoic acid tert-butyl ester semicarbazone, see Example 1, Part B and Example 2, Part A) and N-methylmorpholine (0.066 mL, 0.6 mmol). After stirring at 0°C for 2 hrs and at room temperature for 16 hrs, the mixture was partitioned between EtOAc-water. The organic phase was washed with water, 5% KHSO₄, saturated NaHCO₃ and saturated NaCl solutions, dried over anhydrous Na₂SO₄ and evaporated to dryness. Trituration of the residue with Et₂O-hexane gave the title compound (0.201 g, 61%) as a solid. TLC(MeOH-CH₂Cl₂; 1:9) Rf = 0.38.


20 Part D: (3S)-3-[N-((3'-Trifluoromethylsulfonylamino-2'-Naphthyloxy)Acetyl)
Valinyl]Amino-4-Oxobutanoic Acid Semicarbazone

A solution of (3S)-3-[N-((3'-trifluoromethylsulfonylamino-2'-naphthyloxy)acetyl)-valinyl]amino-4-oxobutanoic acid tert-butyl ester semicarbazone (0.201 g, 0.30 mmol) in 6.0N HCl/AcOH (3.0 mL) was stirred at room temperature under nitrogen for 1 hr. The resulting mixture was evaporated to dryness and chased with toluene. The residue was triturated with Et₂O to give the title compound (0.146 g, 80%) as a solid. TLC(MeOH-CH₂Cl₂; 1:9) Rf = 0.08.

Part E: (3S)-3-[N-((3'-Trifluoromethylsulfonylamino-2'-Naphthyloxy)Acetyl)Valinyl]Amino-4-Oxobutanoic Acid

A solution of (3S)-3-[N-((3'-trifluoromethylsulfonyl-amino-2'-naphthyloxy)acetyl)valinyl]amino-4-oxobutanoic acid semicarbazone (0.146 g, 0.24 mmol) in MeOH-acetic acid-37% aqueous formaldehyde (3.0 mL, 3:1:1, v:v:v), was stirred at room temperature under nitrogen for 16 hrs. The mixture was concentrated, diluted with water, frozen and lyophilized. The residue was taken up in methanol, filtered and evaporated to dryness. The residue was triturated with Et₂O to give the title compound (0.103 g, 78%) as a solid. MS(ES) for C₂₂H₂₄F₃N₃O₈S (MW 547.50): negative 546(M-H).

EXAMPLE 188



15 (3S)-3-[N-((5'-Trifluoromethylsulfonylamino-1'-Naphthyloxy)Acetyl)Valinyl]Amino-4-Oxobutanoic Acid

Part A: (5-Trifluoromethylsulfonylamino-1-Naphthyloxy)Acetic Acid

To a solution of 5-amino-1-naphthol (0.790 g, 5.0 mmol) in acetone (25 mL) at room temperature under nitrogen was added methyl bromoacetate (0.57 mL, 6.0 mmol) and powdered anhydrous potassium carbonate (2.075 g, 15 mmol). After stirring at room temperature for 18 hrs, the mixture was partitioned between EtOAc-water. The organic phase was washed with water (2X) and saturated NaCl solution, dried over anhydrous sodium sulfate and evaporated to an oil (1.16 g).

25 To a solution of the above crude product (1.16 g, ca 5.0 mmol) in CH₂Cl₂ (17 mL) at -78°C under nitrogen was added triethylamine (0.84 mL, 6.0 mmol) followed by trifluoromethanesulfonic anhydride (1.00 mL, 6.0 mmol). After stirring at -78°C for 30 min, the mixture was allowed to warm to room temperature. After stirring

at room temperature for 1 hr, the mixture was partitioned between EtOAc-water. The organic phase was washed with 5% KHSO₄, saturated NaHCO₃ and saturated NaCl solutions, dried over anhydrous Na₂SO₄ and evaporated to dryness to give the crude sulfonamide (1.82 g, 100%) as a solid.

5 The above crude product was taken up in dioxane-water (16.7 mL, 3:1, v:v) and treated with 1.0N LiOH solution (11 mL, 11 mmol). After stirring at room temperature for 16 hrs, the mixture was acidified with conc HCl, and extracted with EtOAc. The EtOAc extract was washed with saturated NaCl solution, dried over anhydrous Na₂SO₄ and evaporated to dryness. The residue was triturated with Et₂O to 10 give the title compound (1.27 g, 73%) as a solid.

Part B: (3S)-3-[N-((5'-Trifluoromethylsulfonylamino-1'-Naphthyloxy)Acetyl)Valinyl]Amino-4-Oxobutanoic Acid tert-Butyl Ester Semicarbazone

15 To a solution of (5-trifluoromethylsulfonylamino-1-naphthyloxy)acetic acid (0.175 g, 0.5 mmol) and (3S)-N-(valinyl)amino-4-oxobutanoic acid tert-butyl ester semicarbazone (0.165 g, 0.5 mmol) in N-methylpyrrolidone(2.5 mL)-CH₂Cl₂(2.5 mL) at 0°C (ice bath) under nitrogen was added O-(7-azabenzotriazol-1-yl)-N,N,N',N'-tetramethyluronium hexafluorophate (0.165 g, 0.5 mmol) followed by diisopropylethylamine (0.17 mL, 0.98 mmol). After stirring at 0°C for 1 hr and at room temperature for 16 hrs, the mixture was partitioned between EtOAc-water. The organic 20 phase was washed with water, 5% KHSO₄, saturated NaHCO₃ and saturated NaCl solutions, dried over anhydrous Na₂SO₄ and evaporated to dryness. Trituration of the residue with Et₂O-hexane gave the title compound (0.067 g, 20%) as a solid. TLC(AcOH-MeOH-CH₂Cl₂; 1:1:20) Rf = 0.29.

Part C: (3S)-3-[N-((5'-Trifluoromethylsulfonylamino-1'-Naphthyloxy)Acetyl)Valinyl]Amino-4-Oxobutanoic Acid


25 A solution of (3S)-3-[N-((5'-trifluoromethylsulfonylamino-1'-naphthyloxy)acetyl)-valinyl]amino-4-oxobutanoic acid tert-butyl ester semicarbazone (0.067 g, 0.10 mmol) in 6.0N HCl/AcOH (1.0 mL) was stirred at room temperature

under nitrogen for 1 hr. The resulting mixture was evaporated to dryness and chased with toluene. TLC(AcOH-MeOH-CH₂Cl₂; 1:1:8) R_f = 0.55.

A solution of the above crude product (ca 0.10 mmol) in MeOH-acetic acid-37% aqueous formaldhyde (3.3 mL, 3:1:1, v:v:v), was stirred at room temperature under nitrogen for 16 hrs. The mixture was concentrated, diluted with water, frozen and lyophilized. The residue was taken up in methanol, filtered and evaporated to dryness. The residue was triturated with Et₂O to give the title compound (0.041 g, 75%) as a solid. TLC(AcOH-MeOH-CH₂Cl₂; 1:1:8) R_f = 0.73. MS(ES) for C₂₂H₂₄F₃N₃O₈S (MW 547.50): positive 570(M+Na); negative 546(M-H).

10

EXAMPLE 189



(3S)-3-[N-(4-(1'-Naphthyoxy)Butyryl)Valinyl]Amino-4-Oxobutanoic Acid

Part A: (3S)-3-[N-(9-Fluorenylmethoxycarbonyl)Valinyl]Amino-4-Oxobutanoic Acid (tert-Butyl) Ester Semicarbazonyl-4-[2'-(4-Ethyl-Phenoxyacetyl)] Aminomethylpolystrene

Aminomethylpolystyrene resin (10.0 g, 100-200 mesh, 0.71 meq/g) was placed in a 200 mL filter tube equipped with a vacuum stopcock and glass frit and washed successively with CH₂Cl₂(50 mL)/dimethylformamide(50 mL), diisopropylethylamine(5 mL)/dimethylformamide(30 mL), dimethylformamide (2 X 50 mL) and tetrahydrofuran (30 mL). The resin was suspended in tetrahydrofuran(20 mL)/N-methylpyrrolidinone(20 mL) with nitrogen agitation through the bottom of the frit and treated with diisopropylethylamine (1.9 mL, 10.9 mmol) and (3S)-3-(9-fluorenylmethoxycarbonyl)amino-4-oxobutanoic acid (tert-butyl) ester semicarbazonyl-4-[2'-(4-ethyl-phenoxyacetic acid)] (2.24 g, 3.56 mmol). After all of the solid had dissolved (approx. 10 min), the mixture was treated with pyBOP [benzotriazolyloxy-

tris(N-pyrrolidinyl)phosphonium hexafluorophosphate, 2.78 g, 5.34 mmol) in one portion. After mixing by nitrogen agitation for 3 hrs, the supernatant was removed by suction and the resin washed successively with tetrahydrofuran (2 X 50 mL), dimethylformamide (3 X 50 mL) and CH₂Cl₂ (2 X 50 mL). Unreacted amine groups 5 were capped by treatment with a mixture of acetic anhydride(10 mL)/dimethylformamide(30 mL)/diisopropylethylamine(1.0 mL). After mixing by nitrogen agitation for 1 hr, the supernatant was removed by suction and the resin washed with dimethylformamide(4 X 50 mL).

The resin was treated with piperidine(10 mL)/ dimethylformamide(40 10 mL) and mixed by nitrogen agitation for 1 hr. The supernatant was removed by suction and the resin washed with dimethylformamide(4 X 50 mL) and tetrahydrofuran (50 mL).

The resin was suspended in tetrahydrofuran(20 mL)/N-methylpyrrolidinone(20 mL), treated with N-(9-fluorenylmethoxycarbonyl)valine (3.63 15 g, 10.7 mmol), diisopropylethylamine (5.7 mL, 32.7 mmol) and pyBOP (8.34 g, 16.0 mmol) and mixed by nitrogen agitation for 2.5 hrs. The supernatant was removed by suction and the resin washed successively with dimethylformamide (3 X 40 mL) and CH₂Cl₂ (3 X 40 mL), methanol (2 X 40 mL) and Et₂O (2 X 40 mL). The resin was dried in vacuo to give the title product (12.69 g, quantitative). Based on the starting 20 semicarbazone-acid, the resin loading was calculated as approximately 0.28 meq/g.

Part B: (3S)-3-[N-(4-(1'-Naphthoxy)Butyryl]Valinyl]Amino-4-Oxobutanoic Acid


An aliquot of the Part A resin (0.125 g, ca 0.035 mmol) was placed in a 6 mL Supelco™ filtration tube equipped with a 20μm polyethylene frit, treated with 25 piperidine-dimethylformamide (1.0 mL, 1:4 v/v) and mixed on an orbital shaker for 1 hr. The supernatant was removed by suction and the resin washed with dimethylformamide (4 X 1.0 mL) and CH₂Cl₂ (3 X 1.0 mL). The resin was treated with 0.5M iPr₂NEt in N-methylpyrrolidinone (0.40 mL, 0.20 mmol), 4-(1-naphthoxy)butyric acid (0.0264 g, 0.115 mmol) and 0.25M O-(7-azabenzotriazol-1-

yl)-N,N,N',N'-tetramethyluronium hexafluorophosphate in N-methylpyrrolidinone (0.40 mL, 0.10 mmol). The mixture was mixed on an orbital shaker under an nitrogen atmosphere for 16 hrs. The supernatant was removed by suction and the resin washed successively with dimethylformamide (3 X 1.0 mL) and CH₂Cl₂ (3 X 1.0 mL), methanol (2 X 1.0 mL) and Et₂O (2 X 1.0 mL).

The resin was treated with 1.0 mL of CH₂Cl₂ and allowed to re-swell for 15 min. The solvent was removed by suction and the resin treated with trifluoroacetic acid-CH₂Cl₂-anisole (1.0 mL, 4:3:1 v/v/v). After mixing on an orbital shaker under nitrogen for 5.5 hrs, the supernatant was removed by suction and the resin washed with CH₂Cl₂ (4 X 1.0 mL). The resin was treated with 37% aqueous formaldehyde-acetic acid-tetrahydrofuran-trifluoroacetic acid (1.0 mL, 1:1:5:0.025 v/v/v/v) and mixed on an orbital shaker under nitrogen for 4.5 hrs. The supernatant was collected by suction, the resin washed with tetrahydrofuran (3 X 0.5 mL). The combined filtrates were blown down under nitrogen. The residue was taken up in methanol (0.5 mL), filtered and applied directly to a 3 mL SupelcoTM LC-18 reverse phase extraction tube which had been pre-conditioned with water, and eluted successively with 3 mL each of 10% MeOH-water, 30% MeOH-water, 60% MeOH-water and 90% MeOH-water. The product-containing fractions (TLC) were combined and evaporated to dryness to give the title compound (0.0132 g, 88%) as a colorless glass. TLC(AcOH-MeOH-CH₂Cl₂; 1:1:20) R_f = 0.22. MS(ES) for C₂₃H₂₈N₂O₆ (MW 428.48): positive 451(M+Na), 467(M+K); negative 427(M-H).

EXAMPLES 190-194


Starting with (3S)-3-[N-(9-fluorenylmethoxycarbonyl)valinyl]amino-4-oxobutanoic acid (tert-butyl) ester semicarbazonyl-4-[2'-(4-ethyl-phenoxyacetyl)]aminomethylpolystrene (see Example 189, Part A) and following the methods described in Example 189, Part B, the compounds shown below in Table 15 were also prepared:

Table 15

Ex.	R¹	X	n	R²	Formula	MW	MS(ES)	
							pos.	neg.
190	(2-t-Bu)Ph	O	0	H	C₂₁H₃₀N₂O₆	406.48	429(M+Na) 445(M+K)	405(M-H)
191	(2-Ph)Ph	O	0	H	C₂₃H₂₆N₂O₆	426.47	449(M+Na) 465(M+K)	425(M-H)
192	(2-Ph)Ph	O	0	CH₃	C₂₄H₂₈N₂O₆	440.50	463(M+Na)	439(M-H)
193	(2-Ph)Ph	O	1	H	C₂₄H₂₈N₂O₆	440.50	441(M+H) 463(M+Na) 479(M+K)	439(M-H) 553(M+TFA)
194	1-naphthyl	O	1	H	C₂₂H₂₆N₂O₆	414.46	415(M+H) 437(M+Na) 453(M+K)	413(M-H)


EXAMPLE 195

5 Methyl 4-(1H-1,2,3,4-tetrazole-5-yl)(2S)-2-[(phenylmethoxy) carbonylamino] butanoate



The title compound was prepared according to the literature (Tran Thach Van, *et al*, Tetrahedron, 1977, 33, 2299-2302).

EXAMPLE 196




To a stirred and cooled (-15 C) solution of methyl 4-(1H-1,2,3,4-tetrazole-5-yl)(2S)-2-[(phenylmethoxy) carbonylamino] butanoate (4.0 g, 12.53 mmol) and triethylamine (2.62 ml, 18.79 mmol) in DCM (50 ml) was added α -chloromethyl methyl ether (MOMCl, 1.43 ml, 18.79 mmol). The stirring was continued for 2.5 hours and by which time the cold bath was warmed to 0 C. The solution was diluted with saturated aqueous NaHCO₃ (100 ml) and the layers were separated. The aqueous layer was back extracted with DCM (100 ml). The combined organic layers were dried (Na₂SO₄) and evaporated. Flash chromatography of the residue over silica gel (4.5 x 18 cm), using 20, 40, 60, and 80% ethyl acetate in hexanes, gave compound 196-a (1.977 g, 43%) and compound 196-b (2.574 g, 56%). The structures of compounds were tentatively assigned based on proton NMR experiments according to literature (R. Raap, *et al*, *Can. J. Chem.* 1968, **47**, 813). Compound 196-a has: ¹H-NMR (CD₃OD, 300 MHz) δ 2.00--2.40 (m, 2 H), 3.00 (t, 2 H), 3.40 (s, 3 H), 3.70 (s, 3H), 4.20--4.35 (m, 1 H), 5.10 (s, 2 H), 5.82 (s, 2H), 7.22—7.40 (m, 5 H). Compound 196-b has: ¹H-NMR (CD₃OD, 300 MHz) δ 2.08-2.50 (m, 2 H), 3.05 (t, 2 H), 3.32 (s, 3 H), 3.70 (s, 3 H), 4.25--4.38 (m, 1 H), 5.10 (s, 2 H), 5.70 (s, 3 H), 7.24--7.40 (m, 5 H).

20

EXAMPLE 197

(2S)-4-[2-(methoxymethyl)(1,2,3,4-tetrazole-5-yl)]-2-[(phenylmethoxy) carbonylamino] butanoic acid




Aqueous LiOH (1.0 M, 7.88 ml) was added to a stirred solution of compound 196-a (1.91 g, 5.25 mmol) in dioxane (24 ml). After stirring at room temperature for 1 hour, it was diluted with ethyl acetate and washed with aqueous HCl (1.0 N, 20 ml). The organic layer was then washed with brine and dried (Na_2SO_4). Concentration under vacuo gave the title compound as an oil (1.98 g, quantitative). ^1H -NMR (CD_3OD , 300 MHz) δ 2.00--2.40 (m, 2 H), 3.00 (t, 2 H), 3.40 (s, 3 H), 4.20--4.35 (m, 1 H), 5.10 (s, 2 H), 5.82 (s, 2H), 7.20--7.40 (m, 5 H).


10

EXAMPLE 198

(2S)-4-[2-(methoxymethyl)(1,2,3,4-tetrazole-5-yl)]-2-[(phenylmethoxy) carbonylamino] butanoic acid



Aqueous LiOH (1.0 M, 10.3 ml) was added to a stirred solution of (2S)-15 4-[2-(methoxymethyl)(1,2,3,4-tetrazole-5-yl)]-2-[(phenylmethoxy) carbonylamino] butanoic acid (2.50 g, 6.88 mmol) in dioxane (30 ml). After stirring at room temperature for 1 hour, it was diluted with ethyl acetate and washed with aqueous HCl (1.0 N, 20 ml). The organic layer was then washed with brine and dried (Na_2SO_4). Concentration under vacuo gave the title compound as an oil (2.45 g, quantitative). ^1H -NMR (CD_3OD , 300 MHz) δ 2.08-2.50 (m, 2 H), 3.05 (t, 2 H), 3.32 (s, 3 H), 4.25--4.38 (m, 1 H), 5.10 (s, 2 H), 5.70 (s, 3 H), 7.24--7.40 (m, 5 H).

EXAMPLE 199**N-[valinyl] aspartic acid, α -methyl, β -tert-butyl diester**

5 HOBt (3.19g, 20.8 mmol) and EDAC (5.60 g, 29.2 mmol) were added to
a stirred solution of N-carbobenzyloxycarbonyl valine (5.24 g, 20.8 mmol) in
methylene chloride / DMF (60 ml / 30 ml) at 0°C under nitrogen. After 15 min,
aspartic acid α -methyl, β -tert-butyl diester (5.00 g, 20.8 mmol) was added as a solid
followed neat 4-methylmorpholine (2.40 ml, 21.8 mmol). After stirring at 0 C for 1
10 hour and at room temperature for 5 hours, the mixture was partitioned between ethyl
acetate and 5% KHSO₄ solution. The aqueous solution was back-extracted with ethyl
acetate and the combined extracts were washed with saturated NaHCO₃ and brine, dried
over sodium sulfate, and concentrated to give a solid. Trituration with ether afforded of
N-[carbobenzyloxycarbonyl valinyl] aspartic acid, α -methyl, β -tert-butyl diester as a
15 white solid (8.36 g, 92%). TLC (CH₂Cl₂ / MeOH, 95 / 5): R_f = 0.48.

A solution of the above product (4.00 g, 9.17 mmol) in 200 ml of
methanol was stirred with palladium on activated carbon (0.45 g) under an atmosphere
of hydrogen (1 atm) for 50 min. The reaction mixture was then filtered through a pad
of Celite and the filter cake was washed with methanol and methylene chloride. The
20 filtrates were combined and concentrated, and the residue was chased with methylene
chloride to give N-[valinyl] aspartic acid, α -methyl, β -tert-butyl diester as a white solid
(2.75 g, 99%). TLC (CH₂Cl₂ / MeOH, 95 / 5): R_f = 0.10.

EXAMPLES 200-300















Utilizing the above intermediates, the compounds shown below in Table 16 may also be prepared (in the following table, the "Via" column indicates, when applicable, the starting compound from which the title compound is made):

5

















Table 16















Exp	Compound	Via	Exp.	Compound	Via
200		---	201		---
202		201	203		202
204		203	205		204
206		205	207		204
208		207	209		204













210		209
212		211
214		213
216		215
218		217
220		219
222		215
224		223
211		204
213		195
215		214
217		216
219		218
221		220
223		222
225		224

226		198	227		226
228		227	229		228
230		229	231		228
232		231	233		232
234		233	235		234
236		231	237		236
238		237	239		227

240		239	241		240
242		241	243		242
244		243	245		244
246		243	247		246
248		243	249		248
250		243	251		250
252		239	253		252
254		253	255		254

256		253
258		253
260		253
262		198
264		263
266		265
268		267
270		263
257		256
259		258
261		260
263		262
265		264
267		263
269		268
271		270

272		271
274		273
276		275
278		274
280		279
282		281
284		283
286		285
273		197
275		274
277		276
279		278
281		280
283		280
285		280
287		280


288		287
290		289
292		291
294		293
296		295
298		297
300		299
289		278
291		290
293		292
295		292
297		292
299		

Although the invention has been described with reference to the examples provided above, it should be understood that various modifications can be made without departing from the spirit of the invention. Accordingly, the invention is limited only by the claims.

CLAIMS

We claim:

1. A compound of the following formula:




wherein:


n is 0, 1 or 2;

q is 1 or 2;


X is CH₂, C=O, O, S, NH, C=ONH or CH₂OC=ONH;

A is a natural or unnatural amino acid of Formula IIa-i:





B is a hydrogen atom, a deuterium atom, C_{1-10} straight chain or branched alkyl, cycloalkyl, phenyl, substituted phenyl, naphthyl, substituted naphthyl, 2-benzoxazolyl, substituted 2-oxazolyl, $(\text{CH}_2)_m$ cycloalkyl, $(\text{CH}_2)_m$ phenyl, $(\text{CH}_2)_m$ (substituted phenyl), $(\text{CH}_2)_m$ (1 or 2-naphthyl), $(\text{CH}_2)_m$ heteroaryl, halomethyl, CO_2R^{13} , $\text{CONR}^{14}\text{R}^{15}$, $\text{CH}_2\text{ZR}^{16}$, $\text{CH}_2\text{OCO(aryl)}$, $\text{CH}_2\text{OCO}(\text{substituted aryl})$, $\text{CH}_2\text{OCO(heteroaryl)}$, $\text{CH}_2\text{OCO}(\text{substituted heteroaryl})$, or $\text{CH}_2\text{OPO}(\text{R}^{17})\text{R}^{18}$, where Z is an oxygen or a sulfur atom, or B is a group of the Formula IIIa-c:



R¹ is phenyl, substituted phenyl, naphthyl, substituted naphthyl, heteroaryl, or substituted heteroaryl;

R² is hydrogen, alkyl, cycloalkyl, phenyl, substituted phenyl, $(\text{CH}_2)_m\text{NH}_2$, $(\text{CH}_2)_m\text{NHCOR}^{10}$, $(\text{CH}_2)_m\text{N}(\text{C}=\text{NH})\text{NH}_2$, $(\text{CH}_2)_p\text{CO}_2\text{R}^3$, $(\text{CH}_2)_p\text{OR}^{11}$, $(\text{CH}_2)_p\text{SR}^{12}$, $(\text{CH}_2)_m$ cycloalkyl, $(\text{CH}_2)_m$ phenyl, $(\text{CH}_2)_m$ (substituted phenyl), $(\text{CH}_2)_m$ (1 or 2-naphthyl), or $(\text{CH}_2)_m$ heteroaryl, wherein heteroaryl includes (but is not limited to) pyridyl, thienyl, furyl, thiazolyl, imidazolyl, pyrazolyl, isoxazolyl, pyrazinyl, pyrimidyl, triazinyl, tetrazolyl, and indolyl;

R^3 is hydrogen, alkyl, cycloalkyl, (cycloalkyl)alkyl, phenylalkyl, or substituted phenylalkyl;

and wherein

R^4 is alkyl, cycloalkyl, phenyl, substituted phenyl, $(CH_2)_mNH_2$, $(CH_2)_mNHCOR^{10}$, $(CH_2)_mN(C=NH)NH_2$, $(CH_2)_pCO_2R^3$, $(CH_2)_pOR^{11}$, $(CH_2)_pSR^{12}$, $(CH_2)_m$ cycloalkyl, $(CH_2)_m$ phenyl, $(CH_2)_m$ (substituted phenyl), $(CH_2)_m$ (1 or 2-naphthyl), or $(CH_2)_m$ heteroaryl, wherein heteroaryl includes (but is not limited to) pyridyl, thienyl, furyl, thiazolyl, imidazolyl, pyrazolyl, isoxazolyl, pyrazinyl, pyrimidyl, triazinyl, tetrazolyl, and indolyl;

R^{4a} is hydrogen, or methyl, or R^4 and R^{4a} taken together are $-(CH_2)_d-$ where d is an integer from 2 to 6;

R^5 is phenyl, substituted phenyl, $(CH_2)_p$ phenyl, $(CH_2)_p$ (substituted phenyl), cycloalkyl, or benzofused cycloalkyl;

R^6 is hydrogen, alkyl, cycloalkyl, phenyl, substituted phenyl, $(CH_2)_m$ cycloalkyl, $(CH_2)_m$ phenyl, $(CH_2)_m$ (substituted phenyl), or $(CH_2)_m$ (1 or 2-naphthyl);

R^7 is hydrogen, fluorine, oxo, alkyl, cycloalkyl, phenyl, substituted phenyl, naphthyl, $(CH_2)_m$ cycloalkyl, $(CH_2)_m$ phenyl, $(CH_2)_m$ (substituted phenyl), $(CH_2)_m$ (1 or 2-naphthyl), OR¹¹, SR¹², or NHCOR¹⁰;

R^8 is hydrogen, oxo, alkyl, cycloalkyl, phenyl, substituted phenyl, naphthyl, $(CH_2)_m$ cycloalkyl, $(CH_2)_m$ phenyl, $(CH_2)_m$ (substituted phenyl), or $(CH_2)_m$ (1 or 2-naphthyl);

R^9 is alkyl, cycloalkyl, $(CH_2)_m$ cycloalkyl, $(CH_2)_m$ phenyl, $(CH_2)_m$ (substituted phenyl), $(CH_2)_m$ (1 or 2-naphthyl), or COR¹⁰;

R^{10} is hydrogen, alkyl, cycloalkyl, phenyl, substituted phenyl, naphthyl, $(CH_2)_m$ cycloalkyl, $(CH_2)_m$ phenyl, $(CH_2)_m$ (substituted phenyl), $(CH_2)_m$ (1 or 2-naphthyl), OR¹³, or NR¹⁴R¹⁵;

R¹¹ is hydrogen, alkyl, cycloalkyl, phenyl, substituted phenyl, naphthyl, (CH₂)_ncycloalkyl, (CH₂)_mphenyl, (CH₂)_m(substituted phenyl), or (CH₂)_m(1 or 2-naphthyl);

R¹² is alkyl, cycloalkyl, phenyl, substituted phenyl, naphthyl, (CH₂)_mcycloalkyl, (CH₂)_mphenyl, (CH₂)_m(substituted phenyl), or (CH₂)_m(1 or 2-naphthyl);

R¹³ is alkyl, cycloalkyl, (CH₂)_ncycloalkyl, (CH₂)_mphenyl, (CH₂)_m(substituted phenyl), or (CH₂)_m(1 or 2-naphthyl);

R¹⁴ is hydrogen, alkyl, cycloalkyl, phenyl, substituted phenyl, naphthyl, substituted naphthyl, (CH₂)_mcycloalkyl, (CH₂)_mphenyl, (CH₂)_m(substituted phenyl), or (CH₂)_m(1 or 2-naphthyl);

R¹⁵ is hydrogen or alkyl; or

R¹⁴ and R¹⁵ taken together form a five, six or seven membered carbocyclic or heterocyclic ring, such as morpholine or N-substituted piperazine;

R¹⁶ is phenyl, substituted phenyl, naphthyl, substituted naphthyl, heteroaryl, (CH₂)_mphenyl, (CH₂)_n(substituted phenyl), (CH₂)_m(1 or 2-naphthyl), or (CH₂)_mheteroaryl;

R¹⁷ and R¹⁸ are independently alkyl, cycloalkyl, phenyl, substituted phenyl, naphthyl, or phenylalkyl, substituted phenylalkyl, or (cycloalkyl)alkyl;

R¹⁹ and R²⁰ are independently hydrogen, alkyl, phenyl, substituted phenyl, (CH₂)_mphenyl, or (CH₂)_n(substituted phenyl), or R¹⁹ and R²⁰ taken together are -(CH=CH)₂-;

R²¹ is hydrogen, alkyl, phenyl, substituted phenyl, (CH₂)_mphenyl, (CH₂)_n(substituted phenyl);

R²², R²³ and R²⁴ are independently hydrogen or alkyl;

Y¹ is CH₂, (CH₂)₂, (CH₂)₃, or S;

Y^2 is O or NR²⁴;

Y^3 is CH₂, O, or NR²⁴;

a is 0 or 1 and b is 1 or 2, provided that when a is 1 then b is 1;

c is 1 or 2, provided that when c is 1 then a is 0 and b is 1;

m is 1, 2, 3 or 4; and

p is 1 or 2;

or a pharmaceutically acceptable salt thereof.

2. The compound of claim 1 where X is oxygen.

3. The compound of claim 1 where X is sulfur.

4. The compound of claim 1 where X is NH.

5. The compound of claim 1 where X is CH₂.


6. The compound of claim 1 where X is C=O.

7. The compound of claim 1 where X is C=ONH or CH₂OC=ONH.

8. The compound of claim 1 wherein q is 1.

9. The compound of claim 1 wherein q is 2.

10. The compound of claim 1 wherein A is




11. The compound of claim 10 wherein

R⁴ is lower alkyl, cycloalkyl, phenyl, substituted phenyl, (CH₂)_nNH₂, (CH₂)_mOR¹⁰, (CH₂)_mSR¹¹, (CH₂)_ncycloalkyl, (CH₂)_nphenyl, (CH₂)_n(substituted phenyl), or (CH₂)_n(1 or 2-naphthyl); and


R^{4a} is hydrogen.

12. The compound of claim 1 wherein A is




13. The compound of claim 12 wherein R⁵ is phenyl, substituted phenyl, (CH₂)_mphenyl, (CH₂)_m(substituted phenyl), cycloalkyl, or 2-indanyl.

14. The compound of claim 1 wherein A is



15. The compound of claim 14 wherein R⁷ is hydrogen, fluorine, cycloalkyl, phenyl, substituted phenyl, naphthyl, (CH₂)_ncycloalkyl, (CH₂)_nphenyl, (CH₂)_n(substituted phenyl), (CH₂)_n(1 or 2-naphthyl), OR¹⁰, or SR¹¹.

16. The compound of claim 1 wherein A is




17. The compound of claim 16 wherein

R⁸ is hydrogen, oxo, cycloalkyl, phenyl, substituted phenyl, or naphthyl; and

Y¹ is CH₂, (CH₂)₂, (CH₂)₃, or S.

18. The compound of claim 1 wherein A is






19. The compound of claim 18 wherein a is 0.

20. The compound of claim 1 wherein

B is hydrogen, 2-benzoxazolyl, substituted 2-oxazolyl, $\text{CH}_2\text{ZR}^{15}$, $\text{CH}_2\text{OCO}(\text{aryl})$, or $\text{CH}_2\text{OPO}(\text{R}^{16})\text{R}^{17}$; and

Z is O or S.

21. The compound of claim 1 wherein B is



22. The compound of claim 21 wherein R^{19} and R^{20} are independently hydrogen, alkyl, or phenyl, or wherein R^{19} and R^{20} taken together are $-(\text{CH}=\text{CH})_2-$.

23. The compound of claim 1 wherein

X is O or NH;

n is 0 or 1;

q is 1;

R^1 is substituted phenyl, naphthyl, or substituted naphthyl;

R^2 is hydrogen, lower alkyl, $(\text{CH}_2)_p\text{CO}_2\text{R}^3$, $(\text{CH}_2)_m$ (substituted phenyl), $(\text{CH}_2)_m$ (1- or 2-naphthyl), or $(\text{CH}_2)_m$ tetrazolyl; and

R^3 is hydrogen or lower alkyl.

24. The compound of claim 23 wherein R^1 is 1-naphthyl.

25. The compound of claim 23 wherein R¹ is 2-naphthyl.
26. The compound of claim 23 wherein R¹ is substituted naphthyl.
27. The compound of claim 26 wherein substituted naphthyl is 2-carboxy-1-naphthyl.
28. The compound of claim 23 wherein R¹ is substituted phenyl.
29. The compound of claim 28 wherein substituted phenyl is 2-substituted phenyl.
30. The compound of claim 29 wherein 2-substituted phenyl is (2-phenyl)phenyl.
31. The compound of claim 23 wherein A is alanine, valine, leucine cyclohexylalanine, phenylglycine or t-butylglycine.
32. The compound of claim 31 wherein R¹ is 1-naphthyl.
33. The compound of claim 31 wherein R¹ is 2-naphthyl.
34. The compound of claim 31 wherein R¹ is substituted naphthyl.
35. The compound of claim 34 wherein substituted naphthyl is 2-carboxy-1-naphthyl.

36. The compound of claim 31 wherein R¹ is 2-substituted phenyl.
37. The compound of claim 36 wherein 2-substituted phenyl is (2-phenyl)phenyl.
38. The compound of claim 23 wherein R² is (CH₂)₂CO₂R³ and n is 0.
39. The compound of claim 23 wherein R² is (CH₂)_mtetrazolyl and m is 0.
40. A pharmaceutical composition comprising a compound of claim 1 in combination with a pharmaceutically acceptable carrier.
41. A method for treating an autoimmune disease, comprising administering an effective amount of the pharmaceutical composition of claim 40 to a patient in need thereof.
42. A method of treating an inflammatory disease, comprising administering an effective amount of the pharmaceutical composition of claim 40 to a patient in need thereof.
43. A method of treating a neurodegenerative disease, comprising administering an effective amount of the pharmaceutical composition of claim 40 to a patient in need thereof.

44. A method of preventing ischemic injury to a patient suffering from a disease associated with ischemic injury, comprising administering an effective amount of the pharmaceutical composition of claim 40 to a patient in need thereof.

45. A method for expanding of hematopoietic cell populations or enhancing their survival, comprising contacting the cells with an effective amount of the pharmaceutical composition of claim 40.

46. The method of claim 45 wherein the cell populations are granulocytes, monocytes, erythrocytes, lymphocytes or platelets for use in cell transfusions.

47. A method of prolonging the viability of an organ that has been removed from a donor or isolated cells derived from an organ for the purpose of a future transplantation procedure, comprising applying an effective amount of the pharmaceutical composition of claim 40 to the organ or isolated cells to prolong the viability of the same as compared to untreated organ or isolated cells.

48. The method of claim 47 wherein the organ is an intact organ.

49. The method of claim 47 wherein the isolated cells are pancreatic islet cells, dopaminergic neurons, blood cells or hematopoietic cells.

50. Use of a compound of claim 1 as an active therapeutic substance.

INTERNATIONAL SEARCH REPORT

International Application No
PCT/US 99/24756

A. CLASSIFICATION OF SUBJECT MATTER					
IPC 7 C07C237/22 C07D211/60 C07D217/26 C07D209/42 C07D215/233 C07D213/64 C07D277/10 A61K31/195 A61K31/33					
According to International Patent Classification (IPC) or to both national classification and IPC					
B. FIELDS SEARCHED					
Minimum documentation searched (classification system followed by classification symbols)					
IPC 7 C07C C07D A61K					
Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched					
Electronic data base consulted during the international search (name of data base and, where practical, search terms used)					
C. DOCUMENTS CONSIDERED TO BE RELEVANT					
Category *	Citation of document, with indication, where appropriate, of the relevant passages				Relevant to claim No.
P, X	WO 99 47545 A (WANNAMAKER MARION W ;BEMIS GUY W (US); MURCKO MARK A (US); VERTEX) 23 September 1999 (1999-09-23) page 63; examples 5A,5D,5E,5F,5G,5L,5M,5N page 64; examples 5P,5Q,5N,5X,5Y,5AA page 65; examples 5AC,5AL,5AM page 66; examples 5AN-5AZ				1,7,8, 14-17, 20,40-50
X	SEMPLE G ET AL: "Peptidomimetic aminomethylene ketone inhibitors of interleukin-1beta-converting enzyme (ICE)" BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, GB, OXFORD, vol. 8, no. 8, 1998, page 959-964 XP004136999 ISSN: 0960-894X page 959; figure 1; example 2				1,7,8, 10,11, 40-50
					-/-
<input checked="" type="checkbox"/> Further documents are listed in continuation of box C.			<input checked="" type="checkbox"/> Patent family members are listed in annex.		
* Special categories of cited documents : "A" document defining the general state of the art which is not considered to be of particular relevance "E" earlier document but published on or after the International filing date "L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified) "O" document referring to an oral disclosure, use, exhibition or other means "P" document published prior to the International filing date but later than the priority date claimed					
"T" later document published after the International filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention "X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone "Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art. "&" document member of the same patent family					
Date of the actual completion of the International search			Date of mailing of the International search report		
23 February 2000			15/03/2000		
Name and mailing address of the ISA			Authorized officer		
European Patent Office, P.B. 5818 Patentamt 2 NL - 2280 HV Rijswijk Tel. (+31-70) 340-2040, Tx. 31 651 epo nl Fax. (+31-70) 340-3018			O'Sullivan, P		

INTERNATIONAL SEARCH REPORT

Int'l Application No
PCT/US 99/24756

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	WO 96 30395 A (TAKEDA CHEMICAL INDUSTRIES LTD ;FUKUDA TSUNEHIKO (JP); FUJISAWA YU) 3 October 1996 (1996-10-03) examples 12,18,20,28,65-69,86,90,92 -----	1,7, 9-11,20, 40-50
X	WO 97 22618 A (VERTEX PHARMA) 26 June 1997 (1997-06-26) page 20, line 14 -page 22, line 5 page 23, line 3 -page 26, line 5 -----	1,7,8, 12,13, 20,40-50
X	ROLAND E. DOLLE ET AL: "Pyridazinodiazepines as a High-Affinity, P2-P3 Peptidomimetic Class of Interleukin-1-Beta-Converting Enzyme Inhibitor" JOURNAL OF MEDICINAL CHEMISTRY., vol. 40, no. 13, 20 June 1997 (1997-06-20), pages 1941-1945, XP002131158 AMERICAN CHEMICAL SOCIETY. WASHINGTON., US ISSN: 0022-2623 page 1942; figure 1; example 1 -----	1,7,8, 10,11, 40-50
E	WO 99 66945 A (MERCK & CO INC ;RESZKA ALFRED A (US)) 29 December 1999 (1999-12-29) page 22; claim 6 -----	1,7,8, 10,11, 40-50
P,X	US 5 919 790 A (WALKER NIGEL ET AL) 6 July 1999 (1999-07-06) column 18; example 8 -----	1,7,8, 10,11, 40-50
X	WO 95 05192 A (MERCK & CO INC ;HAGMANN WILLIAM K (US); MJALLI ADNAN M (US); ZHAO) 23 February 1995 (1995-02-23) page 35; example 12 page 36; example 13 -----	1,7,8, 10,11, 14-17, 40-50
X	US 5 656 627 A (BEMIS GUY W ET AL) 12 August 1997 (1997-08-12) column 52, line 39; example Q column 56, line 39; example W column 109; example 62 -----	1,7,8, 10,11, 40-50
X	US 5 714 484 A (BECKER MARK ET AL) 3 February 1998 (1998-02-03) column 23; example 10 -----	1,7,8, 10,11, 21,22, 40-50

-/-

INTERNATIONAL SEARCH REPORT

Int'l Application No
PCT/US 99/24756

C(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	EP 0 761 680 A (ONO PHARMACEUTICAL CO) 12 March 1997 (1997-03-12) page 12, line 1 - line 55	1,7,8, 10,11, 40-50
X	GB 2 292 149 A (FERRING RES LTD ;YAMANOUCHI PHARMA CO LTD (JP)) 14 February 1996 (1996-02-14) page 16; examples 7AA,8AA	1,7,8, 10,11, 20,40-50
X	EP 0 644 197 A (STERLING WINTHROP INC) 22 March 1995 (1995-03-22) page 10; example 6	1,7,8, 10,11, 20,40-50
X	EP 0 623 592 A (STERLING WINTHROP INC) 9 November 1994 (1994-11-09) page 19; example 63	1,7,8, 10,11, 20,40-50
X	EP 0 623 606 A (STERLING WINTHROP INC) 9 November 1994 (1994-11-09) page 9; example 12	1,7,8, 10,11, 21,22, 40-50
X	WO 93 09135 A (SANDOZ AG ;SANDOZ AG (DE); SANDOZ LTD (CH)) 13 May 1993 (1993-05-13) page 20; example 14 page 21; examples 25,27 page 22; examples 32-34,40,41,46-51	1,7,8, 10,11, 20,40-50

INTERNATIONAL SEARCH REPORT

International application No.

PCT/US 99/24756

Box I Observations where certain claims were found unsearchable (Continuation of Item 1 of first sheet)

This International Search Report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. Claims Nos.: 41-46

because they relate to subject matter not required to be searched by this Authority, namely:

Remark: Although claims 41-46

are directed to a method of treatment of the human/animal body, the search has been carried out and based on the alleged effects of the compound/composition.

2. Claims Nos.:

because they relate to parts of the International Application that do not comply with the prescribed requirements to such an extent that no meaningful International Search can be carried out, specifically:

see FURTHER INFORMATION sheet PCT/ISA/210

3. Claims Nos.:

because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

Box II Observations where unity of invention is lacking (Continuation of Item 2 of first sheet)

This International Searching Authority found multiple inventions in this International application, as follows:

1. As all required additional search fees were timely paid by the applicant, this International Search Report covers all searchable claims.

2. As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.

3. As only some of the required additional search fees were timely paid by the applicant, this International Search Report covers only those claims for which fees were paid, specifically claims Nos.:

4. No required additional search fees were timely paid by the applicant. Consequently, this International Search Report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:

Remark on Protest

The additional search fees were accompanied by the applicant's protest.

No protest accompanied the payment of additional search fees.

INTERNATIONAL SEARCH REPORT

International Application No. PCT/US 99 24756

FURTHER INFORMATION CONTINUED FROM PCT/ISA/ 210

Continuation of Box I.2

The initial phase of the search revealed a very large number of documents relevant to the issue of novelty. So many documents were retrieved that it is impossible to determine which parts of the claim(s) may be said to define subject-matter for which protection might legitimately be sought (Article 6 PCT). For these reasons, a meaningful search over the whole breadth of the claim(s) is impossible. Consequently, the search has been restricted to:..... The structure according to claim 1, formula 1, with:

R2 = not a hydrogen atom

R3 = H

q = 1

Although the search was restricted to the above criteria, the search revealed some of the compounds excluded by this restriction: see W09630395 for q = 2. See GB2292149 and W09309135 for R3 = alkyl (these documents are cited in the Search Report)

The applicant's attention is drawn to the fact that claims, or parts of claims, relating to inventions in respect of which no international search report has been established need not be the subject of an international preliminary examination (Rule 66.1(e) PCT). The applicant is advised that the EPO policy when acting as an International Preliminary Examining Authority is normally not to carry out a preliminary examination on matter which has not been searched. This is the case irrespective of whether or not the claims are amended following receipt of the search report or during any Chapter II procedure.

INTERNATIONAL SEARCH REPORT

Information on patent family members

International Application No	
PCT/US 99/24756	

Patent document cited in search report	Publication date	Patent family member(s)		Publication date
WO 9947545 A	23-09-1999	AU	3098699 A	11-10-1999
WO 9630395 A	03-10-1996	AU	5122196 A	16-10-1996
		CA	2215211 A	03-10-1996
		EP	0820464 A	28-01-1998
		JP	9165360 A	24-06-1997
WO 9722618 A	26-06-1997	US	5843904 A	01-12-1998
		AU	1465897 A	14-07-1997
		BR	9612191 A	13-07-1999
		CA	2240489 A	26-06-1997
		CN	1207743 A	10-02-1999
		CZ	9801905 A	11-11-1998
		EP	0876395 A	11-11-1998
		HU	9902254 A	28-09-1999
		NO	982774 A	19-08-1998
		PL	327333 A	07-12-1998
WO 9966945 A	29-12-1999	NONE		
US 5919790 A	06-07-1999	NONE		
WO 9505192 A	23-02-1995	AU	7714594 A	14-03-1995
		US	5866545 A	02-02-1999
US 5656627 A	12-08-1997	US	5756466 A	26-05-1998
		AU	709114 B	19-08-1999
		AU	2944695 A	15-01-1996
		BG	101130 A	29-08-1997
		BR	9508051 A	21-10-1997
		CA	2192089 A	28-12-1995
		CN	1159196 A	10-09-1997
		CZ	9603698 A	11-06-1997
		EP	0784628 A	23-07-1997
		FI	965036 A	14-02-1997
		HU	76622 A	28-10-1997
		JP	10504285 T	28-04-1998
		NO	965365 A	17-02-1997
		NZ	289560 A	29-09-1999
		PL	318220 A	26-05-1997
		SK	160996 A	10-09-1997
		WO	9535308 A	28-12-1995
		US	5847135 A	08-12-1998
		US	5716929 A	10-02-1998
		US	5973111 A	26-10-1999
		ZA	9504988 A	17-12-1996
US 5714484 A	03-02-1998	US	5486623 A	23-01-1996
		AU	713934 B	16-12-1999
		AU	6100996 A	30-12-1996
		CA	2223268 A	19-12-1996
		EP	0863883 A	16-09-1998
		JP	11507912 T	13-07-1999
		WO	9640647 A	19-12-1996
		AU	1266495 A	27-06-1995
		CA	2177495 A	15-06-1995
		EP	0731696 A	18-09-1996
		JP	9506368 T	24-06-1997

INTERNATIONAL SEARCH REPORT

Information on patent family members

Int'l. Appl. No.
PCT/US 99/24756

Patent document cited in search report	Publication date	Patent family member(s)		Publication date
US 5714484 A		WO 9515749 A		15-06-1995
		US 5663380 A		02-09-1997
		US 5925772 A		20-07-1999
EP 0761680 A	12-03-1997	JP 9136878 A		27-05-1997
		US 5710153 A		20-01-1998
GB 2292149 A	14-02-1996	NONE		
EP 0644197 A	22-03-1995	AT 170868 T		15-09-1998
		AU 685447 B		22-01-1998
		AU 6451494 A		08-12-1994
		CA 2125080 A		05-12-1994
		CZ 9401379 A		14-06-1995
		DE 69413167 D		15-10-1998
		DE 69413167 T		06-05-1999
		ES 2122145 T		16-12-1998
		FI 942625 A		05-12-1994
		IL 109901 A		20-06-1999
		JP 7025887 A		27-01-1995
		NO 942065 A		05-12-1994
		NZ 260675 A		26-04-1996
		SK 68694 A		08-02-1995
		US 5843905 A		01-12-1998
EP 0623592 A	09-11-1994	AU 676887 B		27-03-1997
		AU 6075294 A		03-11-1994
		CA 2122227 A		30-10-1994
		CZ 9401035 A		16-11-1994
		FI 942005-A		30-10-1994
		HU 68563 A		28-06-1995
		IL 109471 A		22-02-1998
		JP 7025865 A		27-01-1995
		NO 941580 A		31-10-1994
		NZ 260410 A		25-06-1996
		SK 50294 A		08-02-1995
		US 5985838 A		16-11-1999
EP 0623606 A	09-11-1994	US 5462939 A		31-10-1995
		AT 161849 T		15-01-1998
		AU 668465 B		02-05-1996
		AU 6190694 A		10-11-1994
		CA 2123055 A		08-11-1994
		CZ 9401083 A		15-12-1994
		DE 69407654 D		12-02-1998
		DE 69407654 T		21-01-1999
		ES 2113606 T		01-05-1998
		FI 942107 A		08-11-1994
		GR 3026556 T		31-07-1998
		HK 1008146 A		30-04-1999
		HU 68791 A,B		28-07-1995
		JP 7025839 A		27-01-1995
		NO 941675 A		08-11-1994
		NZ 260477 A		21-12-1995
		SK 50994 A		08-02-1995
		US 5585486 A		17-12-1996
WO 9309135 A	13-05-1993	AU 2885292 A		07-06-1993

INTERNATIONAL SEARCH REPORT

Information on patent family members

Int'l Application No
PCT/US 99/24756

Patent document cited in search report	Publication date	Patent family member(s)		Publication date
WO 9309135 A		CA	2116653 A	13-05-1993
		CZ	9401067 A	15-12-1994
		EP	0611375 A	24-08-1994
		FI	942061 A	04-05-1994
		HU	68200 A	29-05-1995
		JP	7500828 T	26-01-1995
		MX	9206306 A	01-05-1993
		NO	941629 A	04-07-1994
		NZ	244985 A	27-06-1995
		PT	101027 A	28-02-1994
		SK	51194 A	08-02-1995
		ZA	9208511 A	04-05-1994